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Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) is the most recently identified
human herpesvirus and is the causative agent of not only Kaposi's sarcoma but also
B-cell primary effusion lymphomas and some forms of multicentric Castleman's
disease. During latency, translation of viral open reading frames is tightly regulated.
Only two transcripts, encoding ORFs 71-73 (LANA, vCyclin and vFLIP), are truly
type 1; that is, there is no increase in the rate of their transcription after the induction
of lytic replication. Both transcripts are transcribed from a common start point and
are subsequently spliced to produce a tricistronic transcript, encoding ORFs 71-73,
and a bicistronic transcript encoding ORFs 71 and 72 (vFLIP and vCyclin).
Translation of ORF 71, vFLIP, has been shown to be mediated via an internal
ribosome entry site (IRES) contained within the upstream vCyclin coding sequence.
This is the first example of cap-independent translation in a DNA virus. vFLIP has
been demonstrated to have anti-apoptotic activity and is also capable of activating
the cellular transcription factor NF-kB.
In this thesis the contribution of vFLIP toward viral pathogenesis has been
investigated through the construction and use of recombinant murine
gammaheipesviruses (MHV-76). KSHV vFLIP under the control of either the
Cytomegalovirus immediate early (CMV-IE) or the murine phosphoglycerol kinase
(PGK) promoter, together with enhanced green fluorescent protein (EGFP) and a
hygromycin resistance marker, has been inserted into the left-hand end of the MHV-
76 genome to produce recombinant viruses that have been used for in vivo and in
vitro studies. All recombinant viruses display similar in vitro growth kinetics to
wild-type MHV-76 during infection of BHK cells. Intranasal infection of Balb/c
XII
mice with the CMV vFLIP viruses resulted in a 2 fold greater infectious virus titre in
the lungs, at day 5, compared with the control and wild-type MHV-76 viruses.
However, this enhanced viral replication was not observed following infection with
the PGK vFLIP viruses. In all cases the vFLIP expressing and control viruses
displayed a decreased establishment of splenic latency. The influence of vFLIP on
viral replication in an in vitro system has been investigated through the infection of
NSO cells, a murine myeloma cell line. These data indicate that the expression of
vFLIP, in the context of a herpesvirus infection, increases the initial establishment of
a latently infected pool of cells, by up to 3-fold at day 8 post infection. The
correlation of this process with the activation ofNF-kB has been investigated.
A number of techniques have been applied to investigate the nature of any IRES
interacting factors (ITAFs) necessary for translation of vFLIP from the KSHV IRES.
Through the use of an in vitro pull-down assay it has been possible to demonstrate
that a known ITAF, poly-pyrimidine tract binding protein (PTB), can associate with
the KSHV IRES. Electrophoretic mobility shift assays indicate that additional
cellular proteins interact with the IRES sequence and investigations indicate that one








1.4 FLICE inhibitory proteins
1.5 Internal ribosome entry sites
1.6 Project Aims
1.1 Herpesviruses
It is likely that the majority of animal species harbour one or more herpesvirus. To
date more than 130 different herpesviruses have been identified from organisms as
diverse as oysters and humans. They are responsible for a range of diseases of
medical and veterinary importance including infectious mononucleosis of humans
and malignant catarrhal fever of cattle. Inclusion in the family Herpesviridae is
dependent upon the architecture of the virion; it is currently under debate as to
whether DNA sequence conservation should also be taken into account.
All known herpesviruses share four significant properties;
1. They encode a large number of enzymes required for metabolic processes
including nucleic acid metabolism and protein modification.
2. The viral DNA and capsid is synthesised within the host cell nucleus.
3. Production of progeny virions results in death of the host cells.
4. They are able to become latent; the viral genome becomes circularised and
only a small subset of viral genes are expressed. The viral genome retains
the capacity to reactivate and cause disease.
Despite these similarities herpesviruses can differ greatly in their biological
properties. The host-cell range, length of replication cycle and site and mechanisms
of latency can all vary (Roizman and Pellet, 2001).
1.1.1 Classification
Members of the family Herpesviridae have been classified into three subfamilies, the
alpha-, beta- and gammaherpesvirinae, on the basis of their biological properties and
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genomic analysis (Roizman and Pellet, 2001). A phylogenetic tree showing the
relationships between all eight human herpesviruses, and selected others, can be seen
in figure 1.1. A table providing examples of each sub-family and detailing selected
disease associations is also provided (table 1.1). A brief description of the major
characteristics of each sub-family follows;
Alphaherpesvirinae: Members of this subfamily are characterised as having a
generally broad host range, a relatively short reproductive cycle, rapid spread in
culture, efficient destaiction of the infected host cell and the ability to establish
latency in the sensory ganglia. Examples of alphaherpesviruses include Herpes
Simplex virus 1 (HSV-1) and Varicella Zoster virus (VZV).
Betaherpesviruses: The majority of members of this subfamily exhibit a restricted
host range, a long replication cycle in vitro and a slow progression of infection in
culture. Despite the long in vitro replication cycle of human CMV there is strong
evidence that the virus replicates much more rapidly in vivo (Emery et al., 1999).
Through investigation of the viral load in patients subject to antiviral therapy, or in
whom immunodeficiency resulted in active viral infection, the doubling time of the
virus was estimated to be between 1 and 2 days (Emery et al., 1999). Latency can be
maintained in a variety of cell types and tissues including secretory glands and the
kidneys. Examples include members of the genera Cytomegalovirus.
Gammaherpesviruses: Viruses belonging to this subfamily have a restricted host
range, being confined to the family or order of the natural host. They replicate in
lymphoblastoid cells, though some can lytically infect epithelial and fibroblastic





Figure 1.1 Phylogenetic tree illustrating the relationship between selected
herpesviruses. Taken from Talbot and Whitby, 1999.
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Table 1.1 Table of selected herpesviruses and disease associations.
Compiled from information in Fields Virology 4th edition (ed. Knipe and
Howley).
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into two genera, the lymphocryptoviruses and the rhadinoviruses on the basis of
genome structure and content.
1.1.2 Virion structure
A typical virion consists of a core, containing the viral DNA, which is surrounded by
a capsid approximately lOOnm in diameter and consisting of 162 capsomeres.
Between the capsid and the envelope is the tegument the distribution and thickness of
which may vary but which appears to be an ordered structure. Herpesvirus
envelopes have a trilaminar appearance and are apparently derived from different
cellular membranes. All herpesviruses have glycoproteins protruding from their
envelopes although the number of different glycoproteins encoded and their copy
number varies between different viruses. A complete, mature virion may range in
size from 120nm to 300nm in diameter depending on, amongst other factors, the
thickness of the tegument (Roizman and Pellet, 2001). A diagrammatic
representation of the KSHV virion is shown in figure 1.2.
1.1.3 Herpesvirus genomes
Herpesvirus genomes consist of linear, double-stranded DNA, within the virion,
which is immediately circularised once in the nucleus of a host cell. Genomes range
in size from 120 to 250kbp and in composition from 31-75% G-C. Herpesvirus
genomes have been divided into six groups, A-F, based upon their genome
organisation, figure 1.3.
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Figure 1.3 Diagram of the six classes of herpesvirus genomic
arrangements, A-F. Unique regions are shown as horizontal lines whilst
the coloured blocks represent repeat regions. The KSHV genome is of
type B, having a central coding region flanked by large terminal repeats,
whilst EBV is type C, having smaller terminal repeats than type B but also
other smaller repeat sequences dividing the genome. In all six classes the
signals for packaging of the genome into capsids are located at the termini.
Figure adapted from Roizman and Pellet in Fields Virology 4th ed.
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Heipesvirus genomes range in size from 70 to 200 genes, though these figures may
prove to be underestimates as the potential for alternative splicing, frameshifting and
identification of further ORFs is large (Roizman and Pellet, 2001). Most herpesvirus
genes consist of a single ORF flanked by 5' and 3' untranslated regions, of 30 to
300bp and 10 to 30bp respectively, a promoter sequence upstream of a TATA box
and a 3' polyadenylation signal. It is common for genes to overlap which results in
the regulatory sequences of some genes being located within the coding sequence of
others. The vast majority of genes are transcribed by RNA polymerase II and most
are unspliced. Some instances where splicing does occur allow the differential
regulation of transcription; it enables the same ORF to be transcribed from different
promoters depending upon the stage of the viral replication cycle. Some
herpesviruses additionally encode noncoding RNAs, for example the EBERs of EBV
and the tRNAs ofMHV-68.
Aside from those genes responsible for viral replication, herpesvirus gene products
act to manipulate the host resulting in an environment best suited for viral replication
or the establishment of latency. Furthermore herpesviruses encode proteins designed
to inhibit the host immune defence. In the case of HSV more than half of the viral
genes are dispensable for growth in tissue culture; however, the majority are
absolutely required for replication within an animal model. The regulatory proteins
encoded by herpesviruses are adapted to the cell types which the virus infects in vivo;
much remains to be determined concerning their function.
Whilst the establishment of latency is common to all herpesviruses the mechanisms
by which it is achieved and maintained differ greatly between different viruses.
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There is no apparent consensus on factors necessary for establishment, maintenance
or termination of latency. Some viruses, including EBV and KSHV, encode latently
expressed proteins whereas others, for example HSV, have no requirement to express
viral genes during latency.
The regulation of herpesvirus genes goes beyond merely lytic or latent expression.
During productive infection viral genes differ in the order of their expression and the
factors necessary to drive it. During a productive infection of HSV at least four
different groups of viral genes can be identified. These are the immediate early (IE)
genes, which require no viral protein synthesis; the early (E) genes which are
expressed independently of viral DNA synthesis; partial late genes, whose expression
is enhanced by viral DNA synthesis; and the late (L) genes the expression of which
has an absolute requirement for viral DNA synthesis.
Sequencing of entire viral genomes or smaller sections has shown that approximately
26 genes, the core genes, are conserved across all of the herpesvirus subfamilies.
They are found in seven core gene blocks each encoding 2 to 12 genes. In general
block and gene order is conserved within subfamilies. Other genes are conserved at
subfamily level; gammaherpesviruses, for example, encode more cell homologous
genes than do alpha- and betaherpesviruses, though all herpesviruses seem to encode
at least one protein of cellular origin (Roizman and Pellet, 2001).
1.1.4 Herpesvirus life cycle
The general principles of herpesvirus replication can be outlined through a
description of HSV replication, the system about which most is known; though it
must be remembered that the details for individual viruses can vary substantially.
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HSV-1 and HSV-2 express at least a dozen envelope glycoproteins, however, only
five have been shown to have a role in viral entry (reviewed in Spear and
Longnecker, 2003). Glycoproteins gC and/or gB mediate binding of the virus to the
cell through interactions with heparan sulphate. Fusion of the viral envelope with the
cell membrane is then induced by the glycoproteins gB, gD, gH and gL; all four of
which have been demonstrated to be essential for viral entry. Binding of virus to
heparan sulphate does not necessarily result in viral entry, generally there is a
requirement for at least one co-receptor. At least three different classes of co-
receptor have been identified (Spear et al., 2000) all of which appear to be receptors
for gD. The proteins shown to act as co-receptors are a TNF receptor, several
members of the immunoglobulin superfamily and a product of sulphotransferase
activity on heparan sulphate. The presence and localisation of viral receptors
determines, at least in part, the cellular tropism of herpesviruses.
Flaving entered a host cell either through fusion with the plasma membrane or, in
some cases, the endocytic membrane, the capsid is transported to the nuclear pore via
the microtubule network (Roizman and Knipe, 2001). The viral DNA is released
into the nucleus at the nuclear pore, leaving the capsid complex at the cytoplasmic
side, apparently after a conformational change in the capsid proteins induced by
association with components of the nuclear pore (Ojala et al., 2000).
Transcription, by host cell RNA polymerase II, occurs in the nucleus in a highly
regulated manner (Honess and Roizman, 1974). First to be transcribed are the six
immediate early (IE) genes. Their transcription is mediated by the tegument protein
VP 16, which interacts with cellular proteins to recognise IE promoter elements, and
requires no prior viral protein synthesis (Campbell et al., 1984; reviewed in Roizman
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and Knipe, 2001). Next to be transcribed are the early (E) genes. ICP4, one of the
IE proteins, is required for all post-IE gene expression and is thought to mediate
transcription through association with cellular proteins. The expression of the E
genes requires only the production of ICP4 and not the onset of viral DNA
replication. The early gene products promote viral DNA replication, and thus the
expression of late genes, and down-regulate the expression of IE genes. The
expression of the final set of genes, the late genes, is enhanced by viral DNA
synthesis. The late genes are loosely divided into two categories; those whose
expression does occur under early conditions but which are markedly increased by
viral DNA synthesis, and those that are utterly dependent on viral DNA synthesis. In
general the early gene products are involved in viral DNA replication and the late
gene products are structural. HSV DNA is replicated in the nucleus in a process
requiring several viral proteins. Replication occurs by the rolling-circle mechanism
resulting in head-to-tail concatamers of the genome. The DNA is then packaged into
pre-formed capsid complexes, empty shells containing internal scaffolding which are
assembled initially in the cytoplasm and subsequently completed in the nucleus.
Entry of the DNA displaces the scaffold from the capsid. Once the capsid is filled
the DNA is cleaved at specific sites, by a packaging complex, and fully encapsidated
(reviewed in Roizman and Knipe, 2001). Following assembly the capsid leaves the
nucleus by budding through the inner nuclear membrane whereby it acquires an
envelope consisting of the inner leaflet of the membrane (reviewed in Mettenleiter,
2002). Current opinion supports a de-envelopment/ re-envelopment model for
subsequent steps in maturation. In this model the primary envelope is lost through
fusion with the endoplasmic reticulum membrane. The capsid then gains its final
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tegument and envelope in cytoplasmic compartments. Tegumentation appears to
involve a complex series of protein-protein interactions resulting in a first layer with
some icosohedral structure, due to interactions with the capsid, and further less
structured layers. The tegument acts, amongst other roles, to link the capsid with the
envelope glycoproteins. Final envelopment is still not fully understood but is
believed to take place in the trans-Golgi compartment where the cytoplasmic tails of
viral glycoproteins associate with the tegument. Mature virions then bud from the
plasma membrane into the intracellular space.
1.2 Gammaherpesviruses
As previously mentioned the gammaherpesvirus subfamily contains two genera the
lymphocryptoviruses (LCV), of which Epstein-Barr virus (EBV) is the prototype, and
the rhadinoviruses (RDV), which include KSHV and MHV-68. The LCV so far




Suggestions that an infectious agent may be the causative agent of Burkitt's
lymphoma (BL), a common childhood cancer throughout equatorial Africa, led to a
search for the etiological agent. Epstein-Barr virus was discovered in 1964 by
electron microscopy which was carried out on cell lines derived from a BL biopsy
(Epstein et al., 1965). EBV is endemic globally; over 90% of the adult population
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are seropositive for EBV infection. EBV is the only human LCV so far identified
and is the prototype gammaherpesvirus.
Disease associations
EBV has been associated with a range of diseases including:
Infectious mononucleosis: In developed countries primary infection with EBV is
often delayed until adolescence. In this circumstance the result can be infectious
mononucleosis (IM), also known as glandular fever, in around 50% of infections. It
is likely that the disease symptoms (fever, lymphadenopathy, sore throat,
hepatosplenomegaly, fatigue) are the result of the immune response rather than a
direct result of viral replication (Crawford, 2001).
Burkitt's Lymphoma: Burkitfs Lymphoma (BL) is a tumour of the jaw, and other
sites, that occurs most commonly in children in equatorial Africa and Papua New
Guinea but also arises sporadically throughout the world. BL consists of rapidly
proliferating non-cleaved B cells infiltrated with histiocytes. A common feature of
BL is chromosomal translocations that result in deregulation of expression of the c-
myc oncogene. EBV DNA is found in around 96% of African BL cases; however,
the association with sporadic BL is much weaker. The mechanisms by which EBV
contributes to BL pathogenesis are unclear; it is hypothesised that EBV infection
may play an initiating role, driving the proliferation of infected B cells or increasing
the survival of a clone in which translocation has occurred (Rickinson and Kieff,
2001; Crawford, 2001; Young and Murray, 2003).
Hodgkin's disease: Hodgkins lymphoma accounts for 20% of lymphomas in the
developed world. It consists of 1-2% malignant Reed-Sternberg (RS) and Hodgkin's
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cells, which are derived from B lymphocytes, and a cellular infdtrate of mixed
characteristics. Differences in the cellularity of the infdtrate between EBV positive
and negative cases indicate underlying etiological differences. Within EBV positive
lymphomas the malignant component has been shown to harbour latent EBV
(Latency II). EBV is proposed to contribute to the pathogenesis by preventing
apoptosis of B cells with hypermutated Ig genes which go on to form RS and
Elodgkin's cells (Rickinson and Kieff, 2001; Crawford, 2001; Young and Murray,
2003).
Post-transplant lymphoproliferative disease (PTLD): Individuals who are
immunosuppressed exhibit decreased EBV-specific cytotoxic T lymphocyte (CTL)
activity and consequently there is an increase in virus replication and an expansion of
latently infected B lymphocytes (Haque et al., 1997). PTLD tumour cells generally
express all of the latency-associated genes of EBV which are presumed to be able to
induce proliferation. Tumours are initially polyclonal but progress to become
monoclonal lymphomas. PTLD has been successfully treated with infusions of
EBV-specific CTLs (Haque et al., 2002; Rooney et al., 1998).
Nasopharyngeal carcinoma (NPC): EBV is associated with 100% of
undifferentiated NPC; a tumour characterised by the presence of undifferentiated
carcinoma cells with a prominent lymphocytic infdtrate. NPC shows distinct
geographical localisation; it is very common in southern China and occurs at high
frequency in the Inuit, Malaysians, Dyaks, Indonesians, Filipinos and Vietnamese.
This distribution suggests that there is a genetic component to its development and
there are indications that environmental factors, such as diet, can also influence
disease development. EBV is implicated as NPC tumours are found to be
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monoclonal for EBV, suggesting infection prior to expansion. Additionally the EBV
genes EBNA1 and EBERs are expressed in all EBV associated cases and LMP-1 is
expressed in 65% of cases (Crawford, 2001; Young and Murray, 2003).
EBV structure and genome
The general architecture of EBV is the same as other herpesviruses. The virion
contains a range of envelope glycoproteins some of which are homologous to the
HSV glycoproteins. The most abundant glycoprotein and tegument protein of EBV,
however, do not have HSV homologues. The genome, which is type C, is
approximately 184kbp in length with 0.5kb terminal and 3kb internal repeats (Kieff
and Rickinson, 2001).
EBV infection and replication
EBV is transmitted via oral secretions and possibly also via sexual intercourse. It is
believed that EBV may be able to directly access tonsillar B lymphocytes. Unlike
many other herpesviruses the initial interaction of EBV with its target cell involves
complement receptor 2 (CD21), rather than heparan sulphate. This interaction is
mediated by the major envelope glycoprotein gp350/220 deletion mutants of which
can still infect cells but at reduced efficiency. Following this initial interaction gp42
binds to HLA class II molecules, which are abundantly expressed on B lymphocytes,
and membrane fusion then occurs due to the actions of gB, gH and gL. Besides B
lymphocytes EBV is also able to enter some epithelial cell types in a gp350/220,
gp42 independent manner. Infectious virus produced in epithelial cells has greater
tropism for B lymphocytes, and vice versa, as gp42 is not sequestered by cellular
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HLA class II (Spear and Longnecker, 2003). Following entry into B lymphocytes
the expression of EBV latent genes drives cellular proliferation thus amplifying the
number of latently infected cells in the body. In order to complete its replicative
cycle EBV must reactivate from latency and produce infectious virions with which to
infect a new host; the switch from latent to lytic replication is as yet uncharacterised
but may be physiological (Macsween and Crawford, 2003). Following induction of
lytic replication the immediate-early genes expressed are principally BZLF1 and
BRLF1. These proteins are transactivators of lytic gene expression; BZLF1
expression activates lytic infection (Grogan et al., 1987) and both proteins up-
regulate expression from early gene promoters (Chevallier-Greco et al., 1986).
There are more than 30 early genes whose products have activities ranging from
transcriptional activation (e.g. BMRF1; Oguro et al., 1987), DNA replication (e.g.
the DNA polymerase BALF5; Kallin et al., 1985) and prevention of apoptosis (a Bcl-
2 homologue BE1RF1; Flenderson et al., 1993b). The EBV late genes encode the
viral glycoproteins and some non-glycoproteins including the nucleocapsid protein
BcLFl and the predicted tegument protein BNRF1 (Kieff and Rickinson, 2001).
EBV latency
During latent infection the viral genome is maintained as an episome in infected
lymphocytes. EBV latency is more complex than that of other herpesviruses; three
different forms have been identified. These are designated "latency I, II or III" and
are distinguished by the pattern of gene expression (Young et al., 2000):
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• Latency I has been identified in BL biopsies and early passage BL-derived cell
lines. During this form of latency the EBERs and EBNA1 are the only EBV
transcripts produced.
• Latency II involves transcription of the EBERs, EBNA1, LMP1, LMP2A and
LMP2B. This form was identified in NPC and is also seen in EBV-associated
Hodgkin's disease and some EBV-positive T cell lymphomas.
• Latency III has the most extensive expression of viral genes; the EBERs,
EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, LMP1, LMP2A
and LMP2B. Lymphoblastoid cell lines (LCLs) generated by infecting resting B
lymphocytes with EBV in vitro display latency III, as do immunoblastic
lymphomas in transplant recipients. Latency III is accompanied by a distinct
cellular phenotype in vivo and in vitro with high expression of B cell activation
markers and cellular adhesion molecules.
Following infection of a resting B lymphocyte the first latent transcripts produced are
EBNA-LP and EBNA-2 both of which act to up-regulate transcription from viral and
cellular promoters. They reach their final level within 24-32 hours of infection. As
well as some cellular genes EBNA2 up-regulates transcription of the EBNAs, LMP1
and LMP2. Levels of these transcripts reach those that are maintained throughout
infection by 48 hours post infection. By 70 hours post infection EBER expression
has reached substantial levels. The EBERs constitute the most abundant EBV RNAs
within latently infected B lymphocytes, estimated at approximately 50,000 copies per
cell (Rickinson and Kieff, 2001).
A model for EBV latency which includes a fourth type of latency, latency 0, during
which no viral genes are expressed has been proposed (Thorley-Lawson and Gross,
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2004). The premise of this model is that following infection of a naive B cell EBV
forces the differentiation of the cell into a memory B cell, which has exited the cell
cycle, in which the virus can persist silently. This arrangement is beneficial to both
the virus and the host as there is no immune response directed against the infected
cell and, as the cell is resting, there is no threat to the host because no viral growth-
promoting genes are expressed. It is proposed that in the newly infected naive cell
the growth programme (latency III) is entered, in which all latent transcripts are
expressed, and the B cell becomes activated. Having differentiated to a germinal
centre cell the viral programme switches to the default programme (latency II) which
enables differentiation into a memory B cell where latency 0 is established. When
the memory B cell does divide, following a host stimulus, the virus enters latency I
which allows the viral DNA to replicate. According to this model disease results
when there is a blockage to this sequence of events resulting in constitutive
expression of the EBV latent genes. An example would be Hodgkin's disease
resulting from a blockage following differentiation into a germinal centre cell and
subsequent expression of the latency II programme.
Roles of the EBV latent genes
EBNA-LP: EBNA-LP is encoded by the leader sequence of each EBNA mRNA and
is of variable size depending on the number ofBamHIW repeats present. It has been
shown to be required for efficient growth of LCLs (Allan et ah, 1992). Its proposed
role is enhancement ofEBNA2 mediated transcription (Rickinson and Kieff, 2001).
EBNA1: EBNA1 is a DNA-binding nuclear phosphoprotein; it binds to the plasmid
origin of viral replication and consequently aids replication and maintenance of the
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episome. Additionally it has been demonstrated to act as a negative regulator of its
own expression (Nonkwelo et al., 1996) and a transcriptional transactivator of the Cp
and LMP1 promoters (Rickinson and Kieff, 2001). In vivo experiments in which
EBNA1 is expressed in B lymphocytes in transgenic mice suggest a possible role in
oncogenesis as B cell lymphomas developed (Wilson et ah, 1996).
EBNA2: EBNA2 is required for cellular transformation. An EBV strain, P3HR-1,
in which EBNA2 is deleted is unable to induce transformation in vitro. The gene
product is an acidic phosphoprotein which activates transcription of cellular and viral
genes including the c-myc oncogene (Kaiser et ah, 1999).
EBNA3A, B, C: All three genes are transcribed from a common origin and encode
hydrophilic nuclear proteins containing potential dimerisation domains. EBNA3A
and 3C are essential for transformation in vitro (Tomkinson et ah, 1993). The
EBNA3 proteins act as transcriptional regulators; they can up and down-regulate
both cellular and viral genes and can work together with EBNA2 to control activity
of the RBP-Jk transcription factor (Young and Murray, 2003).
LMP1: LMP1 is essential for EBV-induced transformation in vitro (Kaye et ah,
1993). It has six transmembrane helices, a short cytoplasmic N-terminal and a longer
cytoplasmic C-terminus which is important for cell transformation. Functionally,
LMP1 has been demonstrated to resemble CD40, a member of the tumour necrosis
factor receptor (TNFR) superfamily; LMP1 can partially replace CD40 function in
CD40 knockout mice (Uchida et ah, 1999). It is able to activate the transcription
factor NF-kB, via domains in its C-terminus (Huen et ah, 1995), resulting in
expression of various antiapoptotic and cytokine genes. Additionally LMP1 can
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activate the MAP kinase cascade and phosphatidylinositol 3-kinase (Dawson et ah,
2003).
LMP2A, B: These proteins are essentially identical to one another consisting of
twelve transmembrane domains and a small cytoplasmic C-terminus, the only
difference is the additional 119 amino acid cytoplasmic N-terminus of LMP2A.
Neither protein is essential for transformation in vitro (Longnecker, 2000). LMP2A
appears to negatively regulate protein tyrosine kinase (PTK) activity, via its N-
terminus, resulting in an abrogation of normal B lymphocyte development in favour
of maintenance of EBV latency (Young and Murray, 2003). LMP2B is suggested to
aid regulation of LMP2A function (Longnecker, 2000).
EBERs: EBV encodes two non-coding RNAs, EBER 1 which is transcribed by
RNA polymerases 11 and III, and EBER 2 which is transcribed by RNA polymerase
III (Kieff and Rickinson, 2001). The EBERs localise to the nucleus where they are
found in complex with the La autoantigen (Lerner et ah, 1981) and the ribosomal
protein L22 (Toczyski et ah, 1994). The EBER complex is able to bind to PKR
which in involved in mediating the effects of interferons; it has been proposed that
inhibition of PKR by EBERs may be involved in viral persistence (Clemens et ah,
1994). More recently there has been some evidence to suggest that the EBERs may
increase the tumourigenicity ofBL (Komano et ah, 1999; Kitagawa et ah, 2000).
Immune evasion
EBV encodes a number of potentially immunomodulatory proteins. The
glycoprotein gp42 may interfere with HLA class II maturation or epitope
presentation (Rickinson and Kieff, 2001). BARE1 acts as a soluble colony-
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stimulating factor-1 receptor and interferes with interferon-a release (Cohen and
Lekstrom, 1999). A viral homologue of cellular interleukin-10 (BCRF1) augments B
lymphocyte growth and differentiation and inhibits antigen presentation by
monocytes and dendritic cells. Unlike cIL-10, BCRF1 cannot directly impair T
lymphocyte function, however, inhibition of priming of T-cell responses has been
observed (Bejarano and Masucci, 1998).
1.2.2 Rhadinoviruses
1.2.2.1 Kaposi's sarcoma-associated herpesvirus
Discovery, epidemiology and pathogenesis
Despite suspicions of a viral aetiology for Kaposi's sarcoma (KS) (Beral, 1991) it
was not until 1994 that herpesvirus-like sequences were identified in samples of
AIDS-associated KS lesions using representational difference analysis (Chang et al.,
1994). Subsequently numerous epidemiological studies have shown that KSHV is
the causative agent of not only KS but also B-cell primary effusion lymphomas
(PEL) and some forms of multicentric Castleman's disease.
KSHV strains, transmission and world-wide prevalence
Unlike other herpesviruses which tend to be wide spread within a host population
KSHV seropositivity shows a more complex distribution. The prevalence of
seropositivity in the USA, and central, northern and western Europe is low, up to
10% with regional variation. In some Mediterranean countries the frequency is
22
increased and can be as high as 35% in some areas, again there is regional variation.
In sub-Saharan Africa KSHV infection is much more widespread (reviewed in
(Boshoff and Weiss, 2001).
Subtyping of KSHV is based on ORFK1 which encodes a glycoprotein related to the
immunoglobulin superfamily and is the most variable part of the genome. To date
five different subtypes have been identified, designated A-E. Within subtypes A-D
there are more than fifteen different clades (Hayward, 1999). Subtype B is found
almost exclusively in patients from Africa, subtype C in those from the
Mediterranean and Middle East, subtype A in western Europe and North America
and subtype D in areas of the Pacific (Hayward, 1999; Zong et al., 1999). Subtype E
is the most recently described and was found in South American indigenous people
(Biggar et ah, 2000). The view of the majority of researchers is that KSHV is an
ancient pathogen of humans with a particularly low rate of horizontal transmission
(Hayward, 1999). Others, however, suggest that KSHV may have entered the human
population more recently as a result of interspecies transfer from another primate
host (McGeoch and Davison, 1999).
Disease associations
Kaposi's sarcoma: Kaposi's sarcoma was first described by the dermatologist
Moritz Kaposi in 1872 (Kaposi, 1872). It is a mesenchymal tumour, involving blood
and lymphatic vessels, which usually presents as brownish-purple lesions at the
extremities but that can progress to internal organs. KS lesions contain a number of
cell types but are characterised by the presence of spindle cells the origin of which is
disputed (Talbot and Whitby, 1999). KS spindle cells have been shown to express
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markers for smooth muscle, macrophage and dendritic cells (Sturzl et al., 1992).
More recently it has been shown that all spindle cells express vascular endothelial
growth factor receptor 3 (Jussila et al., 1998). As this is a marker for lymphatic
endothelium and neoangiogenic vessels, but not mature vascular endothelial cells, it
indicates that KS spindle cells are probably of endothelial lineage and can
differentiate into lymphatic cells (Boshoff and Weiss, 2001). Most recently two
groups have shown that KSHV infection of blood vascular endothelial cells leads to a
shift in the gene expression profile of the infected cell towards that of lymphatic
endothelial cells (Wang et al., 2004; Hong et al., 2004). These data raise the
possibility that KS spindle cells do not represent a particular cell lineage but, instead,
the virus is able to infect cells of both the blood and lymphatic lineage and drive their
gene expression profiles towards one another. Tumour development is dependent on
viral oncogenesis, cytokine mediated growth and some immunological compromise
in the host (Hengge et al., 2002).
KSHV has been causally linked to KS by four different observations which
individually do not prove a link but taken together show KSHV to be the etiological
agent of KS (reviewed in Boshoff and Weiss, 2001);
1. KSHV DNA can be detected by PCR in all forms of KS, however, it is rarely
detected in other mesenchymal tumours.
2. HIV positive patients carrying a higher viral load of KSHV, assessed by
PCR, are at greater risk of developing KS.
3. The incidence of classic and AIDS-KS correlates broadly with the level of
KSHV within a population.
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4. Latent KS transcripts can be found in nearly all spindle cells of advanced KS
lesions.
Prior to the onset of the AIDS pandemic KS had a low profde being mainly endemic
in areas around the Mediterranean and in sub-Saharan Africa. The incidence of
classic and endemic KS is more common in men than women despite similar levels
of seropositivity suggesting that there may be sex-specific co-factors involved in
disease development (Serraino et al., 2001). In the early 1980's KS appeared, in an
aggressive form, in young homosexual men in the USA (CDC, 2004), one of the first
signs of the AIDS epidemic. KS is now amongst the most common forms of cancer
in several African countries (Wabinga et al., 1993; Wabinga et al., 2000), in some
areas there has been a twenty-fold increase in the number of cases since 1988, and
the previous bias towards male patients has rescinded (Sitas and Newton, 2001),
reviewed in (Dedicoat and Newton, 2003).
There are four, clinically distinguishable, manifestations of KS;
1. Classic KS
The form of KS described by Kaposi affects mainly elderly males of
Mediterranean, east European or Jewish descent and generally presents as
plaques and nodules on the lower extremities. Classic KS rarely metastasises and
patients survive for a mean of 10- 15 years and die of an independent cause
(Hengge et al., 2002; Wahman et al., 1991).
2. Endemic KS
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In the 1960's an unusually high prevalence of KS in some sub-Saharan African
countries was noticed. The high incidence of KS was confined to distinct
geographical locations. Endemic KS is generally more aggressive than classic
KS and occurs in younger individuals, particularly children, in whom the lymph
node is often involved and the disease often proves fatal (Hengge et ah, 2002;
Talbot and Whitby, 1999).
3. Iatrogenic KS
Iatrogenic, or post-transplant, KS develops in solid organ transplant recipients as
a result of either primary infection with KSHV or reactivation of latent virus.
The course of the disease can be rapid but withdrawal of immuno-suppression
usually results in spontaneous remission. Recent work has shown that not only
the virus but also KS progenitor cells can originate from the organ donor
(Barozzi et ah, 2003).
4. AIDS-associated KS
The risk of KS is greatly increased in AIDS patients, estimated to be 20,000
times that of the general population and 300 times that of other
immunosuppressed individuals (Hengge et ah, 2002). Additionally the means of
HIV transmission seems to influence the likelihood of developing KS. The
incidence of KSHV in Africa as tested by seropositivity has not altered since the
onset of the AIDS pandemic; however, prior to AIDS, development of KS was
much more common in some geographical locations than others and in males
than females. Concurrent infection with HIV seems to abrogate these effects
suggesting that development of KS is dependent on co-factors, other than
immunodeficiency, which are overcome by HIV infection (Dedicoat and Newton,
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2003). The introduction of HAART (highly active anti-retroviral therapy) has
seen a huge decrease in incidence of AIDS-KS in the West, however, in the
developing world it remains a common disease.
Primary Effusion Lymphoma (PEL): PEL typically presents as malignant
effusions in the visceral cavities usually without significant tumour mass or
lymphodenopathy. Such lymphomas are mostly seen in HIV positive patients in the
advanced stages of AIDS, but they are occasionally seen in HIV negative
individuals. PEL was specifically associated with KSHV by PCR and Southern
blotting analysis; KSHV sequences were not identified in any other lymphomas
(Cesarman et ah, 1995). Analysis of the cells shows that they lack many lineage
markers; a B cell origin was indicated by clonal rearrangement of Ig genes. The
presence of CD 138, a molecule associated with the late stages of B cell
differentiation, and frequent mutations in the 5' non-coding region of BCL-6 define
PEL cells as pre-terminally differentiated, post-germinal centre stage B cells
(Gaidano et ah, 1999; reviewed in Boshoff and Weiss, 2001). PEL cells lack many
adhesion molecules present on other diffuse lymphomas which may contribute to
their phenotype (Boshoff et ah, 1998). The KSHV genome is present in PEL cells at
a very high copy number compared with KS (Boshoff and Weiss, 2001).
It has been possible to establish KSHV positive cell lines from PEL and from the
peripheral blood of PEL patients, the latter suggesting that malignant cells are not
confined to the malignant effusions (Boshoff et ah, 1998). These cell lines have
proved invaluable in the study of KSHV gene expression as they express KSHV
latent genes and can be induced into lytic replication.
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Multicentric Castleman's Disease (MCD): MCD is a lymphoproliferative disorder
associated with the development of secondary B cell lymphoma (reviewed in
Boshoff and Chang, 2001). KSHV can be identified in >95% of AlDS-associated
cases and in around 40% of cases in HIV-negative patients. KSHV-associated MCD
is distinguished from other forms of the disease by the presence of plasmablasts of B
cell lineage (Dupin and Calvez, 2000; Dupin et ah, 1999).
It is possible, but unusual, for an individual to develop more than one KSHV
associated tumour (Jones et ah, 1998).
KSHV genome
The KSHV genome (see figure 1.4) is approximately 165kbp in length and consists
of a long unique coding region of 140.5kbp flanked by variable numbers of 801bp
repeats (Russo et ah, 1996; Talbot and Whitby, 1999). Ninety ORFs have been
identified though whether some encode exons or complete genes remains to be
identified. Of these, sixty-six have homologues within HVS and the remainder,
thought to be unique to KSHV, are numbered with the prefix "K". Subsequent to
naming two of these, K8 and K13, have been found to have homologues in other
viruses. KSHV is unusual in that it encodes a large number of proteins with cellular
homologues which may contribute to the subversion of cellular pathways (Jenner and
Boshoff, 2002).
Having entered the nucleus, the KSHV genome, in common with other
herpesviruses, is transcribed in a controlled manner. Initial studies carried out on
PEL- derived cell lines identified three classes of viral transcript based on the
response to phorbol ester mediated induction of lytic replication (Sarid et ah, 1998).
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Class I genes comprise those transcripts that are constitutively transcribed under
standard conditions, induction of lytic replication has very little effect on their levels
and they are therefore considered to be true latent transcripts. Class II genes are
transcribed in the absence of lytic replication, however, following induction of lytic
replication using TPA, levels of these transcripts significantly increase. The final
class, class III, includes those genes that are only transcribed following TPA
treatment and contains mostly structural and replication proteins. Subsequently
KSHV transcription in PEL- derived cell lines has been studied using microarray
technology (Jenner et ah, 2001; Paulose-Murphy et ah, 2001). These studies confirm
the previous data and provide more detailed information about the timing and
coordination of gene expression. Clustering analysis allowed classification of the
lytic transcripts into three classes namely primary, expression peaks within 10 hours
post-induction; secondary, with a peak of expression between 10 and 24 hours; and
tertiary, which are expressed predominantly between 48 and 72 hours (Jenner et ah,
2001). It was observed that genes sharing similar functions were expressed at very
similar times post-induction. For example, genes involved in virus gene regulation
are all expressed similarly, as primary lytic genes, and genes encoding components
of the virion are expressed much later on. Subsequently the transcription of KSHV
genes in Kaposi's sarcoma lesions has been analysed by real-time quantitative RT
PCR (Dittmer, 2003). In all 21 KS biopsies examined, LANA, vCyclin and vFLIP
were found to be expressed indicating that they are latent transcripts in KS as well as
PEL. It was found that transcription of some latent genes was dependent upon the
nature of the KSHV-associated tumour i.e. K9/vIRF-l was only detected in KS
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Figure 1.4 Representation of the genomes of three g-herpesviruses, KSHV,




In vivo KSHV DNA and transcripts have been found in B cells, macrophage,
keratinocytes, endothelial and epithelial cells; in vitro KSHV has been shown to be
able to infect a number of different cell types including B cells, endothelial, epithelial
and fibroblast cells (Renne et ah, 1998; Blackboum et ah, 2000). The initial
interaction of KSHV with a host cell is mediated by the envelope glycoproteins gB
and gpK8.1A which recognise heparan sulphate-like molecules on the cell surface
(Akula et ah, 2001; Wang et ah, 2001; Birkmann et ah, 2001). Additionally gB has
been demonstrated to interact with cell surface alphalbeta3 integrin and expression
of this molecule in CHO cells increased the infectivity of the virus (Akula et ah,
2002). Interaction with integrin is dependent upon the RGD motif found within gB
and independent of binding to heparan sulphate. Association of the viral gB with
alphalbeta3 integrin activates focal adhesion kinase, this is the first step in a
signalling cascade which results in cytoskeletal rearrangement and cell adhesion and
thus, presumably, aids entry of the virus (Wang et ah, 2003; Akula et ah, 2002).
Investigations utilising inhibitors of clathrin-mediated endocytosis imply that this
may be the mechanism by which KSHV enters its target cells (Akula et ah, 2003).
During latency the KSHV genome is maintained as an episome within the nucleus
where it is tethered to chromosomes by the latently expressed protein LANA. In
asymptomatic individuals latency is maintained primarily in CD19+ B cells
(Ambroziak et ah, 1995). As KSHV- associated tumours affect other cell types,
however, the virus must also be able to establish latency in a wider range of host
cells e.g. cells of endothelial lineage found in KS lesions. Reactivation from latency
into the lytic replication cycle is initiated by the replication and transcription
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activator (RTA), the product of ORF 50. Expression ofRTA was shown to interfere
with the maintenance of latency in infected B cells (Lukac et ah, 1998) and to
upregulate the promoters of several KSHV (Lukac et ah, 1999; Lukac et ah, 2001)
and cellular (Roan et ah, 2002) genes. RTA has been demonstrated to bind directly
to the promoters of the KSHV genes ORF57 and K-bZIP (Lukac et ah, 2001) and to
interact with A/T trinucleotide motifs within the promoter region (Liao et ah, 2003a).
Production of ORF50 itself appears to be under epigenetic control. It has been noted
that activity of the ORF50 promoter is induced in response to demethylation (Chen et
ah, 2001) and expression of histone acetyltransferase (HAT) (Lu et ah, 2003) which
implies a role for chromatin remodelling of the promoter region in ORF50
transcription. RTA dependent gene expression is mediated through interactions of
RTA with cellular proteins responsible for chromatin remodelling (the Brgl subunit
of SWI/SNF and the TRAP230 subunit of TRAP/Mediator) via a short acidic region
within its C-terminus (Gwack et ah, 2003). Additionally the RTA protein has been
shown to interact directly with the product of ORF K8, a member of the basic
domain leucine zipper family, both in vitro and in vivo. This interaction apparently
serves to regulate the expression of K8 and other immediate early genes as the RTA-
K8 complex represses transcription from RTA response element-containing
promoters (Liao et ah, 2003b).
Latency associated genes
As is the case for other herpesviruses, KSHV gene transcription during latency is
very tightly regulated. Only two transcripts are truly type I, that is, induction of lytic
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Figure 1.5 Schematic representation of the right-hand end of the KSHV
genome showing the position and sizes of the latent transcripts. Adapted
from Talbot et al, 1999.
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Both transcripts are located at the right-hand end of the genome and are transcribed
from a common start point, see figure 1.5. In fact, the smaller 1,7kb transcript results
from splicing of the larger 5.32kb transcript (Talbot et al., 1999; Sarid et ah, 1998).
Northern blotting analysis indicated that the larger transcript encodes ORFs 71-73:
vFLIP; vCyclin and LANA, whilst the smaller transcript encodes vCyclin and vFLIP
only. A monocistronic transcript encoding vFLIP only has never been identified; it
has since been demonstrated that there is an internal ribosome entry site (IRES) at
the 3' end of the vCyclin coding sequence by which vFLIP may be translated
(Bieleski and Talbot, 2001; Low et ah, 2001b; Grundhoff and Ganern, 2001).
vFLIP: This protein was originally identified by database mining (Thome et al.,
1997). Flice inhibitory proteins (FLIP) have been identified in a number of viruses
and subsequently a cellular homologue has been discovered (Irmler et al., 1997).
The KSHV vFLIP has been demonstrated to display anti-apoptotic behaviour in vitro
(Djerbi et al., 1999) and to activate the NF-kB (Liu et al., 2002) and JNK/AP-1 (An
et al., 2003) pathways in vitro.
vCyclin: KSHV encodes a type D cyclin (Chang et al., 1996) with 32% amino acid
similarity to HVS vCyclin and 31% amino acid similarity to cellular cyclin D2 (Li et
al., 1997). The synthesis and degradation of cyclins is fundamental to progression
through the cell cycle; D-type cyclins are synthesised primarily during the G1 and S
phases of the cell cycle and activate cyclin dependent kinases (cdk's) to
phosphorylate target proteins including the tumour suppressor pRBl. KSHV
vCyclin has specificity for cdk-6 and the cyclin-cdk-6 complex is able to
phosphorylate pRBl and histone HI in vitro (Li et al., 1997; Godden-Kent et al.,
1997) and the cdk inhibitor p27/Kip (Ellis et al., 1999). Phosphorylation of histone
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H1 represents a change in substrate specificity of cdk6 in comparison to its activity
following association with cellular cyclinD. Phosphorylation of pRBl blocks its
activity (including the repression of transcription factors involved in DNA synthesis)
and drives transition of the cell cycle from G1 to S phase. Through its
phosphorylation of p27, which results in destruction of the inhibitor, vCyclin also has
a mechanism by which it can mediate escape from the normal controls of cdk
activity. Together, these activities imply that vCyclin acts to drive progression of the
cell cycle and it may, therefore, contribute towards cellular proliferation and
oncogenesis (Moore and Chang, 2001). Additionally, expression of vCyclin in cells
with a high level of cdk6 induces apoptosis independently of pRBl and p53 (Ojala et
al., 1999). KSHV vCyclin-driven apoptosis can be inhibited by the KSHV Bcl-2
homologue whereas the cellular Bcl-2 is ineffective (Ojala et ah, 1999). This
observation may be explained by the susceptibility of the two Bcl-2 proteins to
phosphorylation by vCyclin. The vCyclin-cdk6 complex can phosphorylate and thus
inactivate cellular Bcl-2 destroying its anti-apoptotic function. Investigation of a
PEL-derived cell line in which lytic replication was induced showed that apoptotic
cells contained phosphorylated cBcl-2 which was not detected in a KSHV-negative
cell line (Ojala et ah, 2000).
LANA: The product of ORF73 is an acidic nuclear protein which appears as a
~220kDa doublet following SDS-PAGE. Antibodies to LANA are used as the main
serological evidence for KSE1V infection and are found in almost all cases of KS
(Dupin et ah, 1999). LANA is a multi-functional protein with roles in the
maintenance of the viral genome and in subversion of cellular processes. In a role
analogous to that of EBV EBNA1, LANA tethers the KSHV episome to
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chromosomes thus enabling maintenance of the viral DNA and probably aiding
efficient segregation of the episome during cell division (Ballestas et al., 1999).
Through co-localisation studies the association of LANA with chromosomes was
seen to be maintained throughout interphase and mitosis (Ballestas et al., 1999).
LANA binds to two nucleotide motifs within the terminal repeat region of the KSHV
genome via a DNA-binding domain at its C-terminus (Garber et al., 2001; Ballestas
and Kaye, 2001). Association of the LANA-episome complex with cell
chromosomes involves two cellular proteins, MeCP2 and DEK. Following
identification by yeast-2-hybrid screening and immunoprecipitation MeCP2 and
DEK have been demonstrated to associate with the N and C terminus of LANA
respectively. Their expression in vitro enables LANA to localise to mouse
chromosomes (Krithivas et al., 2002). LANA is able to promote latent DNA
replication via interactions with an origin of replication found within the terminal
repeat sequence (Grundhoff and Ganem, 2003; Hu et al., 2002).
Analysis of the amino acid sequence of LANA revealed a putative Zinc finger DNA
binding domain, a leucine zipper and a nuclear localisation signal making it a
candidate for involvement in interactions influencing transcription. Subsequent
studies revealed that it activates transcription from promoters including IL-6 (An et
al., 2002), telomerase reverse transcriptase (Knight et al., 2001) and E2F regulated
promoters (Radkov et al., 2000), and can also act to repress transcription (Krithivas
et al., 2000; Garber et al., 2002). LANA's influence over transcriptional activity is
mediated, at least in part, by its ability to affect the activity of cellular transcription
factors. LANA binds to CBP, RING3, ATF/CREB2 and mSin3A all of which are
cellular proteins involved in transcription regulation reviewed in (Verma and
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Robertson, 2003). LANA is one of several potential oncogenes encoded by KSHV;
mechanisms by which it may contribute to tumourigenesis continue to be proposed.
It is known that LANA can interact with the tumour suppressors p53 and pRb. In co-
transfection experiments using p53 and a reporter gene under the control of p53
response elements it was demonstrated that LANA substantially inhibited p53-
dependent transcriptional activity (Friborg, Jr. et ah, 1999). Direct interaction
between p53 and LANA was demonstrated, as was LANA-mediated protection
against apoptosis induced by over-expression of p53. Having demonstrated that
LANA was able to act as a transcription co-factor for E2F-dependent transcription,
Radkov et al (Radkov et ah, 2000) aimed to identify which regulatory proteins were
involved. Immunoprecipitation experiments showed that LANA was able to interact
with pRb both in vivo and in vitro. Further evidence of LANA's potential role in
tumourigenesis comes from the observation that primary REF cells co-transformed
with LANA and the cellular oncogene HRAS formed foci of transformed cells
greater than those observed when transfected with HRAS alone (Radkov et ah,
2000). The most recently proposed mechanism by which KSHV may promote
tumourigenesis is through subversion of the Wnt-p-catenin pathway (Fujimuro et ah,
2003; Boshoff, 2003). High levels of p-catenin are observed in PEL and KS cells
and can be induced in Vero cells following the transfection of a LANA-encoding
plasnrid (Fujimuro et ah, 2003). p-catenin enters the nucleus, where it activates
genes involved in cell proliferation via association with cellular transcription factors
(Boshoff, 2003). A yeast-2-hybrid screen revealed that LANA is able to associate
with Glycogen Synthase Kinase-3p (GSK-3P), which is part of a complex required
for phosphorylation, subsequent ubiquitination, and degradation of P-catenin
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(Fujimuro et al., 2003). LANA appears to sequester GSK-3(3 and redistribute it to
the nucleus; this was also observed in a PEL-derived cell line. Co-transfection of
LANA with GSK-3P significantly reduced p-catenin turnover and resulted in an
accumulation of p-catenin within the cell (Fujimuro and Hayward, 2003). The
accumulation of p-catenin is observed in several cancers (Polakis, 2000) further
supporting the hypothesis that LANA-mediated down-regulation of GSK-3P activity
may contribute to viral transformation (Fujimuro and Hayward, 2003; Boshoff,
2003).
Immune evasion and tumourigenesis
Besides the latent genes, vFLIP, vCyclin and LANA, a number of other KSHV
proteins are potentially able to subvert the host immune response and/or contribute to
tumourigenesis. These include a Bcl-2 homologue (Sarid et al., 1997) and the
product of ORF K7 (Wang et al., 2002; Feng et al., 2002) both of which are anti-
apoptotic. Neither protein is significantly expressed in KS lesions or latently
infected cells, however, they may help to prevent apoptosis of cells harbouring lytic
virus thus aiding the spread and persistence of the infection. KSHV is able to
subvert the host interferon response through the product of ORF K9, viral Interferon
Regulatory Factor (vIRF) (reviewed in Moore and Chang, 2001). vIRF inhibits
interferon (IFN) activated signalling pathways within the cell through binding of
transcriptional co-adaptors. The result is a repression of transcription from the
majority of IFN-responsive promoters and an activation of promoters that are
normally repressed by IFN signalling e.g. c-myc. Consequently vIRF is able to drive
infected cells through the cell cycle and thus contribute toward cellular proliferation.
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KSHV ORF K2 encodes an interleukin 6 (IL-6) homologue with 25% identity and
62% similarity to cellular IL-6 (Moore et al., 1996). vIL-6 is expressed at very low
levels in KSHV positive tumours and PEL-derived cell lines. Following induction of
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lytic replication vIL-6 is abundantly expressed (Moore et al., 1996). KSHV vIL-6 is
implicated in tumourigenesis as an autocrine growth factor, inducing B cell
proliferation and preventing apoptosis (Burger et al., 1998; Moore et al., 1996), and
as an antagonist of IFN signalling, blocking IFN-mediated cell cycle arrest and
growth inhibition (Chatterjee et al., 2002). In contrast to cIL-6, vIL-6 requires only
one of the two receptor subunits, gpl30, for its activity (Wan et al., 1999). This
suggests that it may have a broader range of target cells than its cellular homologue.
Additionally, expression of IFNa down-regulates the gp80 component of the
receptor, which is required for cIL-6 binding, but has no effect on gpl30, allowing
vIL-6 to overcome this regulation (Chatterjee et al., 2002). Interestingly, it has
recently been shown that KSHV vFLIP is able to induce expression of cellular IL-6
(An et al., 2003) suggesting a possible mechanism by which growth signals can be
supplied to lesions in which the virus is latent. Another viral gene with host cell
origins is the G protein-coupled receptor homologue, vGPCR. The receptor has
homology to the cellular CXCR1 and CXCR2 receptors (Cesarman et al., 1996). In
contrast to its cellular counterparts, the KSHV protein is constitutively active once it
has been expressed and is bound by an unusually wide range of ligands (Arvanitakis
et al., 1997). The vGPCR is able to activate a number of signalling pathways within
the cell, these include activation of the transcription factors AP-1 and NF-kB, with
resultant induction of cytokines and chemokines (Schwarz and Murphy, 2001).
Signalling of the vGPCR in NIH 3T3 cells results in tumour formation, following
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injection into nude mice, and expression of vascular endothelial growth factor
(VEGF) which contributes toward angiogenesis (Arvanitakis et ah, 1997; Bais et ah,
1998). Despite being expressed in only a fraction of cells within a tumour, vGPCR
has been shown, in one mouse model, to be capable of inducing tumours with
resemblance to KS and to promote tumour formation by latently infected cells
(Montaner et ah, 2003). ORF Kl, at the far left hand side of the genome, can
transform fibroblast cells (Lee et ah, 1998b) and contains a functional
immunoreceptor tyrosine activation motif (ITAM) (Lee et ah, 1998a). The ITAM
domain has constitutive signalling activity and is able to transduce cellular signalling
pathways (Lee et ah, 1998a; Lagunoff et ah, 1999). A further strategy by which
KSHV acts to dampen the immune response is through down-regulation of MFIC
class I molecules from the surface of infected cells. Two lytic proteins, K3 and K5,
reduce the cell surface expression of MHC class I through promotion of endocytosis
(Coscoy and Ganem, 2000). It has been suggested that this mechanism of immune
evasion is also employed during latent infection as expression ofMHC class I is also
reduced on cells harbouring latent virus (Tomescu et ah, 2003). In addition to its
ability to down-regulate MHC class I expression, K5 is also able to inhibit natural
killer (NK) cell activity through down-regulation of the ligands for NK cell-mediated
cytotoxicity receptors, ICAM-1 and B7-2 (Ishido et ah, 2000).
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1.2.2.2 Murine Gammaherpesviruses: MHV-68 and MHV-76
isolation
During field studies in Slovakia five novel herpesviruses were isolated from murid
hosts; MHV-60, -68 and -72 from the bank vole (Clethrionomys glareolus) and
MHV-76 and -78 from the yellow-necked wood mouse (Apodemus flavicollis)
(Blaskovic et al., 1980). Subsequent analysis revealed that MHV-68 was a member
of the genus Rhadinovirus (Efstathiou et al., 1990b; Efstathiou et al., 1990a).
Genome
The MHV-68 genome consists of 118kbp of unique DNA which is flanked at either
end by variable numbers of 1,23kbp terminal repeat regions. It encodes 73 ORFs
and 8 tRNA-like molecules (Virgin et al., 1997; Nash et al., 2001). Investigation of
MHV-76 revealed its genome to be identical to that of MHV-68, with the exception
of a 9,538bp deletion at the left-hand end of the genome resulting in the loss of 4
MHV-68 specific ORFs, M1-M4, and the tRNA-like molecules (Macrae et al.,
2001). Both MHV-68 and -76 share large blocks of homology with other gamma
herpesviruses (see figure 1.4).
As is the case for other gamma herpesviruses, MHV-68 and -76 appear to have
carried out extensive piracy from their host's genome during their evolution; they




The natural route by which infection is spread is unknown, however, analogy with
other animal gamma herpesviruses suggests that it is likely to be via the respiratory
tract. Intranasal infection of 3-6 week old laboratory mice with MHV-68 results in a
productive infection in the epithelial cells of the lung accompanied by bronchiolitis
which is resolved by the second week following infection. The virus leaves the lung,
via the mediastinal lymph node, where dendritic cells, macrophage and B cells
become infected. These cells transport the vims to the draining lymph node where
they seed B cells. Following infection in the lymph node there is a rapid expansion
of latently infected B cells which traffic to the spleen and other lymphoid tissues.
Once in the spleen splenomegaly occurs due to a rapid increase in the number of
latently infected B cells present; this is resolved 3-4 weeks after initial infection.
Thereafter a constant number of latently infected spleen cells (approx. 5xl05) are
maintained throughout the life of an infected animal (Nash et ah, 2001). It has been
suggested that long term latency requires the CD40 dependent development of
memory B cells (Kim et ah, 2003). Whilst splenic B cells constitute the major
reservoir of MHV-68 latency, the vims has also been reported to persist in splenic
macrophage and dendritic cells (Flano et ah, 2003) and in lung epithelial cells
(Stewart et ah, 1998).
Long term infection of BALB/c mice (>9 months) with MHV-68 results in the
development of lymphoma in approximately 10% of animals (Sunil-Chandra et ah,
1994). The frequency of tumour development increased to >50% following
treatment with immunosuppressive agents.
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As MHV-76 was isolated from a different murid species investigations were carried
out to determine whether it had any different characteristics to MHV-68 (Macrae et
ah, 2001). Comparison of the in vitro growth characteristics of MHV-68 and -76
showed no significant difference in their replication. In vivo analysis, however, has
shown that MHV-76 has a more attenuated pathology than MHV-68. Levels of
infectious MHV-76 in the lung peak earlier and at a lower titre than does MHV-68
indicating more rapid clearance from the site of primary infection. The initial
inflammatory response to MHV-76 in the lung is more severe than that caused as a
response to MHV-68 infection although by day 8 post infection the response to both
viruses is similar. In contrast to MHV-68, MHV-76 induces significantly less
splenomegaly and establishes much lower levels of latency in the spleen although the
virus is found in the same cell subsets as MHV-68. Both viruses maintain long term
persistence in the spleen but, in contrast to MHV-68, MHV-76 does not appear to
persist efficiently in the lung. The differences between the two viruses suggest roles
for the genes M1-M4 and 8 tRNAs in pathogenecity though they appear not to be
necessary for lytic replication or the establishment of latency.
Use as a model
The study of gamma herpesviruses, particularly KSHV and EBV, is limited by the
lack of cell lines that support permissive replication in vitro. The fact that MHV-68
and -76 will readily infect fibroblast and epithelial cell lines from a number of
species makes them an ideal system for the study of gamma herpesvirus replication
(Simas and Efstathiou, 1998). Additionally, MHV-68 will establish lytic and latent
infection in laboratory mice (Sunil-Chandra et ah, 1992) making it an ideal system in
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which to study pathogenesis and virus-host interactions. Finally, it is possible to
study the function of individual viral genes because it is possible to manipulate the
viral genome permitting the creation of knock-out or knock-in viruses.
Latency associated genes
During latency viral gene expression is very tightly regulated. Transcription of viral
genes in a latently infected cell line SI 1, derived from a B cell lymphoma in a MHV-
68 infected mouse, was investigated by microarray (Martinez-Guzman et ah, 2003).
The data confirmed previous reports that M2, Mil, ORF73 and ORF74 were
transcribed during latency (Virgin et ah, 1999) and additionally identified ORFs 75a,
75b and 75c as candidate latency-associated genes. A brief description of each
follows;
M2: The M2 gene is located in the unique left hand region of MFIV-68. It encodes
a 30kDa protein the expression of which appears to be restricted to splenic B-cells.
Analysis of MFIV-68 in which M2 translation was prematurely terminated showed
that the increase in splenic infective centres following infection was inhibited
(Macrae et ah, 2003).
Mil: Mil encodes a viral Bcl-2 homologue that has been shown to inhibit both
CD95 and TNF induced apoptosis (Roy et ah, 2000; Wang et ah, 1999). Use of
mutant MHV-68 in which Ml 1 is not translated has shown that Ml 1 is not necessary
for lytic replication or the establishment of latency; however, it is needed for
efficient reactivation of latent virus (Gangappa et ah, 2002). The authors speculate
that M11 protects cells in which viral replication is occurring from apoptosis induced
by either viral or cellular products (Gangappa et ah, 2002).
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ORF73: MHV-68 ORF73 encodes a homologue of KSHV LANA. It was found to
be the most abundantly expressed viral transcript in latently infected Sll cells
(Martinez-Guzman et al., 2003). In vivo analysis, using a mutant MHV-68 in which
ORF73 is not translated, shows a role for ORF73 in the establishment of splenic
latency (Moorman et al., 2003); this result is supported by studies utilising an ORF73
knockout virus (Fowler et al., 2003). This would be consistent with a proposed role
for LANA in the replication of the latent viral episome indicated by studies on the
KSHV and HVS homologues.
ORF74: MHV-68 ORF74 encodes a G protein-coupled receptor homologue of the
cellular CXCR2 chemokine receptor (Virgin et al., 1997). Homologues are also
present in other herpesviruses including all rhadinoviruses that have been sequenced.
ORF74 transcripts were detected, by RT-PCR, in the spleen and lung of persistently
infected mice (Wakeling et al., 2001). The MHV-68 GPCR was shown to have
transforming activity (Wakeling et al., 2001) and to mediate chemokine-dependent
enhancement of viral replication (Lee et al., 2003) in vitro. Furthermore, a mutant
MHV-68 unable to express ORF74, showed significantly less ability to reactivate
from latently infected murine lymphocytes in vitro (Lee et al., 2003).
K3: Latency associated expression of K3 was not detected by microarray analysis of
SI 1 cells (Martinez-Guzman et al., 2003). K3 was, however, identified as a latency
transcript by RNase protection assay on material from infected spleens (Rochford et
al., 2001). The K3 protein has been shown to down regulate MHC I on mice and
hamster cells (Stevenson et al., 2000). In comparison to wild type virus, MHV-68 in
which K3 is disrupted shows no differences in lytic replication in the lung or entry
into latency. It appears that K3 acts to prevent CTL recognition of infected cells as
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the normal expansion of latently infected B cells was inhibited; this phenotype was
reversed following depletion of the CD8+ T cells (Stevenson et al., 2002). Proteins
homologous to K3 are found in some other rhadinoviruses including KSHV and
HVS.
ORF75: ORF75 is a tegument protein of unknown function.
1.2.2.3 Herpesvirus Saimiri
Herpesvirus Saimiri (HVS) is the prototype rhadinovirus having significant
homology to KSHV and MHV-68 as well as to the lymphocryptovirus EBV (figure
1.4). Its natural host is the squirrel monkey (Saimiri sciureus) which is native to
South American rainforests. In its host HVS establishes an asymptomatic infection;
however, within two months of injection into other new world primates it induces
acute peripheral T- cell lymphoma (Fickenscher and Fleckenstein, 2001).
The HVS genome is approximately 140kbp in size and contains up to 77 ORFs
(Albrecht et ah, 1992). Different strains tend to show considerable variation only in
their left-hand region; it is this variation upon which classification is based
(Medveczky et ah, 1984). Depending on their sequence and pathogenic properties
HVS strains are subdivided into three groups, A, B and C. Of these, subgroup C
strains are the most oncogenic; strain C488 causes a T-cell lymphoma in cynomolgus
monkeys with a histopathology very similar to EBV-induced PTLD (Knappe et ah,
2000) and they are able to transform human T-cell lines in vitro (Biesinger et ah,
1992). The transforming activity of HVS has been attributed to sequences within
this variable left-hand end of the genome. Subgroup C strains encode two genes with
limited homology to cellular genes, StpC (a form of the STP oncogene) and Tip
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(tyrosine kinase interacting protein), which are required for T-cell transformation and
pathogenecity (Duboise et ah, 1998). Subgroup A strains have a single gene at the
homologous position; StpA has limited homology to StpC and is required for
transformation.
In common with other gammaherpesviruses HVS has acquired several cell-
homologous genes, the majority of which are expressed during lytic replication.
They include genes involved in nucleotide metabolism, cell cycle regulation,
complement system regulation, apoptosis inhibition and the cytokine network
(Fickenscher and Fleckenstein, 2001). Additionally HVS, like KSHV, encodes a
latently expressed polycistronic mRNA encompassing ORFs 71-73 (which are
homologous to their KSHV counterparts) (Hall et ah, 2000).
1.3 Apoptosis
The phenomenon of cell death has been documented for over a century; the first
description, noting the disappearance of some cells during normal toad development,
was made in 1842 (reviewed in Hacker, 2000). The term apoptosis was proposed by
Kerr, Wyllie and Currie in 1972 to describe "a hitherto little recognised mechanism
of controlled cell deletion, which appears to play a complementary but opposite role
to mitosis in the control of animal cell populations" (Kerr et ah, 1972). Originally
described in morphological terms it is now appreciated that that the changes
observed result from the activation of an intracellular signal transduction pathway. It
is probable that the sole function of the pathway is to bring about cell death and
subsequent disposal of the cell body.
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1.3.1 The morphology of apoptosis
In most situations cells dying by apoptosis display very similar morphology,
independent of the mechanism by which apoptosis was instigated. Exceptions do
occur, however, including differing "degrees" of morphology in the same cell line, in
vitro, depending upon the agent used to induce cell death. Differences may be
explained by the limited opportunity for observation in vivo, artificial apoptotic
inducers affecting more than just the apoptotic pathways or differing protein
expression within a cell at the time of apoptosis induction (Hacker, 2000).
Morphological events occurring as a result of apoptosis are often categorised into
events necessary for death of the cell and those that are dispensable "post-mortem"
events. Post-mortem events include nuclear changes which, although very useful in
the identification of apoptotic cells, are not required for cell death to occur. It is
difficult to study morphology in vivo because apoptotic cells are swiftly engulfed by
their neighbours. Consequently the majority of studies have been carried out using
in vitro systems identifying changes using specific dyes or microscopy. Briefly,
early events include the severing of attachments to other cells and the extracellular
matrix, rounding up of cells and the appearance of protrusions from the plasma
membrane. Subsequently nuclear chromatin begins to condense along the perimeter
of the nucleus. This is followed by complete nuclear condensation and
fragmentation, dilation of the endoplasmic reticulum and formation of cytoplasmic
vacuoles. Finally, the entire cell condenses and is re-organised into apoptotic bodies,
a term coined by Kerr et a! in 1972, to describe membrane bound vesicles of
differing size and composition which contain the entire contents of the cell. These
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apoptotic bodies are taken up by other cells and digested via the lysosomal pathway.
These morphological events occur in the same sequence in all cases and take
between thirty minutes and an hour to complete (reviewed in Hacker, 2000).
1.3.2 Caspases
Apoptosis is an active form of cell death which is executed by specialised cellular
machinery. The morphological changes seen are the direct result of the action of a
family of cysteine proteases, the caspases.
Studies on C.elegans led to the recognition that the pathway to developmental cell
death in the nematode was regulated by the same principles as apoptotic cell death in
mammalian cells. A homologue of Ced-3, a product required for nematode cell
death, was cloned in mammals and identified as interleukin-l(3-converting enzyme,
or caspase 1 (Yuan et ah, 1993). This was the first ofmore than a dozen mammalian
caspases, all of which are similar in terms of sequence, structure and substrates, to be
identified (reviewed in Nicholson and Thornberry, 1997). Caspases function both to
disassemble the cell and also further upstream in the initiation of disassembly in
response to pro-apoptotic signals.
Caspases are all expressed as pro-enzymes containing three separate domains; an
NH2 terminal domain, a large (~20kD) and a small (~10kD) subunit. The caspase
becomes activated via proteolytic processing between the domains which is followed
by association of the large and small subunits to form a heterodimer. Two
heterodimers then associate, forming a tetramer, which has two independent active
sites containing catalytic residues from both subunits (Walker et ah, 1994). Caspases
are very specific proteases with an absolute requirement for cleavage after an
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aspartic acid, consistent with the fact that proteolytic cleavage during apoptosis is not
indiscriminate but is coordinated (Thornberry and Lazebnik, 1998).
1.3.3 Apoptotic pathways
In mammalian cells there are two major pathways by which apoptosis can be
triggered; through death receptors, in response to external stimuli, or via the
mitochondria, in response to external signals and intracellular damage.
Death receptors are members of the tumour necrosis factor receptor (TNF-R) gene
superfamily. They are present on the cell surface and contain a cytoplasmic "death
domain" which enables the receptor to engage the cell's apoptotic machinery
(Tartaglia et al., 1993). The receptors are activated by their natural ligands, which
are type II transmembrane proteins (of the TNF family) of which a soluble form can
be generated by proteolysis (reviewed in Smith et al., 1994). The best characterised
death receptor is CD95 (also called Fas or Apol). Amongst other roles CD95
signalling is important in the killing of virus-infected or cancer cells by cytotoxic T
cells and natural killer cells (Sayers et al., 1998). Cross-linking of CD95, following
association with its natural ligand, or anti-CD95 antibody, results in receptor
oligomerisation, probably trimerisation. The death domains of the receptors are
consequently brought together into a conformation which allows association with the
adaptor molecule Fas- associated death domain (FADD). As well as a death domain,
through which it interacts with CD95, FADD also contains a death effector domain
(DED) which binds to a homologous region of the pro-caspase 8. This complex of
proteins is termed the death-inducing signalling complex (DISC). The resulting high
concentration of pro-caspase 8 at the DISC allows the low intrinsic protease activity
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of pro-caspase 8 to autocatalytically cleave, and activate, itself and subsequently
downstream effector caspases (figure 1.6) (Muzio et al., 1998).
A large number of apoptotic signals, both extra- and intracellular, converge at the
mitochondria where, in a process regulated by members of the Bcl-2 family, they
result in changes to the permeability of the mitochondrial membranes. Pro-apoptotic
signalling leads to an increase in mitochondrial membrane permeability and the
subsequent release of soluble inter-membrane proteins, including cytochrome c and
Smac/DIABLO, into the cytosol. As a consequence pro-caspase-3 is cleaved and
activated (reviewed in Hengartner, 2000).
The death receptor and mitochondrial pathways converge at caspase-3 and
downstream apoptotic events are independent of the pathway by which they were
initiated. In some cells, termed type I, large amounts of caspase 8 are activated at the
DISC resulting in rapid downstream caspase activation. In other, type II, cells the
amount of caspase 8 activated at the DISC is much reduced; the apoptotic signal is
amplified by the mitochondria which are activated by caspase 8 cleavage of a Bcl-2
family member, Bid. In type I cells mitochondrial activation is not necessary for cell
death and anti-apoptotic Bcl-2 proteins cannot inhibit apoptosis. In type II cells the
apoptotic signal initiated at the death receptor can be inhibited by proteins acting at
the mitochondria (Krammer, 2000).
1.3.4 Viruses and apoptosis
Upon viral infection many cells undergo apoptosis so as to prevent viral replication
and release of progeny. In response, many viruses have acquired mechanisms by
which they can subvert the apoptotic process. Viral modulation of apoptosis was
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first studied in adenoviruses; strains lacking a functional E1B 19kDa gene led to a
greatly enhanced cytopathic effect following infection (Ezoe et al., 1981) and the
ElA oncogene dependent transformation was dependent upon co-expression of E1B
19kDa. Analysis of E1B 19kDa showed it to contain a region of sequence homology
to the Bcl-2 protein which was essential for its anti-apoptotic function (Chiou et al.,
1994). Subsequently Bcl-2 homologues have been detected in other virus families
including the herpesviruses. EBV encodes BHRF1 which has limited homology to
cellular Bcl-2 and is able to enhance the survival of latently infected B cells when
they are challenged with apoptotic stimuli (Elenderson et al., 1993a) and a second
Bcl-2 homologue that interacts with cellular family members, Bax and Bak, to inhibit
apoptosis (Marshall et al., 1999). Both E1VS and KSHV also encode Bcl-2
homologues; the KSHV vBcl-2 is lytically expressed and, like BHRF1, is thought to
aid the release of progeny virus (Sarid et al., 1998 ).
Several viruses also target p53, an essential tumour suppressor gene that induces cell
cycle arrest or apoptosis in response to a number of stimuli (reviewed in Fridman and
Lowe, 2003). Small DNA tumour viruses, such as adenovirus and SV40, activate
genes necessary for cell cycle progression by releasing the E2F transcription factors;
however, this also results in p53 activation so these viruses also encode products that
disrupt p53 activity. An example is the SV40 large T antigen which sequesters p53
(Yanai and Obinata, 1994). KSHV LANA has also been demonstrated to interact
with p53 and reduce its transcriptional and cell death inducing activity (Friborg, Jr. et
al., 1999).
As previously mentioned, the inhibition ofmitochondrially initiated apoptosis cannot
prevent cell death in type I cells. To overcome this problem some viruses have yet
52
another mechanism by which they can subvert apoptosis; disruption of the DISC by
viral FLICE inhibitory proteins or vFLIPs (see section 1.4). These proteins prevent
association of FADD with pro-caspase 8 and have been shown to confer resistance to
CD95- mediated apoptosis and apoptosis initiated from some other death receptors
(Irmler et ah, 1997; Thome et ah, 1997). All viruses encoding a vFLIP protein are
associated with tumour formation e.g. HVS, EHV2 and KSHV. In addition, they all
encode Bcl-2 homologues and therefore can potentially inhibit apoptosis in type I
and type II cells. Pro-apoptotic CD95 signalling is manipulated in different ways by
other viruses; mechanisms include the internalisation and degradation of the receptor
by adenoviruses (Elsing and Burgert, 1998) and interactions between components of
the CD95 signalling pathway and HIV gene products (Geleziunas et ah, 2001).
1.4 FLICE inhibitory proteins
1.4.1 The discovery of vFLIPs
Using the knowledge that deletion mutants of FADD or caspase 8 (FLICE) lacking
the DED domain, could inhibit death receptor mediated apoptosis, protein databases
were screened using a generalised profile of DEDs for potential inhibitors of
apoptosis. This approach led to the initial identification of the EHV-2 E8 and MCV
MCI 59 proteins, both of which contained two DED motifs, and subsequently similar
proteins were found in the genomes of BHV-4, HVS and KSHV (Thome et ah, 1997;
Hu et ah, 1997; Bertin et ah, 1997). They were named, amongst other things, vFLIPs
(viral FLICE inhibitory proteins) (Thome et ah, 1997) and this is how they are now
most commonly referred to. The homology of the viral DED domains with those of
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caspase-8 and FADD led to the hypothesis that vFLIPs may bind to the adaptor
molecule FADD and somehow interfere with death receptor signalling at the level of
FADD-caspase 8 association. The proposed interaction between EHV-2 vFLIP and
FADD was confirmed by co-immunoprecipitation experiments which also indicated
that the CD95-FADD interaction could still occur in the presence of vFLIP (Thome
et al., 1997). It was also demonstrated that expression of EF1V-2 vFLIP inhibited
recruitment and activation of caspase-8 and conferred considerably decreased
susceptibility to CD95 mediated apoptosis in a B cell line; apoptosis induced by
alternative means was unaffected (Thome et al., 1997).
1.4.2 Identification of cFLIPs
Soon after the discovery of viral FLIP proteins a cellular homologue was identified
by several groups and named cFLIP (Irmler et al., 1997). cFLIP was identified
through database searching using a consensus FLIP sequence, derived from the viral
proteins previously identified, and subsequent screening of a cDNA library with the
corresponding EST. There have been two variants of cFLIP protein identified to date
(cFLIPs and cFLIPl); both contain two DEDs and the longer version (cFLIPl)
additionally contains an inactive caspase like domain (Irmler et al., 1997). An anti-
apoptotic role for both forms of cFLIP was indicated by experiments in which stably
transfected BJAB cell lines expressing high levels of cFLIP protein were challenged
with CD95L and found to be resistant to apoptosis (Krueger et al., 2001). The
mechanisms by which cFLIP functions have not, as yet, been elucidated, however, it
has been demonstrated that both forms of cFLIP are recruited to the DISC (Scaffidi
et al., 1999) where they may prevent autocatalytic activation and processing of
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caspase 8. The role of cFLIPs as an apoptosis inhibitor is now well established,
however, there is more controversy surrounding cFLIPl. It has been demonstrated
that the long form, cFLIPl, can act in a pro-apoptotic manner (Chang et ah, 2002).
cFLIPl" knockout mice expressed a phenotype very similar to caspase 8 or FADD
knockouts (Yeh et ah, 2000). The pro-apoptotic function is dependent on the
protease domain which heterodimerises with caspase 8, at the DISC, raising
concentrations of caspase 8 and resulting in its auto-catalytic activation. At higher
levels of expression cFLIPl was found to inhibit apoptosis, as demonstrated by
Krueger et al, (Chang et ah, 2002). It now appears that cFLIPl is a regulator of
apoptosis and that whether it acts in a stimulatory or inhibitory manner is dependent
upon the levels of its expression. cFLIP expression has been implicated in immune
escape and resistance to apoptosis in a number of tumours (in which cFLIPl levels
are probably enhanced) (Medema et ah, 1999; Okano et ah, 2003; Ryu et ah, 2001).
Additionally, up-regulation of cFLIP has been suggested as a possible mechanism of
EBV tumourigenesis (Tepper and Seldin, 1999).
1.4.3 KSHV vFLIP
KSHV vFLIP is expressed during latency
As previously described, analysis of KSHV gene transcription in PEL cell lines
showed that vFLIP (ORF 71) is latently expressed. It is transcribed from the same
promoter as vCyclin and LANA (ORFs 72 and 73) as a ~6kB polycistronic transcript
which is subsequently cleaved to produce a ~2kB transcript encoding vFLIP and
vCyclin (figure 1.5). Induction of lytic replication using TPA does not cause an
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increase in total levels of the transcripts. A vFLIP only transcript has never been
seen (Sarid et al., 1999; Talbot et al., 1999).
In situ hybridisation studies have suggested that vFLIP expression increases from
early to late stage KS lesions and that this is accompanied by a drop in the number of
apoptotic cells within the lesion (Sturzl et ah, 1999). Flowever, this study quantified
vFLIP transcripts and does not indicate whether an increased rate of transcription is
accompanied by increased levels of translation.
Translation of KSHV vFLIP
The failure to detect a monocistronic vFLIP transcript led to investigation of the
mechanism by which vFLIP was translated and identification of an internal ribosome
entry site (IRES) at the 3' end of ORF72 (Bieleski and Talbot, 2001; Low et ah,
2001b; Grundhoff and Ganem, 2001). A 233bp sequence (nucleotides 123206 to
122973; GeneBank accession number U75698) was able to direct translation of
downstream sequences in KSHV positive, but not negative, cell lines perhaps
reflecting a requirement for virally expressed, or induced, interacting factors
(Bieleski and Talbot, 2001).
Roles of KSHV vFLIP
1) Resistance to death receptor mediated apoptosis
Transduction of the B lymphoma cell line, A20, with a retroviral vector expressing
KSHV vFLIP, and subsequent challenge with CD95L, demonstrated that KSHV
vFLIP was able to confer resistance to CD95 mediated apoptosis. The cleavage of
fluorescent caspase -8, -3 and -9 substrates was almost completely blocked in vFLIP
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expressing cells indicating that the anti-apoptotic activity of vFLIP is due to its
prevention of caspase activation (Djerbi et ah, 1999). Expression of KSHV vFLIP
permitted the clonal outgrowth of A20 cells which were continually exposed to death
receptor stimuli and was, therefore, implicated in tumour establishment and
progression in vivo (Djerbi et ah, 1999). vFLIP is expected to act as cFLIPs and
inhibit the autocatalytic processing of pro-caspase 8 at the DISC (Belanger et ah,
2001; figure 1.6).
2) Activation of cellular transcription
In addition to its anti-apoptotic role KSHV vFLIP has recently been shown to be able
to activate the transcription factor NF-kB. NF-kB binding sites have been identified
in more than 150 cellular genes; initially described as a central regulator of the innate
and adaptive immune response, it has since been demonstrated to be important in the
control of cell proliferation and survival (reviewed in Santoro et ah, 2003). NF-kB is
activated in response to a large number of stimuli via multiple signalling pathways.
Most pathways converge on the IKK signalsome complex, a multi-subunit complex
with kinase activity that phosphorylates, and thus causes the degradation of, proteins
that normally keep NF-kB sequestered in the cytoplasm and inactive. KSHV vFLIP
has been demonstrated to bind to the IKK signalsome complex, via the regulatory
subunit IKKy (Field et ah, 2003). When all IKK subunits are present vFLIP-
mediated NF-kB activation can occur (Matta et ah, 2003).
Transient expression of vFLIP in vitro has been shown to induce NF-kB activation
(Liu et ah, 2002) and provide protection against growth factor withdrawal-induced
apoptosis, through NF-kB activation; a possible mechanism through which vFLIP















Figure 1.6 Schematic representation of CD95-mediated induction of
apoptosis and the predicted anti-apoptotic activity of KSHV vFLIP.
Trimerisation of CD95 following binding of its ligand results in association of
the adaptor protein FADD with the C-terminus of the receptor via interaction
between there homologous death domains (DD). FADD also contains a
death effector domain (DED) through which it associates with pro-caspase 8.
The resulting high local concentration of pro-caspase 8 enables auto-catalytic
cleavage, and thus activation, to take place thereby beginning the caspase
cascade that ultimately results in apoptosis. KSHV vFLIP is believed to
prevent incorporation of sufficient quantities of pro-caspase 8 into the death
inducing signalling complex (DISC), preventing its auto-catalytic activation.
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In contrast to the EHV-2 and MCV vFLIPs, KSHV vFLIP is able to transform cells
in vitro and promote tumour development in vivo. Rat-1 cells stably expressing
KSF1V vFLIP showed greater proliferation, loss of contact inhibition and anchorage-
independent growth, additionally their injection into nude mice gave rise to tumours.
This in vitro phenotype was accompanied by an increase in NF-kB activity and
could be reversed by application ofNF-kB inhibitors (Sun et ah, 2003b). Moreover,
the constitutive expression of activated NF-kB is essential for the survival of PEL
cells (Keller et ah, 2000) and this expression has been attributed to vFLIP (Guasparri
et ah, 2004). Besides anti-apoptotic factors and growth factors, it is possible that
NF-kB activation is needed to promote the expression of viral and/ or cellular genes
necessary for the production of infectious virions (Sgarbanti et ah, 2004). It was
demonstrated that virions produced from BCBL-1 cells which stably expressed a
repressor of NF-kB activation were unable to initiate de novo infection of an
endothelial cell line. Interestingly, the ability to activate NF-kB signalling appears to
be a common feature of gamma-herpesviruses; the Tip and Stp proteins of HVS and
LMP-1 of EBV activate NF-kB via both the canonical and non-canonical pathways
(Atkinson et ah, 2003; Herrero et ah, 1995; Merlo and Tsygankov, 2001; Sorokina et
ah, 2004).
In addition to activation of NF-kB, KSHV vFLIP has been shown to activate a
second signalling pathway, the JNK/AP1 pathway, resulting in activation of the cIL-
6 promoter (which is also activated by NF-kB). All KSHV neoplasms employ IL-6
as a growth factor so this may be another mechanism by which vFLIP contributes
towards the transforming capacity of the virus (An et ah, 2003).
59
1.5 Internal Ribosome Entry Sites
In both prokaryotes and eukaryotes the translation of an mRNA, to produce protein,
proceeds through three phases; initiation, elongation and termination. Translation is
dependent upon aminoacyl-tRNAs, single-stranded RNA molecules of about 80
nucleotides with a specific three-dimensional structure and covalently attached
amino acid. Base pair interactions, between the anticodon of the tRNA and the
codon of the mRNA, enable transfer of the genetic data into protein. The processes,
through which tRNAs are aligned on the mRNA and peptide bonds are formed
between amino acids are mediated by ribosomes, large RNA-protein complexes
consisting of a large and a small subunit.
In all cases the first codon translated is AUG, which encodes methionine.
Throughout a messenger RNA there will typically be several AUG codons, however,
only one of these will normally be utilised as a start codon. During eukaryotic post-
transcriptional modification of the mRNA, in the nucleus, a 7-methylguanosine cap
structure is added to the 5' end and a poly-adenosine tail to the 3'end. The 5'cap is
essential for translation initiation as it allows the ribosome to locate the correct AUG
codon to commence synthesis. The small ribosomal subunit recognises the cap
structure, by means of a complex of proteins, and then proceeds to scan along the
mRNA until it reaches an AUG codon from where translation commences. It is
usually the first AUG encountered that is used as the start codon, however, the
nucleotides surrounding the AUG influence the efficiency of recognition. If
recognition is poor the small subunit will move on until it reaches a suitable AUG
codon. This "leaky scanning" can be used to produce two or more proteins from the
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same mRNA. The initiation process is complicated, involving several steps
catalysed by initiation factors (elF) (Alberts et al., 1994).
1.5.1 5'cap-dependent initiation of translation in eukaryotic cells
Cap-dependent translation is a complex process, see figure 1.7. Initiation requires
assembly of a multi-protein translation initiation complex on the mRNA. The 5'cap,
a methylated guanine, is recognised by the eIF4F complex. The eIF4F complex
consists of elF4G, which acts as a scaffold; eIF4E, which binds to the cap and
eIF4G, and eIF4A, an ATP-dependent RNA helicase which is also associated with
eIF4G. This complex binds to the 5'end of the mRNA and removes any secondary
structure present. The small ribosomal subunit, associated with eIF2-GTP-met tRNA
and eIF3, is then brought to the complex through interactions of eIF3 with the
ribosomal subunit and eIF4G. Additionally the mRNA is circularised as the polyA-
binding protein (PABP) binds the 3'polyA tail and eIF4G simultaneously. Following
phosphorylation of eIF4E, by protein kinases associated with the C-terminus of
eIF4G, the complex scans the mRNA until it identifies the start AUG codon. The
large ribosomal subunit then joins with the small subunit allowing translation to






Figure 1.7: The eukaryotic translation initiation complex. The complex
assembles on the mRNA following recognition of the 5'cap structure by elF4E.
Subsequent protein-protein interactions result in circularisation of the mRNA
and recruitment of the small ribosomal subunit (40S). This complex scans the
mRNA until a suitable start codon is located at which point the large ribosomal
subunit joins and translation commences.
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1.5.2 Identification of internal ribosome entry sites
Whilst 5'cap dependent scanning is the most common mechanism by which
eukaryotic ribosomes locate the AUG start codon, translation can also be initiated in
a cap-independent manner. This process utilises a different method of recruitment of
the small ribosomal subunit to the mRNA, mediated by Internal Ribosome Entry
Sites (IRES).
Since the 1970s it has been recognised that the rate of protein synthesis within a
eukaryotic cell is cell-cycle dependent. Cells arrested at the G2/M phase, or that are
undergoing mitosis carry out translation at only 25% the rate of interphase (Gl, S,
G2) cells. This down-regulation is partly due to inhibition of the translation
initiation step as a consequence of reduced cap binding (reviewed in Sachs, 2000).
Despite this general reduction in protein synthesis the production of some viral and
cellular proteins is unaffected indicating an alternative, cap independent, mechanism
of translation initiation. The internal entry of ribosomes was discovered through
investigation of picornaviral mRNAs which, despite being uncapped and containing
complex features at their 5' end which would be expected to impede ribosome
scanning, efficiently recruit the ribosome (Pelletier et ah, 1988; Jang et ah, 1988;
Jackson, 1988). Internal ribosome entry sites (IRES) have subsequently been
identified in many viral RNAs and an increasing number of cellular mRNAs. The
principle assay used to define a section of RNA as an IRES is a bicistronic reporter
system. In these assays the levels of expression of a reporter gene translated via
conventional 5' cap dependent translation is compared to that of a reporter gene
under the control of the suspected IRES. Under conditions refractory for cap-
dependent translation the IRES-dependent reporter gene should continue to be
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translated (Vagner et al., 2001). The nature of the RNA transcript must also be
investigated as the possibility that translation results from aberrant splicing events
producing monocistronic transcripts in transfected cells must be ruled out.
The majority of IRES elements require protein co-factors for their activity, these
proteins are termed IRES transactivating factors (ITAFs).
1.5.3 Viral IRESs
IRES elements were first identified in picornaviruses in 1988 (Jang et al., 1988;
Jackson, 1988; Pelletier et al., 1988) and since then internal initiation of translation
has been demonstrated in a number of different RNA viruses including members of
the pestivirus, hepacivirus and retrovirus families and in some gamma-herpesviruses,
which have DNA genomes. Some examples of viral IRESs include;
Picornaviruses: It was initially observed that infection of cultured cells with
poliovirus results in a general shut down of cellular protein synthesis whilst viral
proteins continue to be translated (Holland and Peterson, 1964; reviewed in Bushell
and Sarnow, 2002). It subsequently became clear that this is true of the majority of
picomaviral infections which result in cleavage of the translation initiation factor
eIF4G, resulting in inhibition of cap-dependent translation. Investigation of the
mechanism by which viral proteins could continue to be translated despite eIF4G
cleavage resulted in identification of IRES elements (Pelletier and Sonenberg, 1988)
Picornavirus IRESs are categorised into three types according to their sequence and
structure. Enteroviruses and rhinoviruses have type I structures; aphthoviruses,
cardioviruses and parechoviruses are type II; the hepatitis C virus IRES is distinct
from the other picornaviral IRES elements. The different IRES groups differ in their
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ITAF requirements and therefore influence viral host range; mutations in the IRES
sequence can affect the virulence of the virus (Shiroki et ah, 1997).
Cricket Paralysis Virus: An unusual IRES has been discovered in the family of
cricket paralysis virus (CrPV)-like viruses (Wilson et ah, 2000b) which, in at least
two members of the family, has been shown to initiate translation at a non-
methionine codon (Sasaki and Nakashima, 1999; Wilson et ah, 2000a) and to
function independently of any initiation factors (Wilson et ah, 2000a). The CrPV are
positive strand RNA viruses similar to mammalian picornaviruses. They encode two
open reading frames both of which are translated by internal ribosome entry (Wilson
et ah, 2000a).
Flaviviruses: The HCV IRES was first identified in 1993 (Wang et ah, 1993). The
minimal functional IRES is approximately 330bp long and is highly conserved. The
IRES binds directly to the 40S ribosomal subunit and eIF3 independently of any
other translation initiation factors (Pestova et ah, 1998) and through these
interactions other factors such as eIF2 and initiator tRNA are recruited (Kieft et ah,
2001). An IRES sequence has also been identified in classical swine fever virus
(CSFV) at the 5' end of the genome (Rijnbrand et ah, 1997).
Lentiviruses: Internal ribosome entry has been described for a number of members
of the lentivirus family. These include SIV (Ohlmann et ah, 2000), which encodes
an IRES at the 5' end of its genomic mRNA, and HIV-1 which has an IRES within
the gag ORF (Buck et ah, 2001) and within the 5' leader sequence of its genomic
mRNA (Brasey et ah, 2003). It is proposed that, as the IRES is functional during the
G2/M phase of the cell cycle, it may play a role in virus replication during virus-
induced cell cycle arrest (Brasey et ah, 2003).
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Gamma-herpesviruses: As mentioned previously, an IRES has been identified
within the vCyclin mRNA of KSHV that controls the expression of the downstream
ORF, vFLIP (Bieleski and Talbot, 2001; Grundhoff and Ganem, 2001; Low et al.,
2001b). More recently an IRES has been identified within the 5' untranslated region
(UTR) of EBV nuclear antigen 1 (EBNA1), the only protein absolutely required to
maintain EBV latency (Isaksson et al., 2003). EBNA1 expression is controlled at
multiple levels including the use of four alternative transcription start sites depending
upon whether the virus is lytic or latent and the stage of latency. Transcription from
each of the four start sites results in a 5'UTR of differing lengths, however, the U
leader exon is common to all four transcripts. Using a bicistronic reporter system an
IRES was identified in the 5'UTR which was most efficient in EBV-positive
Burkitt's Lymphoma cell lines. Experiments using fragments of the 5'UTR, to
identify the minimal sequences necessary for activity, identified sequences with both
a positive and negative effect on translation. The IRES was found to be highly
conserved between different EBV strains. It is proposed that the IRES provides a
mechanism by which protein levels can be maintained independent of the stage of the
cell cycle, throughout which mRNA levels fluctuate. In addition to EBV and KSHV,
an IRES has recently been identified in MHV-68. Following the observation that the
latently expressed protein K3 was encoded by a bicistronic transcript (Coleman et al.,
2003) investigations were undertaken to determine the mechanism by which K3 is
produced. An IRES was subsequently identified within the intergenic region of the
transcript. The K3 protein is involved in evasion of the T cell response (Stevenson et
al., 2000) a role also attributed to KSHV vFLIP (Djerbi et al., 1999). In light of this
similarity it is striking that the translation of both proteins is achieved via an IRES.
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1.5.4 Cellular IRES elements
Whilst the majority of cellular mRNAs are translated in a cap-dependent manner an
increasing number of cellular transcripts are being identified which are able to
support cap-independent translation. The majority of mRNAs exhibiting such
properties encode proteins involved in gene expression, apoptosis and cell signalling.
These include c-myc (Nanbru et al., 1997), x linked inhibitor of apoptosis (XIAP)
(Holcik and Korneluk, 2000), apoptotic protease-activating factor (Apaf-1)
(Coldwell et al., 2000) and fibroblast growth factor 2 (FGF-2) (Vagner et ah, 1995).
Several IRES elements have been demonstrated to operate in a cell cycle specific
manner. Through the synchronisation of cultured cells and subsequent study of
protein expression it has been demonstrated that ornithine decarboxylase (ODC)
(Pyronnet et ah, 2000), p58PITSLRE (Cornelis et ah, 2000) and La (Qin and Sarnow,
2004) are preferentially translated at specific points of the cell cycle, namely G2
and/or mitosis. It seems likely that IRES mediated translation enables expression of
specific proteins to be maintained whilst general protein synthesis levels are
decreased.
1.5.5 IRES structure
Whilst there is very little conservation of primary sequence between IRES elements
encoded by viruses of the same family, the secondary structure adopted by the RNA
is phylogenetically conserved (Stoneley and Willis, 2004). Mutations in the IRES
primary sequence, with implications for the secondary structure, have been observed
to affect the virulence of poliovirus (Shiroki et ah, 1997) and cellular tropism of
HCV (Lerat et ah, 2000). Additionally, studies of naturally occurring genetic drift in
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virus sequence show that, in the vast majority of instances, any substitutions that do
occur result in compensatory changes in IRES secondary structure (Martinez-Salas et
al., 2002). These findings imply that the secondary structure of the viral IRES is
fundamental to its successful interaction with the translational machinery. In
contrast, cellular IRES elements display very little similarity in secondary structure
even when they are located in the mRNA of similar genes (Le Quesne et al., 2001;
Jopling et al., 2004; reviewed in Stoneley and Willis, 2004).
1.5.6 IRES transactivating factors (ITAFs)
Translation from IRES elements is, obviously, independent of the 5'cap-associated
translation initiation complex; however, in the vast majority of cases additional
factors are required to assist ribosomal assembly on the mRNA. At present the only
IRES elements capable of mediating formation of the complete ribosome
independently of additional factors are those encoded by cricket paralysis virus-like
viruses (Wilson et al., 2000a). To date all other IRES elements that have been
investigated have a requirement for additional host proteins. With the exception of
CrPV-like viruses all viral IRES elements, for which essential interacting factors
have been identified, interact with one or more eukaryotic initiation factors (elFs).
The specific requirements vary, for example EMCV and FMDV require eIF4A, eIF3,
eIF2 and the C-terminus of eIF4G (Pestova et al., 1996; Kolupaeva et al., 1998;
Lopez et al., 2001; Lopez and Martinez-Salas, 2000) whilst the HCV and CSFV
IRESes require only eIF2 and eIF3 (Pestova et al., 1998). A number of non-
canonical factors have also been demonstrated to be necessary for the activity of
certain viral and cellular IRES elements. These include the polypyrimidine tract
68
binding protein (Mitchell et al., 2003; Kaminski and Jackson, 1998; Kaminski et al.,
1995; Hunt and Jackson, 1999), upstream of N-ras (Mitchell et al., 2003; Hunt et al.,
1999) and La (Holcik and Korneluk, 2000). Research in the area of cap-independent
translation is fast moving; novel IRES elements are identified on a regular basis and
it therefore seems likely that the range of ITAFs will extend as further studies are
conducted.
1.5.7 The KSHV IRES
As mentioned above, the KSHV IRES, located in the 3' coding sequence of the
vCyclin mRNA (Bieleski and Talbot, 2001; Grundhoff and Ganem, 2001; Low et al.,
2001a) is responsible for the translation of vFLIP. This was the first example of an
IRES element to be identified in a DNA virus. The predicted secondary structure is
shown in figure 1.8. Biophysical analysis of its structure by electron microscopy
supports the predicted structure and reveals that the KSHV IRES is similar to the
HCV IRES (Beales et al., 2003), having two stem-loops and a flexible hinge region
between. Using a bicistronic reporter assay the activity of the KSHV IRES was
estimated to be approximately one third that of the EMCV IRES, the most efficient





































Figure 1.8 Predicted secondary structure of the KSHV IRES generated
using RNA mfold version 3.0. Shown in upper case are the nucleotides
123206- 122973. The polyprimidine tract is highlighted in bold type and
the 11 nucleotide sequence complementary to 18s rRNA is boxed. Taken
from Bieleski and Talbot, 2001.
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1.6 Project Aims
This thesis aimed to investigate two separate aspects of KSHV vFLIP biology. The
first aim was to further understanding of the contribution of vFLIP towards viral
pathogenesis through the use of recombinant MFIV-76 viruses. As KSHV is a
human virus it is very difficult to study the in vivo contribution of individual viral
gene products towards pathogenesis. We hypothesised that expression of KSHV
vFLIP in the closely related MHV-76 would enable comparison of a vFLIP
expressing virus with viruses lacking vFLIP to determine any changes in virus
replication or disease outcome that may be attributable to vFLIP.
Secondly, I aimed to continue investigations, already underway in the lab, into the
mechanisms by which vFLIP translation is achieved. The cell type specificity of the
IRES activity, and past precedent of other IRES systems, mean that it is unlikely that
translation of vFLIP is achieved without ITAF involvement. Several methods were
utilised in order to investigate the identity of these ITAFs.
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Restriction enzymes were purchased from either NEB or Roche. All were used as
instructed by the manufacturer, typically 1 unit per pg DNA, in the supplied reaction
buffer, in a total volume ranging from 10-40pl. Incubation at the appropriate
temperature (usually 37°C) was typically for 2 hours.
2.2.2 Dephosphorylation
The 5' phosphate groups of linearised DNA were removed using Shrimp Alkaline
Phosphatase (Roche). 1 pi (10 units) was added to restriction digests and incubated at
37°C for 20 minutes. The enzyme was inactivated by incubation at 70°C for 10
minutes.
2.2.3 Blunt ending
DNA fragments were treated with DNA polymerase I, large (klenow) fragment
(NEB), to remove 3' overhangs and fdl in 5' overhangs. The DNA was dissolved
either in lx restriction enzyme buffer or lx EcoPol reaction buffer (NEB)
supplemented with 20pM of each dNTP (Amersham). Generally lpl (10 units) of
enzyme was added per reaction. Following 15 minutes incubation at 25°C the




5pmoles of each oligonucleotide were mixed together in a total volume of lOpl. The
mixture was heated to 95°C for 90 seconds then allowed to cool to room temperature.
2pl of lOx restriction buffer (NEB) were added to provide salts necessary for
annealing and the mixture cooled to 4°C.
2.2.5 Gel purification
DNA was run on a 0.8-2% high-grade agarose gel and, using UV to visualise, the
desired fragment was cut from the gel. DNA was then extracted from the agarose
using the QIAquick gel extraction kit (Qiagen). Briefly, the gel slice was weighed
and then solubilised in 3 volumes buffer QG by incubation at 50°C and occasional
vortexing. Once the gel had dissolved 1 volume isopropanol (Sigma) was added,
mixed and the mixture transferred to a QIAquick column, containing a silica-gel
membrane to which the DNA binds. The column was washed with 0.75ml buffer
PE, containing ethanol, by centrifugation and the DNA was eluted in 30- 50pl buffer
EB (lOmM Tris-HCl, pH 8.5).
2.2.6 Site directed mutagenesis
Site directed mutagenesis was earned out using the QuikChange XL Site-Directed
Mutagenesis Kit (Stratagene). Primers containing the desired mutation were
designed to comply with the manufacturers recommendations. The sample reaction
was set up to contain lOng template DNA; 125ng primer 1; 125ng primer 2; 5pl lOx
reaction buffer (lOOmM KC1; lOOmM (NIT^SO^ 200mM Tris-HCl, pH8.8; 20mM
MgS04; 1% (v/v) Triton X-100; 1% (w/v) nuclease free BSA); lpl dNTP mix and
3pl QuikSolution in a total volume of 50pl. Following addition of 2.5U PfuTurbo
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the reaction mix was heated to 95°C for 1 minute then subjected to 18 rounds of the
following reaction cycle before a final elongation step of 7 minutes at 68°C;
95°C 50 seconds
60°C 50 seconds
68°C 2 minutes per Kb plasmid.
Following cycling the reaction was cooled to 37°C and 10U Dpnl restriction enzyme
was added to each reaction. The reactions were then incubated at 37°C for 1 hour to
digest the parental, methylated and unmutated, plasmid.
45pl XL 10-Gold competent cells were transformed with 2pl of the Dpnl treated
DNA by heat-shock. Transformation reactions were plated onto LB-agar plates
containing the appropriate selection agent and incubated overnight at 37°C.
Typically 10 colonies per plate were then picked, overnight cultures grown and
plasmid minipreps carried out. Restriction digests and DNA sequencing were used
to confirm that the mutagenesis had been successful.
2.2.7 Ligation
The insert was incubated with the digested vector (at a ratio varying from 1:1 to 5:1)
and 1- 2U T4 DNA ligase (Roche) in 2x ligation buffer (Roche) for either 5 minutes,
for sticky ended ligations, or 15 minutes, for blunt ended ligations. Ligation was
carried out at room temperature. Aliquots of the ligation mixture, typically 2pl, were
then used to transform competent cells by heat shock.
2.2.8 Transformation of competent cells with plasmid DNA
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Approximately 0.1-50pg plasmid DNA was incubated with 20pl TOP 10 competent
cells (Invitrogen) on ice for 30 minutes. Cells were heat shocked at 42°C for 30
seconds then returned to ice for 5 minutes. 200pl SOC medium (Gibco) was then
added to the cells and they were incubated, with shaking, at 37°C for 1 hour. Up
to lOOpl of cells were then plated onto LB-agar plates containing the appropriate
selective medium and incubated overnight at 37°C to allow colony formation.
2.2.9 Agarose gel electrophoresis
The concentration of the agarose gel used to analyse nucleic acids was dependent
upon the predicted fragment size; gels were typically in the range of 0.8- 2% (w/v).
Agarose was dissolved in the appropriate volume of 0.5x TBE by heating in a
microwave. Ethidium bromide, ~10pg per 100ml, was added whilst the gel was
molten to allow later visualisation of the nucleic acid. The appropriate volume of
lOx loading buffer (lOOmM EDTA pH8, 60% (w/v) sucrose, 0.1% (w/v)
bromophenol blue, 0.1% (w/v) xylene cyanol) was added to nucleic acid samples
which were then loaded into the set gel. Agarose gels were typically run at 100-
150V in TBE buffer. The bands of nucleic acid were visualised using a UV
transilluminator (UVP).
2.2.10 DNA sequencing
DNA was sequenced using the BigDye Terminator Cycle Sequencing system
(Applied Biosystems). 200ng of the PCR product to be sequenced was made up to a
total volume of 5pl with nuclease-free water. 4pi Big Dye reaction mix and lpl





The cycle was repeated 25 times.
Amplified DNA was ethanol precipitated and sent to Jill Lovell at I.C.A.P.B.,




Single colonies of transformed bacteria were inoculated into 4ml LB broth,
containing the appropriate selection agent, and grown overnight, shaking at 37°C.
The bacteria were pelleted by centrifugation, 8,000g, 4 minutes, and plasmid was
DNA extracted using a Rapid Plasmid Miniprep System (Marligen Bioscience Inc).
Briefly, cells were resuspended in 250pl buffer G1 (50mM Tris-HCl, pH 8; lOmM
EDTA; RNase A O.lmg/ml) by vortexing and then lysed by addition of250pl buffer
G2 (200mM NaOH; 1% (w/v) SDS) and incubation at room temperature for 5
minutes. Following lysis 350pl buffer M3 (containing acetate and guanidine
hydrochloride) was added, the mixture was inverted several times to mix and then
centrifuged at 12,000g for 10 minutes. The supernatant was added to a spin cartridge
which was subsequently centrifuged at 12,000g for 1 minute. The cartridge was
washed with 700pl buffer G4 (containing NaCl; EDTA; Tris-HCl, pH 8; ethanol) by
centrifugation. Finally, the plasmid DNA was eluted by addition of 75pi TE to the
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cartridge, incubation at room temperature for 1 minute and centrifugation at 12,000g
for 2 minutes. Plasmid DNA was stored at either 4°C or -20°C.
2.3.2 Plasmid midi and maxipreps
Larger quantities of plasmid DNA were prepared using QIAfdter plasmid Midi or
Maxi kits (Qiagen). Briefly, competent bacteria transformed with the required
plasmid DNA were grown overnight in LB broth, containing the appropriate
selection agent, in a volume of 25-100ml and 100-200ml (Midi and Maxi kits
respectively, volumes were dependant upon whether the plasmid was high or low
copy number). The cells were pelleted by centrifugation at 6,000g for 15 minutes at
4°C. The pellet was resuspended in buffer PI (50mM TrisHCl, pH8, lOmM EDTA,
RNase A (O.lmg/ml)) by vortexing. Buffer P2 (200mM NaOH, 1% (w/v) SDS) was
added to lyse the cells. Following a 5 minute incubation at room temperature
genomic DNA and cell debris was precipitated by addition of chilled buffer P3 (3M
potassium acetate, pH 5.5). The lysate was poured into a QIAfdter cartridge and
incubated at room temperature for 10 minutes during which the precipitate floated to
the top. The lysate was then fdtered into equilibrated QIAGEN-tips (containing an
anion-exchange resin to which plasmid DNA binds in low salt and pH conditions)
and allowed to fdter through under gravity flow. The tips were washed with buffer
QC (1M NaCl; 50mM MOPS, pH7; 15% (v/v) isopropanol) to remove RNA,
proteins and other low Mr impurities (by raising the salt concentration and pH).
Plasmid DNA was eluted by addition of buffer QF (1.6M NaCl; 50mM MOPS, pH7;
15% (v/v) isopropanol) and concentrated and desalted by isopropanol precipitation
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and washing in 70% (v/v) ethanol. DNA was air-dried prior to resuspension in
approximately 100- 200pl water or TE and storage at 4°C or -20°C.
2.3.3 Phenol: chloroform extraction
1 volume of phenol: chloroform: isoamyl alcohol (25:24:1 ratio) (Sigma) was added
to the DNA, which was then shaken and centrifuged at 13,000g for 1 minute. The
aqueous layer, containing the DNA, was removed to a clean tube and the procedure
repeated until no protein remained at the interface. 1 volume of chloroform was then
added, mixed and centrifuged as before. The aqueous layer, containing DNA, was
removed to a clean tube and the DNA extracted by ethanol precipitation.
2.3.4 Ethanol precipitation
0.1 volumes of 3M NaOAc (Sigma), pH 4.6, and 2.5 volumes 95% (v/v) ethanol
(Sigma) were added. The mixture was vortexed and incubated, on ice, for 20
minutes then centrifuged at 13,000g, 4°C for 30 minutes. The pellet was rinsed in
70% (v/v) ethanol and centrifuged at 13,000g, 4°C for 15 minutes. The supernatant
was removed and the DNA pellets air dried before resuspension in either TE or dfEO
and storage at 4°C or -20°C.
2.3.5 Determination of DNA concentration
The concentration of DNA solutions was estimated using a GeneQuant II
spectrophotomer (Pharmacia Biotech). The buffer in which the DNA was dissolved
was used to zero the machine. The OD26o of the DNA was measured and the
concentration estimated using the following formula:
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DNA concentration (pg/ml) = OD260 x dilution factor x 50
2.4 Polymerase Chain Reaction (PCR)
PCR reactions were carried out using Taq DNA polymerase in storage buffer A
(Promega). In a typical reaction mix lOOng- lpg of a DNA template was added to
lOpmoles primer 1; lOpmoles primer 2; 20mM dNTPs (each dNTP at 20mM;
Amersham); 5mM Mg2+ (Promega); 5pl lOx PCR reaction buffer (500mM KC1;
lOOmM Tris pH 9; 1% Triton X-100. Promega) and 2.5 units Taq in a total volume
of 50pl.
Cycling was performed using a Biometra thermocycler. A typical reaction consisted
of an initial denaturation at 94°C for 2 minutes followed by 25- 30 cycles of
denaturation (94°C), annealing (variable depending on the primers in use) and
elongation (72°C, 1 minute per kb). A final elongation step of 10 minutes was
followed by cooling to 4°C before analysis of the products by agarose gel
electrophoresis.
2.5 Southern Blotting
2.5.1 DNA digests and gel electrophoresis
Approximately 5pg DNA was digested with 10 units of restriction enzyme (NEB), in
the correct restriction buffer, in a total reaction volume of 20pl. Digestion was
carried out overnight. The entire digest was run on a 0.8% (w/v) agarose gel at 75V
for 6 hours.
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2.5.2 Blotting to nylon membrane
The gel was briefly rinsed in distilled water to remove any residual TBE. The gel
was then denatured by incubation, with gentle agitation, in 1.5M NaCl; 0.5M NaOH
for 30 minutes at room temperature. Following a brief rinse in water, the gel was
neutralised by incubation in 1.5M NaCl; 0.5M Tris-HCl pH 7.2; ImM EDTA for 30
minutes at room temperature. To transfer the DNA to nylon membrane a large tray
was filled with lOx SSC and a plastic plate was placed over the tray. A piece of
3MM paper was soaked in SSC and placed over the plate so that each end rested in
the SSC in the tray. The gel then was placed onto the 3MM paper and a piece of
nylon membrane was positioned on top of the gel. More pre-soaked 3MM paper and
paper towels were piled on top of the membrane and weighed down. Following
overnight incubation, during which the DNA transferred to the membrane by
capillary action, the membrane was rinsed briefly in 2x SSC and the DNA was cross-
linked to the membrane using a UV Stratalinker 2400 (Stratgene).
2.5.3 Preparation of probe
The DNA fragments to be used as probes were cut using the appropriate restriction
enzymes and gel purified. lOpl DNA and 6pl water were heated to 100°C for 10
minutes. 4pl DIG High Probe reagent (Roche) was added and the mixture was
incubated at 37°C overnight. The enzymatic reaction was inactivated by the addition
of 2pl 0.2M EDTA and incubation at 65°C for 10 minutes. Immediately prior to use
probes were denatured by incubation at 100°C for 5 minutes.
2.5.4 Hybridisation of probe to membrane and detection
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The membrane was incubated in 20ml of pre-warmed prehybridisation buffer (DIG
Easy Hyb (Roche)) for at least 30 minutes at 50°C with gentle agitation. The buffer
was discarded and replaced with 3.5ml pre-warmed DIG Easy Hyb containing 2pl
DIG-labelled probe. The membrane and probe were incubated together, with gentle
agitation, at 50°C overnight. The membrane was then washed twice with 2x SSC;
0.1% (w/v) SDS at room temperature and briefly rinsed in 100ml washing buffer
(0.1M Maleic acid; 0.15M NaCl; 0.3% (v/v) Tween 20 pH 7.5). Blocking was
carried out at room temperature using 100ml blocking buffer (Blocking solution
(Roche) in 0.1M Maleic acid, 0.15M NaCl pH 7.5) for 30 minutes with constant
agitation. The membrane was then incubated in 20ml antibody solution (anti-DIG-
AP conjugate diluted 1:10,000 in blocking solution) for 30 minutes at room
temperature. Following two 15 minute washes in washing buffer the membrane was
transferred to a hybridisation bag and equilibrated for 5 minutes in 20ml detection
buffer (0.1M Tris-HCl; 0.1M NaCl pH 9.5). The equilibration buffer was discarded
and replaced with 2ml CSPD (Disodium 3-(4-metho xyspiro {l,2-dioxetane-3,2-(5-
chloro)tricyclo [3.3.1.13,7]decan}-4-yl)phenyl phosphate), a chemiluminescent
substrate of alkaline phosphatase (Roche), diluted 1 in 100 in detection buffer. The
membrane was incubated with the CSPD for 5 minutes after which it was rinsed in
detection buffer, sealed in a hybridisation bag and incubated for 10 minutes at 37°C.
The membrane was then exposed to Lumi-Film chemiluminescent Detection film
(Roche) at room temperature.
2.5.5 Stripping blots
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In order to remove the labelled probe and allow hybridisation of a second probe to
the same blot the membrane was rinsed thoroughly in distilled water; washed twice
in 0.2M NaOH, 0.1% (w/v) SDS for 15 minutes at 37°C and rinsed twice in 2x SSC.
2.6 Tissue Culture Techniques
2.6.1 Maintenance of cell lines
2.6.1.1 Tissue culture media
Cell lines were maintained at 37°C, 5% CCL in the appropriate medium as indicated
below;
Cell Line Medium Supplements
BHK-21 Glasgows 10% NBCS
2mM L-glutamine
60pg/ml pen/strep
50ml tryptose phosphate broth
BCBL-1 RPMI 20% FBS
2mM L-glutamine
60pg/ml pen/strep
BCP-1 RPMI As BCBL-1
NSO RPMI As BCBL-1




HEK 293 DMEM 10% FBS
2mM L-glutamine
60pg/ml pen/strep
2.6.1.2 Passaging adherent cell lines
The medium was removed from cell monolayers. The cells were then washed with
versene prior to incubation in a small volume of trypsin-EDTA (0.05% v/v; Gibco) at
37°C until the cells became detached from the plastic. Fresh medium was added, to
neutralise the trypsin-EDTA, and the cells were transferred to a 50ml falcon tube.
The cells were pelleted by centrifugation at l,000g for 7 minutes; the supernatant
was removed and the cells were resuspended in fresh growth medium. An
appropriate dilution of cells was then used to seed a new tissue culture flask.
2.6.1.3 Removal of dead cells by Histopaque-1077 separation
Dead cells were removed from cultures of suspension cells by Ficoll separation.
Cells were layered onto approximately 10ml Histopaque-1077 (Sigma) in 50ml
falcon tubes. Following centrifugation at l,500g for 20 minutes dead cells arc
pelleted and viable cells remain at the Histopaque/ medium interface. Viable cells
were transferred to a clean universal and 10ml SPBS was added to dilute the
Histopaque. The cells were pelleted by centrifugation at l,000g for 7 minutes;
resuspended in an appropriate volume of medium and transferred to a new tissue
culture flask.
2.6.2 Transfection of tissue culture cell lines
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2.6.2.1 Effectene
BHK cells were transfected with plasmid DNA using Effectene Transfection reagent
(Qiagen). Cells were seeded (typically 4x105 cells/well in a 6 well plate) the day
before transfection to reach approximately 70% confluence, lpg DNA per well was
made up to 150pl total volume with buffer EC (DNA condensation buffer).
Following addition of 8pl Enhancer, the mixture was vortexed briefly and incubated
at room temperature for 5 minutes. 25pl of Effectene reagent were then added to the
DNA mix and vortexed for 10 seconds. The samples were incubated at room
temperature for 10 minutes. During incubation the cells to be transfected were
washed in SPBS and 4ml fresh medium was added. 1ml medium was added to the
Effectene-DNA complexes, mixed by pipetting and added to the cells drop-wise.
Cells were then incubated at 37°C, 5% COi.
2.6.2.2 Electroporation
BHK cells were trypsinised, washed and resuspended in PBS at a concentration of
lxlO7 cells/ml. A 200pl aliquot (i.e. 2xl06 cells) was placed in a 4mm
electroporation cuvette (Biorad). lOpg plasmid DNA was added to the cells and
mixed gently. Following a brief incubation on ice the cells were electroporated using
an Equibio Easyject Plus electroporator;
Pulse 1 600V, 25pF, 99Q
Pulse 2 250V, 1050pF, 99Q
0.1 second delay between pulses.
Cells were then added to 10ml of fresh medium in a universal and seeded into a 6
well plate at 5ml/well. Cells were incubated at 37°C, 5% CCE.
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2.6.3 Preparation of S10 cytoplasmic protein extract
BCP-1 or BCBL-1 cells were counted in a haemocytometer and 108 cells were
pelleted by centrifugation at l,200rpm for 7 minutes. Cells were then washed 3
times in isotonic buffer (35mM Hepes pH 7.4; 146mM NaCl; llmM glucose) by
resuspension and centrifugation. The cell pellet was then resuspended in 2 volumes
hypotonic buffer (20mM Hepes pH 7.4; lOmM KC1; 1.5mM Mg Acetate; ImM
DTT) and incubated on ice for 10 minutes. Cells were broken open by 25 strokes of
dounce homogenisation on ice. Subsequently 0.1 volumes of lOx buffer (0.2M
Hepes pH 7.4; 1.2M K Acetate; 40mM Mg Acetate; 50mM DTT) were added and
the nuclei removed by centrifugation at 2,000rpm for 10 minutes at 4°C. The
supernatant was removed and centrifuged at 10,000rpm for 15 minutes at 4°C. The
supernatant was removed and 0.01 volumes lOOmM CaCE and 75U/ml S7 nuclease
(Roche) were added. Following 15 minutes incubation at 20°C the nuclease was
inactivated by addition of EGTA to a final concentration of 2mM. The S10
supernatant was then centrifuged at 10,000rpm for 15 minutes at 4°C and small
aliquots stored at -80°C.
2.6.4 Preparation of nuclear protein extract
lxlO7 cells were harvested by centrifugation and resuspended in 1ml PBS.
Following transfer to a 1.5ml eppendorf the cells were pelleted by centrifugation at
500g, 4°C for 5 minutes. The S/N was removed and the cells were washed in lOOpl
sucrose buffer (0.32M sucrose; lOmM Tris HC1 pH 8.0; 3mM CaCl2; 2mM MgOAc;
O.lmM EDTA; 0.5% (v/v) NP-40; ImM DTT and 0.5mM mammalian protease
inhibitors were added immediately prior to use) by gentle resuspension followed by
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centrifugation at 500g, 4°C for 5 minutes. The supernatant, containing the
cytoplasmic protein fraction, was removed. The remaining nuclear pellet was
washed in 1ml sucrose buffer (as above, without NP-40) by resuspension followed
by centrifugation as before. The wash buffer was removed and the cell nuclei were
resuspended in 30pl low salt buffer (20mM HEPES pH 7.9; 1.5mM MgCB; 20mM
KC1; 0.2mM EDTA; 25% (v/v) glycerol; 0.5mM DTT and 0.5mM protease
inhibitors were added immediately prior to use) by gentle flicking of the tube. An
equal volume of high salt buffer (20mM HEPES pH 7.9; 1.5mM MgCb; 800mM
KC1; 0.2mM EDTA; 25% (v/v) glycerol; 1% (v/v) NP-40; 0.5mM DTT and 0.5mM
protease inhibitors added immediately prior to use) was then added very slowly
whilst constantly agitating the tube. The samples were incubated for 40 minutes on a
rotating wheel at 4°C and then the debris was pelleted by centrifugation at 14,000g
for 15 minutes at 4°C. The nuclear protein extract was stored at -80°C.
2.6.5 Preparation of cytospins
Cells were counted and resuspended in PBS at a concentration of lxlO6 cells/ml.
50pl aliquots were spun onto poly-lysine coated microscope slides (BDH) at l,000g
for 3 minutes. Cells were then fixed by incubation in 4% paraformaldehyde in PBS
for 30 minutes at room temperature and stained as appropriate.
2.7 Recombinant Virus Techniques
2.7.1 Purification of recombinant virus
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A total of 1.25xl06 BHK cells were transfected with 10-20pg linearised plasmid
DNA and ~5pg MHV-76 DNA by electroporation. The cells were added to 10ml of
fresh medium and plated into 6 well plates at 5ml/ well. The plates were incubated at
37°C, 5% CO2, and monitored for plaque formation and, if appropriate, GFP
expression. Once obvious plaques had formed, generally after 4-5 days, 4ml of
medium was removed from each well and discarded. The cells were then scraped
into the remaining medium and transferred to a 1.5ml eppendorf. Following three
freeze-thaw cycles the cell debris was pelleted by centrifugation and the supernatant,
containing the virus, was stored in cryovials at -80°C.
Recombinant viruses were then purified by plaque purification in 96 well plates.
BHKs were seeded at 5xl03 cells per well and incubated overnight. Dilutions of the
virus stock were made in Glasgows medium and lOpl added per well. After 1 hour
incubation at 37°C 200pl of medium, containing lOOpg/ml hygromycin if
appropriate, were added to each well. The plates were incubated for 4-5 days or until
plaques had formed. The lowest dilution yielding plaques was harvested by scraping
the cells into the medium. A lOOpl aliquot was subjected to three rounds of freeze-
thawing to give a virus stock. Viral DNA was prepared from the remainder; the
samples were pelleted, the supernatant was removed and the pellet was resuspended
in 50pl TE (20mM Tris, pH 8; ImM EDTA). One freeze-thaw cycle was then
carried out. 1 pi (0.05U) Proteinase K (Roche) was added to the samples which were
then incubated at 55°C overnight. The Proteinase K was inactivated by heating to
90°C. The extracted DNA was subsequently used in PCR reactions to screen for
presence of the insert and wild type virus. Plaque purification was continued until
there appeared to be no wild type virus in the samples.
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2.7.2 Preparation of virus stock
BHK cells were resuspended in Glasgows medium at 107/ml and infected with virus
at a multiplicity of infection (moi) of 0.001. Cells were incubated, with shaking, at
37°C for 1 hour then seeded into 175cm2 tissue culture flasks at 3xl06 cells/ flask.
The flasks were checked daily until C.P.E. was reached. Any cells still attached to
the flask were scraped into the medium, which was then dispensed into 50ml falcon
tubes. The cells were pelleted by centrifugation at 2,500rpm, 4°C, for 20 minutes
and the pellet was resuspended in the smallest possible volume of SPBS. The pellet
was homogenised by 30 strokes with a Dounce. Following transfer to a glass
universal the cells were sonicated in an ice bath for 15 minutes. The resulting
suspension was centrifuged at 2,500rpm, 4°C for 20 minutes and the supernatant was
stored on ice. The pellet was resuspended in 1ml SPBS and another 30 strokes of the
Dounce were carried out. This suspension underwent centrifugation at 2,500rpm,
4°C for 20 minutes after which the two supernatants were pooled. Aliquots were
stored at -80°C.
2.7.3 Virus DNA preparation
BHK cells were resuspended in Glasgows medium at 107 cells/ml and infected with
virus at an moi of 0.1 pfu/cell. Cells were incubated, with shaking, at 37°C for 1
hour and seeded into 175cm2 tissue culture flasks at 5xl06 cells/ flask. Flasks were
incubated at 37°C, 5% CO2 until complete C.P.E. was reached. Cells were scraped
into the medium, which was then decanted into 50ml falcon tubes. The cells were
pelleted by centrifugation at 2,500rpm, 4°C for 20 minutes and resuspended in at
total volume of 1ml SPBS. The pellet was homogenised by 30 strokes with a dounce
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and transferred to a universal. Following centrifugation at 2,500rpm, 4°C, for 30
minutes the supernatant was removed and stored on ice and the pellet was
resuspended in 1ml SPBS. The pellet was re-homogenised and centrifuged as
before. The two supernatants were pooled and lpl RNase A (lmg/ml) was added.
The supernatants were incubated at 37°C for 1 hour. An equal volume of High
Molecular Weight DNA extraction buffer (0.1M EDTA; 0.5% (w/v) SDS; 0.2M
TRIS pH 8; lOOpg/ml proteinase k (Roche)) was added and the supernatant was
incubated overnight at 55°C. The supernatant was transferred to a 15ml falcon tube
and the DNA extracted twice with phenol: chloroform: isoamyl alcohol (25:24:1
ratio) (Sigma) and twice with chloroform (Sigma). The viral DNA was precipitated
by addition of 0.3 volumes 7.5M ammonium acetate and 2.5 volumes 96% (v/v)
ethanol and centrifugation for 30 minutes at 8,000rpm, 4°C. The DNA pellet was
rinsed in 70% (v/v) ethanol and resuspended in TE pH8.
2.7.4 Virus titration
Virus samples were thawed at 37°C and 10 fold dilutions were made in Glasgows
medium each with a volume of 4ml. 2x106 BHK cells were added to each dilution.
Following incubation for 1 hour at 37°C, with shaking, each dilution was plated into
two 60mm Petri dishes containing 3ml Glasgows medium i.e. 2ml dilution/ dish.
Cells were incubated at 37°C, 5% CO2 for 4 days and then fixed in 4% (w/v) neutral
buffered formal saline. Plates were stained with 0.1% (w/v) toluidine blue. Plaques
were counted and the titre calculated as follows;
Titre= no,of plaques x dilution
volume of sample
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2.7.5 One-step growth curve
5xl06 BHK cells were infected with virus at an m.o.i. of 5 pfu per cell in a total
volume of 25ml Glasgow's by shaking at 37°C for 1 hour. Following adsorption the
cells were washed three times with 15ml Glasgow's by centrifugation and then
resuspended to a final volume of 25ml. Cells were aliquoted into a 24 well plate at
2xl05 cells per well (i.e. 1ml). Samples were harvested at the appropriate time
points, typically 0, 4, 8, 12, 18, 24, 30, 36, 48, 60 and 72 hours post infection, by
scraping the cells into the medium with a lOOOpl Gilson tip and storing them at -
80°C. Once all time points were complete virus was released from the cells by
freeze-thawing three times. Samples were titrated as described elsewhere.
2.7.6 Multi-step growth curve
The multistep growth curve carried out to assess cell-to-cell spread of the virus was
carried out mainly as described above with the exception that 1x10s BHK cells per
well were infected at a m.o.i. of 0.01 pfu/cell. Typical time points at which cells
were harvested were 0, 12, 24, 36, 48, 72, 96, 120 and 144 hours post infection.
2.7.7 Infection of mice
All procedures were carried out in the Summerhall animal unit under the home office
project licence 60/2429 and personal licence 60/8831.
Mice were anaesthetised with halothane and infected intranasally with 4xl05 pfu
vims diluted in 40pl SPBS. At appropriate time points, mice were euthanised by
CO2 inhalation.
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2.7.8 Infective centre assay
Spleens were removed from mice and placed into 5ml of RPMI supplemented with
10% (v/v) FBS; 2mM L-glutamine; 60pg/ml pen/strep; fungizone; (3-
mercaptoethanol; 25mM Hepes, in a Petri dish. The end of the spleen was cut with a
scalpel and the spleen cells gently squeezed out. The contents of the Petri dish were
transferred to a universal. 5ml medium was added to the Petri dish, to rinse off the
remaining spleen cells, and this was then added to the universal. The cells were
centrifuged at l,800rpm for 5minutes at 4°C. The supernatant was removed and the
pellet was resuspended by tapping. 1ml of sterile water was added to the cells
followed immediately by 8ml SPBS. Having allowed the red cell ghosts to settle the
remaining cells were transferred to a clean universal and centrifuged at l,800rpm for
5 minutes at 4°C. The supernatant was removed and the cells resuspended in 5ml
medium. Cells were counted using a heamocytometer.
60mm Petri dishes were prepared containing 5ml medium and 2xl06 BHK cells.
12 3
Spleen cells were added to the dishes at 10" , 10" and 10" dilutions (i.e. 500pl, 50pl,
5pil). Petri dishes were then incubated at 37°C, 5% CCL for 5 days. Following
incubation the medium was removed and the cells were fixed with 4% (w/v) neutral
buffered saline and stained with 0.1% (w/v) toluidine blue. Plaques were counted
and the number of infectious centres was calculated per 107 spleen cells.
2.7.9 Virus titration of lung homogenate
Lungs were removed from mice and stored at -80°C, in cryovials, until titrations
were carried out.
Lungs were homogenised in 1ml Glasgow's and the resulting suspension was placed
in a cryovial. The remaining lung was re-homogenised in 0.8ml Glasgow's and then
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pooled with the first suspension. The suspension was then frozen at -80°C for at
least 1 hour. The lung homogenate was thawed and centrifuged at 3,000rpm for
5minutes at 4°C to sediment cellular debris. The supernatant was serially diluted to
give a range of 10"' to 10"6 each in a total volume of 4ml Glasgows. 2xl06 BHK cells
were added to each dilution and the samples were then incubated, with shaking, at
37°C for 1 hour. 2ml of each dilution was added to two 60mm Petri dishes
containing 3ml Glasgows. Following incubation at 37°C, 5% CO2 for 4 days the
cells were fixed with 4% (w/v) neutral buffered saline and stained with 0.1% (w/v)
toluidine blue. The plaques were counted and the titre of each sample determined.
2.7.10 DNA extraction from snap-frozen tissue
Tissues were removed from mice, placed in cryovials and snap-frozen in liquid
nitrogen. DNA was extracted from tissue samples using the QIAamp DNA Mini Kit
(Qiagen) as described by the manufacturer. Briefly, tissue samples were thawed to
room temperature and a section of <25mg (<10mg spleen) removed. This section
was cut into small pieces, with a clean scalpel, and placed into a 1.5ml
microcentrifuge tube. 180pl buffer ATL and 20pl Proteinase K (600U/ml) were
added. Samples were incubated overnight at 56°C, with occasional vortexing, to
allow complete lysing of the tissue. 200pl buffer AL were added to each sample and
mixed by vortexing followed by 10 minutes incubation at 70°C. 200pl high-grade
ethanol was added to each sample and mixed by vortexing. The mixture was then
added to a QIAamp spin column which was subsequently centrifuged at 6, OOOg for 1
minute. 500pl Buffer AW1 was added and the column was centrifuged again. 500pl
Buffer AW2 was added to the column which was then centrifuged at 20, OOOg for 3
minutes. The column was placed in a clean 1.5ml microcentrifuge tube and the DNA
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eluted in 200pl Buffer AE by centrifugation at 6, OOOg for 1 minute. The elution step
was then repeated. DNA concentrations were determined by spectrometry.
2.7.11 NSO growth curve
r NSO cells were infected at an m.o.i. of 5 pfu/cell by shaking at 37°C for 2 hours.
Cells were then aliquoted into 24 well plates at lxlO5 cells/ well. Plates were
incubated at 37°C, 5% CCb. Throughout the course of the assay cells were
monitored and fed as necessary. At each time point the cell proliferation, lytic virus
titre, cell-associated virus titre and latent titre was assessed. The levels of virus
within the supernatant were assayed by titrating the S/N from lml of cells. To assay
cell-associated virus titre lml cells were pelleted and washed x3 with SPBS. The
cells were resuspended in lml SPBS and titrated on BHK cells. Latent virus titre
was calculated by lysing washed cells through repeated freeze-thaw cycles, and
titration of the resultant lysate to calculate the amount of infectious virus that has
remained cell-associated. This figure was then subtracted from the infectious centre
titre to give the latent vims titre. In all cases plates were incubated for 5 days prior to
being fixed in 4% (w/v) neutral buffered formal saline and stained with 0.1% (w/v)
toluidine blue.
Plaques were then counted and the viral titre per 103 cells calculated.
2.8 Northern Blotting
All procedures were carried out using RNase free solutions (prepared by addition of
lml diethyl pyrocarbonate per litre of solution, overnight incubation with stirring at
room temperature and deactivation by autoclaving) and equipment, which had been
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cleaned of contaminating RNase by treatment with either 5M NaOH or RNaseZap
(Ambion).
2.8.1 RNA extraction from virus infected cells
2xl06 CI27 cells were infected at an m.o.i. of 5 with virus, seeded into T75 tissue
culture flasks (Nunc) and incubated at 37°C, 5% CO2 until CPE was reached (usually
3 days p.i.). Cells were then scraped into the medium, decanted into universals and
pelleted by centrifugation at l,000g for 7 minutes. Total RNA was extracted from
the cells using the RNeasy Mini Kit (Qiagen). Briefly, cells were disrupted by
addition of 600pl buffer RLT (containing guanidinium thiocyanate; 1% (v/v)
P-mercaptoethanol) and vortexing. The sample was then homogenised using a
QIAshredder spin column (Qiagen). 600pl 70% (v/v) ethanol was added to the
homogenised sample and mixed thoroughly prior to application to an RNeasy mini
column. Following centrifugation at 10,000g for 15 seconds, 700pl buffer RW1
(containing guanidinium thiocyanate and ethanol) was added and the column was
centrifuged again. The column was washed twice with 500pl buffer RPE (containing
80% (v/v) ethanol) by centrifugation. RNA was eluted from the column with 50pl
RNase free H20.
2.8.2 Estimation of RNA concentration
The concentration of RNA was quantified using a Genequant II spectrophotometer
(Pharmacia Biotech). Water was used to zero the machine. The OD260 of the RNA
was measured and the concentration estimated using the following formula:
RNA concentration (pg/ml) = OD260 x dilution factor x 40.
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2.8.3 Denaturing RNA and electrophoresis
RNA samples were added to 5x RNA loading buffer (0.25% bromophenol blue;
4mM EDTA; 0.9M formaldehyde; 20% (v/v) glycerol; 30.1% (v/v) formamide;
80mM MOPS; 20mM Na acetate) at a 4:1 ratio. The RNA secondary structure was
denatured by incubation at 65°C for 5 minutes followed by rapid cooling on ice. The
RNA samples were loaded onto a formaldehyde agarose gel (1% (w/v) agarose in
20mM MOPS; 5mM Na acetate; ImM EDTA; pH 7.0) to which lOpg ethidium
bromide and 0.67% (v/v) formaldehyde were added once the gel had cooled to 65°C.
Once the gel had set, the tank was fdled with running buffer (20mM MOPS; 5mM
Na acetate; ImM EDTA; 2.5M Formaldehyde) and equilibrated by running at 100V
for 30 minutes after which the samples were loaded. The gel was run overnight at
25V with the buffer being re-circulated through the apparatus continuously.
2.8.4 Blotting onto nylon membranes
The gel was washed in 200ml RNase free water for 10 minutes followed by 15
minutes incubation in 0.05M NaOH. The NaOH was then neutralised by a 10 minute
incubation in lOx SSC. The gel was placed onto filter paper, laid over a glass plate,
each end of which was immersed in a tank containing 20x SSC. A piece of nylon
membrane (Amersham) and 2 pieces of 3MM paper pre-soaked in 20x SSC were
placed on top of the gel followed by a stack of paper towels and finally a 1kg weight.
The RNA was allowed to transfer to the membrane by capillary action overnight.
2.8.5 Preparation of probes
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DNA complimentary to the RNA sequence to be detected was amplified by PCR.
50ng of probe DNA was made up to 45pi volume in TE buffer and denatured by
incubating at 100°C for 2 minutes followed by immediate cooling on ice. The DNA
was added to a Ready-to-Go DNA labelling bead (Amersham) and the bead was
allowed to dissolve. Approximately 50pCi a- P dCTP were added and the DNA
was incubated at 37°C for 25 minutes. The DNA was then denatured by incubation
at 100°C for 2 minutes and unincorporated nucleotides were removed using a G-25
spin column (Amersham).
2.8.6 Hybridisation and detection
The blot was transferred to a hybridisation tube and incubated with 6ml Ultrahyb
(Ambion), which had been warmed to 68°C, for 30 minutes at 42°C with constant
gentle agitation. After 30 minutes approximately 1/3 of the labelled probe was added
to the hybridisation tube and the blot was hybridised overnight at 42°C. Following
hybridisation the Ultrahyb containing the probe was discarded and the blot was
washed twice for 5 minutes in 2x SSC, 0.1% (w/v) SDS and then twice for 15
minutes in O.lx SSC, 0.1% (w/v) SDS, all washes at 42°C. Blots were then covered
in clingfilm and exposed to Lumi-Film Chemiluminescent Detection film (Roche).
2.8.7 Stripping blots
The blot was placed into a hybridisation tube to which boiling 0.1% (w/v) SDS was




2.9.1.1 Purification of GST fusion protein
An overnight culture of bacteria transformed with pGEX4T-l vFLIP was diluted l in
50 into 200ml LB-carb and incubated, shaking at 37°C, until the OD6oo reached 0.6.
IPTG was then added to a final concentration of 0.1 mM and the bacteria incubated
for a further 2- 4 hours. Cells were pelleted by centrifugation at 5,000g for 15
minutes. The supernatant was removed and the pellet resuspended in 10ml ice-cold
SPBS to which protease inhibitor cocktail set 2 (1:100 dilution; Sigma) had been
added. The cells were lysed by sonication on ice. Triton X-100 was then added to a
final concentration of 1% (v/v) and the extract was mixed for 30 minutes at 4°C
followed by centrifugation at 12,000g for 10 minutes at 4°C. The supernatant was
stored at 4°C.
lOOpl Glutathione Sepharose 4B (Pharmacia Biotech) was washed twice with 1ml
PBS, by centrifugation at 500g, then diluted 1:1 in PBS to give a 50% slurry. The
slurry was added to the sonicate prepared previously and incubated, with mixing, at
4°C overnight. Following incubation the slurry, with bound fusion protein, was
washed three times in 1ml PBS by centrifugation at 500g. vFLIP was removed from
the column by thrombin cleavage, leaving the GST moiety bound to the sepharose.
1 pi thrombin solution (1 cleavage unit) was added to 95pl PBS and the sepharose
was then incubated in this solution overnight, with gentle mixing, at room
temperature. The sepharose was pelleted by centrifugation at 500g for 5 minutes and
the eluate, containing vFLIP, was removed and stored at -20°C. GST was removed
from the sepharose by elution with lOOpl glutathione elution buffer (lOmM reduced
glutathione; 50mM Tris-FICl, pH8; Pharmacia Biotech).
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2.9.1.2 Purification of Histidine-tagged protein
An overnight culture of E.coli transformed with pTrc His vFLIP was diluted l in 50
into 200ml LB-carbenicillin (lOOpg/ml) and incubated with shaking at 37°C, until
the OD6oo reached 0.6 at which point IPTG was added to a final concentration of
O.lmM. The culture was incubated for a further 2 hours before being dispensed into
50ml aliquots. Each aliquot was pelleted by centrifugation at 5,000g for 10 minutes,
the supernatant removed and the pellet stored at -20°C.
Prior to purification the bacterial pellet was thawed and lysed by incubation with
1.25ml BugBuster Protein Extraction Reagent (Novagen) supplemented with 25 units
Benzonase Nuclease; lkU recombinant lysozyme (Novagen) and 12.5jj.1 EDTA-free
protease inhibitor cocktail set III (Calbiochem). Following 15 minutes incubation at
room temperature the mixture was centrifuged at 10,000g for 20 minutes at 4°C and
the soluble protein extract decanted to a clean tube.
lml HIS-Select HC Nickel Affinity Gel (Sigma) was aliquoted into a falcon tube and
centrifuged at 5,000g for 3 minutes to pellet the gel. The supernatant was discarded
and the gel was washed twice in 10ml de-ionised water and three times in 10ml
equilibration buffer (50mM sodium phosphate, pH 8.0; 0.3M sodium chloride) by
resuspension and centrifugation. After the final wash the solubilised protein extract,
prepared previously, was added to the pelleted affinity gel and this was then mixed
gently at room temperature for 30 minutes. The affinity gel was pelleted by
centrifugation and the supernatant, containing unbound protein, was removed. The
affinity gel was washed three times with 10ml equilibration buffer. The bound
protein was eluted from the gel by the addition of 2 gel volumes elution buffer
(50mM sodium phosphate, pH 8.0; 0.3M sodium chloride; 250mM imidazole),
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incubation, with gentle mixing, for 15 minutes at room temperature and pelleting of




Following elution from the Ni- agarose, proteins were concentrated by precipitation.
0.1 volumes of 1% (w/v) sodium deoxycholate (Sigma) solution were added to the
eluted protein and mixed thoroughly by pipetting. Following 15 minutes incubation,
at room temperature, 0.22 volumes of 50% (w/v) trichloroacetic acid (BDH) solution
was added and mixed by pipetting. The mixture was incubated, rotating, for 2 hours
at 4°C. The mixture was centrifuged at 20,000g for 20 minutes at 4°C and the
supernatant carefully removed. 500pl of ice-cold acetone (BDH) were added to the
pellet, which was resuspended by gentle pipetting. Following incubation at -20°C for
30 minutes the sample was centrifuged as before. The supernatant was removed
carefully and the pellet allowed to air dry before being resuspended in SPBS.
2.9.2.2 Spin columns
Purified protein was concentrated using VIVASPIN columns with a 10,000
Molecular weight cut-off membrane (Vivascience). Samples to be concentrated (2-
4ml volume) were loaded into the column, which was then centrifuged at 5,000g,
20°C for 7 minutes. Concentrated samples were stored at -20°C prior to analysis by
western blot or silver stain.
101
2.9.3 SDS-PAGE
Proteins were separated by SDS-PAGE prior to visualisation by either Western
blotting or direct protein staining. Both self-poured and pre-cast gels were used with
the particular percentage being dependent upon the size of the protein of interest.
In the case of self-poured gels, protein samples were made up to a total volume of
20pl with 5x loading buffer (50% (v/v) glycerol; 1% (v/v) SDS; 20mM Tris pH 6.8;
0.5% (w/v) bromophenol blue. 35pl/ml p-mercaptoethanol were added immediately
prior to use). Samples were boiled for 5 minutes before loading onto the gel
(resolving gel: .mil 40% acrlamide/bisacrylamide; 0.5M Tris pH 8.8; 0.2% (v/v)
SDS; 0.1% (w/v) ammonium persulphate (APS); 0.01% (v/v) TEMED. Stacking
gel: 3.2% (v/v) acrylamide/bisacrylamide; 80mM Tris pH 6.8; 0.2% (v/v) SDS;
0.1% (w/v) APS; 0.015% (v/v) TEMED). Gels were run at 300mA each in running
buffer (25mM Tris; 192mM glycine; 0.1% (v/v) SDS).
Pre-cast gels were obtained from Invitrogen and used as instructed by the
manufacturer.
2.9.4 Coomassie staining
Gels were incubated in Brilliant Blue R concentrate (Sigma: 0.25% (w/v) Brilliant
Blue R; 40% (v/v) methanol; 7% (v/v) acetic acid) with shaking for at least 1 hour.
After a brief rinse with de-stain (50% (v/v) methanol; 10% (v/v) acetic acid) gels
were incubated in de-stain until bands were clear.
2.9.5 Silver staining
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Gels were fixed in 45% (v/v) ethanol, 35% (v/v) glacial acetic acid for 20 minutes
followed by a 10 minute wash in 10% (v/v) ethanol. Following three 10 minute
washes in de-ionised water gels were incubated in Farmers reagent reducer (0.3%
(w/v) sodium thiosulphate; 0.15% (w/v) potassium ferricyanide; 0.05% (w/v) sodium
carbonate) for 1 minute. Gels were washed three times in de-ionised water and
incubated in 0.1% (w/v) AgNCb for 30 minutes. After a brief rinse in de-ionised
water, gels were developed in 2.5% (w/v) Na2C03, 0.05% (v/v) formaldehyde until
bands were of the desired intensity. Gels were stored in 30% (v/v) methanol, 10%
(v/v) glacial acetic acid.
2.9.6 Western blotting
Generally, proteins were transferred to nitrocellulose membrane in transfer buffer
(25mM Tris; 192mM glycine; 20% (v/v) methanol) at 30mA for at least 1 hour. The
membrane was air dried and then incubated in blocking buffer (lxPBS; 1% (w/v)
BSA; 0.05% (v/v) Tween 20) for 30 minutes at room temperature. The primary
antibody was diluted appropriately in blocking buffer and incubated with the
membrane for at least 1 hour at room temperature with gentle agitation. The
membrane was rinsed three times with PBS. Alkaline Phosphatase conjugated
secondary antibody (Sigma) was diluted 1/ 2,500 in blocking buffer and incubated
with the membrane for 1 hour at room temperature with gentle agitation. The
membrane was rinsed three times in PBS and allowed to dry. A NBT/BCIP tablet
(Roche) was dissolved in 10ml water and poured onto the membrane. Once bands
had reached the desired intensity the membrane was rinsed with distilled water and
allowed to dry.
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2.9.7 Pull down assay
The pull down assay was adapted from that described by Stassinopoulos and
Belsham (Stassinopoulos and Belsham, 2001). The probe sequence was cloned into
a pSP64 polyA vector (Promega). lpg of the plasmid was linearised by EcoRl
digestion and purified by ethanol precipitation. RNA was transcribed using the SP6
Megascript kit (Arnbion) as instructed, briefly, the DNA template was added to 2pi
each of ATP, CTP, GTP and UTP (all at 50mM), 2pi lOx reaction buffer and 2pl
SP6 polymerase (40U) in a total volume of 20pl RNase free water. The reaction was
incubated overnight at 37°C after which the RNA was purified by phenol:chloroform
extraction and isopropanol precipitation and resuspended in lOpl RNase free water.
0.5ml Oligo dT Dynabeads (Dynal) were washed twice in 0.5x SSC and once in
binding buffer (lOmM Tris pH 7.5; lOOmM KC1; 2mM MgCB). The beads were
resuspended in 50pl binding buffer and the RNA transcripts added; this was
incubated on a rotating wheel for 30 minutes at 4°C. The beads were captured with a
magnet and the supernatant removed. Following two washes with 200pl binding
buffer the beads were incubated with 20pl S10 extract on a rotating wheel for 60
minutes at 4°C. The beads were captured as before, washed twice in 200pl binding
buffer and bound proteins eluted by incubation in 20pl SDS loading buffer for 10
minutes at 4°C.
2.9.8 Electrophoretic mobility shift assay (EMSA)
2.9.8.1 EMSA for the detection of RNA binding proteins
The plasmid DNA template was linearised by restriction digest and ethanol
precipitated. RNA was transcribed using the SP6 Megascript kit (Ambion) and
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labelled internally with 32P-UTP. The reaction was set up as follows: 0.5pl ATP
(50mM); 0.5pl CTP (50mM); 0.5pl GTP (50mM); 25pCi 32P-UTP; 0.5pl
RNaseOUT (Invitrogen); 2.5pl lOx reaction buffer; 2pl (40U) SP6 RNA polymerase;
FEO to 25pil. Following overnight incubation at 37°C the RNA was treated with 1U
DNase for 10 minutes at 37°C and unincorporated nucleotides were removed using a
G-25 spin column (Amersham). The binding reaction was set up as follows:
25,000cpm RNA were incubated with ~6pg BCBL-1 S10 extract, 1U RNaseOUT
(Invitrogen) and 0.05pg poly(dl-dT) in a total volume of 20pl binding buffer (20mM
HEPES/KOH pH 7.5; 50mM KC1; lOmM MgCU, 0.1% (v/v) NP40; 5% (v/v)
glycerol). Following 20 minutes incubation at room temperature the samples were
loaded onto a 5% (w/v) polyacrylamide gel containing 0.5x TBE. The gel was run in
0.5x TBE for 1 hour at 30mA prior to exposure to autoradiography film (Roche) at -
80°C.
2.9.8.2 EMSA for the detection of nuclear NF-kB
Oligonucleotides encoding repeats of the NF-kB response element, NFkBfor and
NFkBrev, were separately labelled with 32P by the following reaction: lOOng DNA
32
was incubated with 5 units T4 polynucleotide kinase (NEB) and 1.5pl y- P-ATP
(lOmCi/ml stock; Amersham) in a total volume of 20pl, made up with PNK reaction
buffer (NEB), for 1 hour at 37°C. Unincorporated nucleotides were removed by
passage through G-25 columns (Amersham). The sense and anti-sense oligos were
then mixed together and allowed to anneal at room temperature for 10 minutes.
Probe was either used immediately or stored at -20°C.
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Binding reactions were set up, on ice, as follows: 5pg nuclear protein extract, 2pl 5x
binding buffer (50mM Tris pH 8.0; 750mM KC1; 2.5mM EDTA; 0.5% (v/v) Triton-
X 100; 62.5% (v/v) glycerol; ImM DTT), lpg poly dl-dT and lpl labelled probe
(1:10 dilution). Once all components were added the reaction was incubated at room
temperature for 30 minutes. Samples were then loaded onto a 5% (w/v)
polyacrylamide gel, containing 0.5x TBE, which was then run at 200V for 90
minutes. Once electrophoresis was complete, the gel was wrapped in Saranwrap and
exposed to autoradiography film (Roche) at -20°C.
2.9.9 Isolation of protein from polyacrylamide gel
Reactions were performed as described by Heaton et al (Heaton et al., 2001). The
binding reaction was earned out as described for EMSA but on a larger scale i.e. 1ml
total volume, and using a non-radiolabelled probe. A radiolabeled reaction was used
as a marker. Einlabelled complexes were excised at positions indicated by the
labelled complexes. Proteins were eluted from the gel by overnight incubation in
protein elution buffer (50mM Tris pH 7.9; O.lmM EDTA, 5mM DTT; 150mM NaCl;
0.1% (v/v) SDS) at room temperature with gentle agitation. Proteins were
concentrated using Vivaspin columns.
2.9.10 Raising antiserum against KSHV vFLIP
Following purification and concentration of vFLIP aliquots of protein were sent to
Diagnostics Scotland (Edinburgh, EH 17 7QT). There a rabbit was immunised and
boosted every four weeks for a total of 12 weeks with lOOpl (150/rg) of vFLIP. The
rabbit was bled before immunisation and at monthly intervals before final
106
exsanguination. Serum samples were dispensed into 1ml aliquots and stored at -
20°C.
2.10 Dual Luciferase Reporter Assay
Either lxlO5 BCP-1 or 5xl04HEK 293 cells were seeded in 24 well plates overnight.
Cells were washed with OptiMEM medium (GibcoBRL) prior to infection at
5pfu/cell in 200pl OptiMEM with vTF7-3 (Fuerst et ah, 1986), a recombinant
vaccinia virus expressing T7 RNA polymerase, for 1 hour at 37°C. The cells were
then washed twice with OptiMEM prior to transfection with 0.5pg of linearised
plasmid DNA and 1,5pg Transfast reagent (Promega) according to the manufacturers
instmctions. The DNA and Transfast reagent were added to 200pl OptiMEM and
vortexed rapidly. After a 20 minute incubation at room temperature the transfection
mix was added to the cells. 1ml complete medium was added after 1 hour incubation
at 37°C, 5% CO2 and the cells were incubated overnight. The transfected cells were
washed twice in SPBS prior to lysis in 200pl Passive Lysis Buffer (Promega). After
incubation at room temperature for 15 minutes the lysates were transferred to
Eppendorf tubes and snap-frozen on dry ice. The lysates were then thawed and
vortexed for 1 minute prior to centrifugation at 10,000g for 1 minute to sediment cell
debris. The activities of the Renilla and firefly luciferases were assayed using the
dual luciferase reporter assay (Promega) according to the manufacturer's
instructions. Luciferase activities were determined using a Labsystems benchtop
luminometer.
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Chapter 3 Construction and utilisation of recombinant
MHV-76 expressing KSHV vFLIP to investigate the
contribution of vFLIP toward viral pathogenesis in vivo
3.1 Recombinant virus construction using the CMV IE
promoter
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promoter
3.3 Construction of recombinant viruses 76inFLIP and
76inEGFP
3.4 Investigation into whether an immune response against
EGFP is responsible for the attenuation seen in vivo
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Construction and utilisation of recombinant MHV-76 expressing KSHV
vFLIP to investigate the contribution of vFLIP towards viral
pathogenesis in vivo
The narrow host range of gamma herpesviruses means that assessing the contribution
of individual KSHV genes towards viral pathogenesis in vivo is difficult. The
murine gamma herpesviruses, MHV-68 and MHV-76, represent a potential model
system whereby pathogenesis can be investigated and related to specific gene
products. As mentioned previously it is possible to manipulate the MHV-68 and -76
genomes. This property has been exploited by a number of groups to create both
knock-in and deletion mutants of MHV-68, analysis of which has contributed
toward elucidation of the function of a number of MHV-68 genes including M2
(Macrae et ah, 2003), M4 (Townsley et ah, 2004) and ORF73 (Fowler et ah, 2003).
The genomes ofMHV-76 and KSHV are very similar containing many homologous
gene products; however, KSHV possesses some genes which are not represented
within MHV-76. It was hypothesised that generation of recombinant MHV-76
viruses that express the unique KSHV genes may provide insights into the in vivo
function of these genes. MHV-76 does not encode either a vFLIP or an anti-
apoptotic product targeting caspase-8 activation. Consequently, recombinant viruses
expressing KSHV vFLIP were constructed. It was believed that the degree of
homology between the murine and human components of pathways influenced by
vFLIP is such as to allow any specific interactions to occur.
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3.1 Recombinant virus construction using the CMV IE promoter
The first recombinants to be constructed expressed vFLIP, EGFP and hygromycin
resistance (see figure 3.1); their expression was driven by the CMV IE promoter,
which is a strong promoter and thus should drive expression of the inserted
sequences at a high level. Translation of vFLIP is dependent upon the EMCV IRES;
EMCV is a picornavirus and its IRES element is one of the most efficient to be
discovered so far. This IRES element has been demonstrated to function efficiently
in murine cells (Kim et ah, 1992).
KSHV vFLIP was inserted at the left-hand end (LHE) of the MHV-76 genome by
homologous recombination. A pure virus population was then isolated by plaque
purification and confirmed by PCR and Southern blotting.
The plasmids pAB13 and pAB14 had been constructed previously (Appendix lb;
Brass, 2004). The vOx2 gene was removed by digestion with Ascl and FseI
followed by gel purification of the vector backbone; this was then S.A.P. treated.
KSHV vFLIP was amplified by PCR from BCP-1 DNA using the primers FLIP 76-1
and FLIP 76-2. The resulting product was gel purified, digested with Ascl and FseI,
and ligated into the vector. Correct insertion of vFLIP was confirmed by restriction
digest. The resulting plasmids are termed pFLl and pFL2. Confirmation that the
CMV IE promoter was active was achieved by transfection of 293 cells with both
plasmids; high EGFP expression was observed from both plasmids.
The plasmids were linearised by digestion with EcoRV and Pvull, which cuts the
inserted sequences and MHV-76 LHE from the vector backbone. BHK-21 cells were
transfected with linearised plasmid and MHV-76 DNA by electroporation. The cells
were divided between two wells of a 6 well plate and incubated for 72 hours.
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Subsequent examination of the cells revealed the formation of plaques some of
which expressed EGFP. A vims stock was then prepared by freeze-thaw and used to
infect BHK-21 cells previously seeded in 96 well plates. Recombinant MHV-76
containing the insert was purified from wild-type vims by four rounds of plaque
purification and an agarose overlay. After each round of purification the presence of
vFLIP in the viral DNA was confirmed by PCR. Once all plaques expressed EGFP a
masterstock of each vims, named FL1 and FL2, was made and viral DNA was
prepared. Southern blotting was carried out to confirm that the recombinant vimses
contained the insert in the correct location and orientation and were free of wild-type
contamination.
3.1.1 Southern blotting
DNA extracted from both recombinant vimses and wild type MHV-76 was subjected
to either MfeI or NheI digestion followed by Southern blotting with two different
probes. The expected hybridisation patterns are shown in figure 3.1 and table 3.1.
The resulting Southern blots (figures 3.2 and 3.3) confirmed the presence of the
inserts, in the correct orientation, and the absence of contaminating wild-type MHV-
76. As a further confirmation of purity PCR was carried out for wild-type virus
using primers M4B and Trepeat (figure 3.4); this was only positive in the MHV-76
sample.
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Figure 3.1 Schematic representations of the left hand end sequences of the
recombinant viruses FL1 and FL2. The restriction sites used for Southern
blot digestions and probe hybridisation locations are indicated.
FL1 FL2 MHV-76
Nhe\ Mfe I Nhel Mfe I Nhel Mfe I
GFP probe 6.17kb laddering laddering 4.75kb - -
LHE probe 6.17kb 1.15kb 3.9kb 4.75kb laddering laddering
Table 3.1 The expected band patterns for FL1 and FL2 Southern blots
following either Nhe\ or Mfe I digestion.
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Figure 3.4 PCR for wild type virus. Lane 1: FL1; lane 2: FL2; lane 3: MHV-
76 (positive control); lane 4: water (-negative control).
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3.1.2 In vitro growth characteristics
A one-step growth curve was carried out to assess the kinetics of replication of the
vFLIP expressing recombinant viruses in comparison to wild-type MHV-76. Also
included is the IRES control recombinant virus (Brass, 2004). The IRES control
contains the same inserted sequence as FL1 and FL2, in the FL1 orientation, with the
exception of vFLIP.
Infection of BHK-21 cells was carried out in duplicate and samples were taken at
intervals from 0 to 72 hours post infection. Samples were titrated on BHK-21 cells
and the viral titre at each time point was calculated. The resulting growth curve can
be seen in figure 3.5. The data indicate that the recombinant viruses all replicate
with similar kinetics to MHV-76 during a single round of replication in vitro. The
viral titre for all four viruses is indistinguishable up to 18 hours p.i. after which point
MHV-76 and IRES reach a higher titre than FL1 and, particularly, FL2. At the final
time point, 72 hours p.i., both vFLIP expressing recombinant viruses are at log lower
titre than the wild-type and control viruses.
As all four viruses displayed similar kinetics and were clearly viable in vitro, further
characterisation of their phenotype was undertaken using an in vivo system.
3.1.3 In vivo infection
Transcription of the KSHV vFLIP encoded by FL1 and FL2 is driven by the CMV IE
promoter and subsequent translation of vFLIP is dependent upon the EMCV IRES.
The expression of EGFP seen following infection of cells with pFLl and pFL2
cannot, therefore, be taken as proof that vFLIP is expressed. However, northern





0 6 12 18 24 30 36 42 48 54 60 66 72
Hours P.I
Figure 3.5 One step growth curve of recombinant viruses FL1, FL2, IRES
control and wild-type MFIV-76. The data represent the mean +/- the standard
error of the mean with each time point assayed in duplicate.
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transcribed; probing with a probe against vFLIP results in a band of ~4.2kb in both
FL1 and 2 but not in wild-type MHV-76. A MHV-76 ORF50 probe was used as a
control to confirm the presence of viral transcripts; all viruses produce the
characteristic pattern of a strong band around 2Kb in size and further additional
bands (Liu et ah, 2000; figure 3.6). There is no commercially available antibody
against vFLIP and attempts to raise antiserum proved unsuccessful (see section 3.5).
This meant that expression of the protein could not be directly confirmed. However,
the EMCV IRES has been demonstrated to mediate translation at approximately 30%
the efficiency of cap-dependent translation in vivo (Bieleski and Talbot, 2001) and
consequently we assume that some vFLIP is expressed. As vFLIP is not under the
control of its own promoter (even if it could be, a KSHV promoter would not
necessarily function correctly in a murine system) any expression will be at artificial
levels and not necessarily representative of protein levels achieved during natural
KSHV infection. Despite these limitations the opportunity to study the effect of a
KSHV gene product in the context of an in vivo infection was deemed to be valuable.
Twenty 3-4 week old BALB/c female mice were infected with each vims. At each
time point four mice per virus were euthanized and their organs harvested. The titres
of lytic virus in the lung and cell-associated virus in the spleen were determined by
plaque assay.
In comparison to MHV-68, MHV-76 is attenuated in lytic replication; it is rapidly
cleared from the lung (Macrae et al., 2001). The lytic virus titres in the lung indicate
that both FL1 and FL2 were cleared from the lung as rapidly as MHV-76 and the
control recombinant virus (figure 3.7).
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Figure 3.6 Northern blotting of total RNA extracted from virus infected C127
cells using probe for vFLIP (left hand image, expected size -4.2 Kb) or ORF
50 (right hand image, expected size -2Kb). Lane 1, FL3 (refer to section
3.2); lane 2, FL2; lane 3, FL1; lane 4 PGK-IRES; lane 5, MHV-76.
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MHV-76 reaches peak titre in the lung at day 4 p.i. and is cleared by day 10 (Macrae
et ah, 2001). All three recombinant viruses appear to display similar kinetics in vivo.
No virus could be detected in any animal by day 10 p.i. indicating that they were all
cleared equally efficiently from the site of initial replication. Whilst the viruses all
appear to be cleared at a similar rate the virus titres achieved show considerable
variation. At day 5 p.i. both vFLIP expressing recombinant viruses were at a 2 log
higher titre than MHV-76 and showed an even greater difference with respect to the
control recombinant virus, IRES. It is clear that the difference is not due to outlying
animals as in each group all four animals had very similar titres (figure 3.8). It
seems that the IRES virus is attenuated in lytic replication in the lung; this has also
been noted elsewhere (Brass, 2004).
The MHV-76 titres in the lung are much lower than would be expected from
previous in vivo work carried out in the lab ((Macrae et ah, 2001); B. Dutia; personal
communication). The reason for this is unclear and it would seem presumptive to
take this result as indicating that the vFLIP expressing viruses do attain a higher titre
of lytic virus than MHV-76. This aside, both vFLIP expressing recombinant viruses
attain a greater viral titre than the control, IRES, virus.
Turning to the spleen, titres of cell-associated recombinant virus were significantly
lower than those achieved by the wild-type virus (figure 3.9). This pattern has been
observed previously with other, similarly constructed, recombinant viruses (Douglas



















Figure 3.7 Infectious virus titres determined by plaque assay of lung
homogenates from infected BALB/c mice. Data shown represents the mean
















Figure 3.8 Day 5 lung infectious virus titres. Each point represents the viral
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Day 21
Figure 3.9 Spleen infective centres. Titres represent the amounts of cell-
associated virus in the splenocytes of infected BALB/c mice. Values
represent the mean titre from four animals +/- SEM.
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In comparison to MHV-68, MHV-76 itself displays a significantly reduced splenic
latent titre which peaks sooner post-infection (Macrae et al., 2001). The insertion of
additional sequences at the LHE seems to compound this attenuation.
3.2 Recombinant virus construction using the PGK promoter
There are reports that the CMV IE promoter becomes silenced over time (Gerolami
et ah, 2000). As KSHV vFLIP is latently expressed it was decided that it would be
best to construct recombinant viruses in which expression of the vFLIP gene is
mediated by a promoter which would not undergo silencing.
The murine phosphoglycerate kinase (PGK) promoter was chosen as there is
evidence that it is active in the majority of cell types and over an extended period of
time (Gerolami et ah, 2000). It was decided to make only one vFLIP expressing
recombinant virus, with the insert in the same direction as FL1; there was no
significant difference observed between FL1 and FL2 either in vitro or in vivo.
Additionally, the control recombinant virus is constructed in this orientation.
Site directed mutagenesis, using oligos pJ27 Bglll forward and pJ27 Bglll reverse,
was carried out on pAB13 to generate a Bglll restriction site at the 5' end of the
CMV IE promoter (giving pAB13-BglII). The promoter was then removed by
sequential Mlul digestion; blunt ending and Bglll digestion. The PGK promoter plus
intervening sequence (IVS) sequence was cut from the vector pPGK-EGFP (gift of
Jim Mcwhir; University of Edinburgh) with Bglll/ blunt ends and ligated into pFLl-
Bgllh Correct insertion was confirmed by EcoKl digestion. The vOx2 coding
sequence was cut from the vector by Fsel, Ascl digestion and replaced with, similarly
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digested, vFLIP DNA resulting in plasmid pFL3. Correct insertion was confirmed
by Fsel, Asc\ digestion and PCR. The control recombinant virus, PGK-IRES, was
constructed in a similar way i.e. the CMV IE promoter in the plasmid used to
construct the IRES recombinant virus was replaced by the PGK-IVS sequence
resulting in plasmid pPGK-IRES.
Recombinant viruses were constructed and purified in the same manner as previously
described for FL1 and FL2. Briefly, pFL3 and pPGK-IRES were digested with
iscoRV and Pvull and co-transfected into BHK-21 cells with wild-type MHV-76
DNA. Transfection by electroporation was unsuccessful on several occasions:
eventually transfection was achieved using Effectene reagent (Qiagen).
Recombinant viruses were purified by four rounds of limiting dilution plaque
purification during which selection was achieved via hygromycin resistance, EGFP
expression and in the case of FL3, PCR for vFLIP. Following agarose overlay a
masterstock of each virus and viral DNA were prepared. Southern blotting was
carried out to confirm the presence of the correct insert and the absence of wild-type
MFIV-76 in each recombinant virus preparation.
3.2.1 Southern blotting
DNA was extracted from two different isolates of each of FL3 and PGK-IRES, and
from MHV-76, subjected to either Mfel or Sphl digestion and blotted with two
different probes. Expected digestion patterns and band sizes are detailed in figure
3.10 and table 3.2. The resulting Southern blots had bands of the expected sizes and
confirmed the absence of wild-type viais in all of the recombinant viais samples
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Figure 3.10 Schematic representations of the left hand end sequences of the
recombinant viruses FL3 and PGK-IRES. The restriction sites used for
Southern blot digestions and probe hybridisation locations are indicated.
FL3 PGK-IRES MHV-76
Mfe 1 Sph I MfeI Sphl Mfel Sphl
GFP probe laddering ~5kb laddering ~4.4kb - -
LHE probe 1.15kb ~5kb 1.15kb ~4.4kb laddering laddering
Table 3.2 The expected band patterns for FL3 and PGK-IRES Southern blots
following either Nhe\ or Mfe I digestion.
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Figure 3.11 Southern blot of DNA of MHV-76 and two isolates each of FL3
(F1 and F2) and PGK-IRES (J1 and J2) using GFP probe.
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Figure 3.12 Southern blot of DNA from MHV-76 and two isolates each of FL3
(F1 and F2) and PGK-IRES (J1 and J2) using LHE probe.
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There were some anomalous bands of higher molecular weight than expected; this
phenomenon has been observed previously (Brass, 2004). As none of the additional
bands corresponded to any in MHV-76 both recombinants were deemed to be pure.
Virus stocks were made from FL3-1 and PGK-IRES-1, titred and stored at -80°C.
3.2.2 In vitro growth characteristics
A one-step growth curve was carried out to assess the kinetics of a single round of
replication whilst a multi-step growth curve was used to compare the viruses over
multiple rounds of replication. Infections of BHK-21 cells were carried out in
duplicate and samples were taken at 0-72 hours for the one-step and 0-144 hours for
the multi-step. Samples were subsequently titred on BHK-21 cells. The resulting
curves can be seen in figures 3.13 and 3.14. Both growth curves indicate that the
recombinant viruses replicate with almost identical kinetics to MHV-76.
In order to confirm that the inserted sequences were expressed, Northern blotting of
RNA extracted from infected CI27 cells was carried out. The CI27 cell line was
chosen as it is a murine cell line and expression in it is likely to correlate with
expression in vivo. Total cellular RNA was extracted and probed for ORF 50 and
KSHV vFLIP. The resulting blots (figure 3.6) confirmed the expression of viral
transcripts (ORF 50) and, in the case of FL3, vFLIP. Again, this does not prove that
vFLIP is being translated as this is under the control of the EMCV IRES and the
presence of an mRNA transcript does not mean that protein is being made. As
before, it must be assumed that there is some IRES activity and that some vFLIP will
be produced.
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Figure 3.13 One step growth curve of recombinant viruses FL3 and PGK-
IRES and wild-type MHV-76. The data represent the mean +/- the S.E.M.,
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Figure 3.14 Multi-step growth curve of recombinant viruses FL3 and PGK-
IRES and wild-type MHV-76. The data represent the mean +/- the S.E.M,
each time point was assayed in duplicate.
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3.2.3 In vivo infection
Thirty six 3-4 week old female BALB/c mice were infected with each virus. At each
time point mice were euthanised and their organs harvested. An outline of the work
undertaken is detailed in table 3.3.














6 As day 3 As day 3 -





As day 3 5 per virus in RPMI
1 per virus in OCT
14 As day 10 2 per virus in N2(l) As day 10
21 As day 10 As day 14 As day 10
Table 3.3 Outline of PGK promoter viruses in vivo experiment
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The titres of infectious virus in the lung and cell-associated virus in the spleen were
determined as before. In contrast to the previous in vivo experiment, with the CMV
IE promoter viruses, there was no difference in lung titres reached by the
recombinant viruses and MHV-76 (figure 3.15). When the data is represented so as
to show the titre from each mouse (figure 3.16) it is clear that the viral replication is
similar and not skewed by the presence of outlying animals. Interestingly, the
attenuation of the control recombinant virus seen previously (figure 3.7) is abolished
in this experiment.
Each snap-frozen lung was sectioned and immunohistochemistry was carried out on
the lung sections using a polyclonal antiserum, Rabbit B, raised against MHV-68.
This serum is also able to recognise MHV-76. A FITC conjugated secondary
antibody was used and the slides were mounted using mounting medium containing
propidium iodide to allow visualisation of the cell nuclei. We had hoped that we
would be able to see areas of apoptotic cells that corresponded with areas of infection
and perhaps to see a reduction in apoptosis in animals infected with the vFLIP
expressing recombinant virus. The resulting staining (figure 3.17) shows extensive
infection of all three viruses at days 3, 6 and 8 p.i.: the most virus being present at
day 6 p.i. which corresponds with the data obtained from the plaque assay. By day


















Figure 3.15 Titres of infectious virus in the lungs of infected BALB/c mice,
values represent the mean titres from 6 mice per virus +/- the S.E.M.
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Figure 3.16 Infectious virus titres in the lungs of individual BALB/c mice.
Note that the y axis scale varies.
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FL3 J38 MHV-76
Day 6 virus + P.I.
Day 10
Figure 3.17 Immunostaining of snap-frozen lung sections using a polyclonal antiserum
raised against MHV-68. The primary serum was used at 1/2000 dilution; the secondary
goat anti-rabbit FITC was used at 1/500. Sections were mounted using propidium iodide
containing mounting medium (vector labs). Images at 200x magnification.
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The nuclear staining gives no indication of significant apoptosis occurring at any
time point; no conclusions concerning that anti-apoptotic activity of vFLIP can be
inferred from these sections.
In the spleen FL3 induces no splenomegaly in infected animals (figure 3.18) and
infective centre levels attained by the recombinant viruses are greatly reduced in
comparison to MHV-76 (figure 3.19). No cell associated FL3 or PGK-IRES virus
was detectable from day 14 p.i. and at day 10 p.i. both viruses display severe
attenuation similar to that observed previously for FL1, FL2 and the IRES control
(figure 3.9).
3.2.4 Long term infection
All of the in vivo data presented above relates to the initial stages of infection. As
gamma-herpesvirus infection persists for the life of the host there remained a
possibility that any contribution of vFLIP towards viral pathogenesis is more
pronounced at later time points. Mice from the first, FL1 and FL2, in vivo infection
were euthanised approximately 1 year post-infection. The lungs, spleen, liver,
kidney and salivary gland were removed and either snap frozen in liquid nitrogen for
subsequent DNA extraction or preserved for sectioning. No mice displayed any
obvious pathology in terms of tumour growth or sickness.
Following DNA extraction from all tissue samples a PCR for ORF50 was carried out
to look for the presence of viral DNA. Following two rounds of 40 cycles, in which
2pl of the first round product was used as template for the second round, no viral





Figure 3.18 Total splenocytes per ml following extraction from the spleens of




Figure 3.19 Spleen infective centre titres. Titres represent the amounts of
cell-associated virus in the splenocytes of infected BALB/c mice. Values
represent the mean titre from five animals +/- S.E.M.
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This result implies that either the viruses had been completely cleared from the
animals or that the levels of virus were so low as to be undetectable in this system.
These results for FL1, FL2 and IRES are perhaps unsurprising given the severe
attenuation seen in the infective centre assay (figure 3.9) which suggests that the
recombinant viruses are unable either to establish a latent infection or to reactivate
from latency.
3.3 Construction of recombinant viruses 76inFLIP and 76inEGFP
Concerns have previously been raised over the effects of large inserts on viral
behaviour in vivo. It was demonstrated that whilst a BAC-derived MHV-68
replicated as wild-type virus in vitro, it was necessary to remove the BAC sequences
to achieve wild-type in vivo properties (Adler et al., 2001). Similarly, MHV-68
mutants constructed through the insertion of a large DNA sequence, e.g. lacZ, to
disrupt the gene of interest, show attenuation of the in vivo phenotype (Clambey et
al., 2000).
As the recombinant viruses expressing EGFP and hygromycin resistance were unable
to become latent in vivo, possibly because of an immune response to these inserts,
efforts were made to construct recombinant viruses without these selection markers.
Viruses similar to this had previously been successfully made, with MHV-68 genes
inserted into the left-hand end of MHV-76 (Townsley et al., 2004). In this instance
the gene of interest was inserted with its own promoter sequence driving expression.
Obviously this would not be possible for KSHV vFLIP as it is expressed via an IRES
element from a bicistronic transcript. Instead it was decided to try and insert vFLIP
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under the control of the PGK promoter which would, hopefully, provide long-term
expression of vFLIP. Additionally a second recombinant virus expressing EGFP
from the PGK promoter would be constructed to act as a control.
3.3.1 Cloning strategy
Once again the construction of recombinant viruses was carried out by homologous
recombination following transfection of BHK-21 cells with MHV-76 DNA and
plasmid DNA encoding the sequence to be inserted adjacent to a 3kb section of the
MHV-76 LHE. Two plasmids were prepared, one for each recombinant to be made.
In both cases the plasmid pBS 76-LHE was used as the backbone. p76inPGK-EGFP
was created by the insertion of the PGK-EGFP sequence from pEGFP-PGK into the
vector using Sad and Not\ restriction sites. p76inFLIP was cloned sequentially: the
PGK-IVS sequence was inserted first using the Sac\ and BamW\ restriction sites;
vFLIP, amplified from BCP-1 DNA using primers In flip forward and Flip polyA,
was inserted into the pCR 2.1-TOPO cloning vector (Invitrogen), cut from this with
BamWl and inserted into p76-LHE PGK using the same enzyme. In both cases the
vectors were checked by restriction digest to confirm insertion of the sequence in the
correct orientation.
3.3.2 Purification of recombinant viruses
As the inserted sequence contained no selection markers generation of recombinant
viruses was attempted purely by limiting dilution plaque purification. The presence
of EGFP in 76inEGFP allowed for some degree of selection. Both plasmids had to
be linearised prior to transfection to allow recombination to occur. The only suitable
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restriction sites, EcoRV, resulted in a lObp deletion from the 5' end of the PGK
promoter sequence. Transfection of BHK-21 cells with £coRV digested p76inPGK-
EGFP resulted in strong EGFP expression indicating that the deletion did not have a
detrimental effect on PGK activity.
Plasmid DNA, linearised by £coRV digestion, and MHV-76 DNA were transfected
into BHK cells using effectene transfection reagent (Qiagen). The cells were
incubated and 5 days post transfection plaques had formed; in the case of 76inEGFP
they were green. Purification was then attempted by plaque purification on BHK-21
cells in 96-well plates. After each round of purification the presence of the insert
was confirmed either by PCR, in the case of 76inFLIP (using primers In flip forward
and Flip polyA), or by EGFP expression. A PCR for wild-type MHV-76 using
primers M4B and Trepeat was also performed. At all times plaque picks came up
positive for wild-type virus and, as more rounds of purification were performed, the
number of insert positive samples reduced. In an attempt to accelerate the process an
agarose overlay was carried out. Again, all samples came up positive for wild-type
virus and in the case of 76inFLIP none of the 24 plaques sampled were positive for
vFLIP DNA.
Having failed once to purify 76inFLIP and 76inEGFP a second attempt was made.
Transfection and plaque purification was carried out. Initial results were more
promising as the insert was not lost as rapidly as previously seen and occasionally
plaques were negative for wild-type virus by PCR. However, in all cases wild-type
virus was again detected after a subsequent round of purification. This result
suggests that either the insert was being lost from the recombinant viruses or that a
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very low level of wild-type virus, below the limit of detection by PCR, was present
and had a growth advantage over the recombinant viruses.
Despite the fact that these recombinant viruses would have been very beneficial to
the project, efforts to purify them were halted as it became clear that the
contaminating MHV-76 could not be removed.
3.4 Investigation as to whether an immune response against EGFP is
responsible for the attenuation seen in vivo
Whilst the splenic attenuation of all of the recombinant viruses tested in vivo was
extremely disappointing and frustrating it also raises the interesting question of what
is causing it. There would seem to be two possibilities, firstly that the viruses are
failing to establish latency in the first place and secondly that having established
latency they are unable to reactivate and produce infectious virions. In order to
address the hypothesis, forwarded above, that an immune response against EGFP
results in clearance of the virus, mice tolerant to EGFP were infected and the spleen
cell-associated virus titres at day 10 p.i. were determined.
The mice used were of the ROSA strain (Mao et al, 2001). They have EGFP inserted
into their genome, the expression of which should be dependent on excision of a stop
sequence, located between two lox sites, by ere recombinase. However, it has been
discovered that there is some "leaky" expression of EGFP and we therefore assume
that the mice are tolerant to its presence (B.Dutia; personal communication). The
ROSA mice are on a LI29 background and so different to BALB/c which were used
in the previous experiments. Ideally the experiment would have been performed in
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LI29 and ROSA mice to determine that the behaviour of the viruses in the ROSA
background was the same as that seen in BALB/c mice. Lack of availability of the
LI29 strain meant that this was not possible but MHV-68 is known to display similar
behaviour in the ROSA mice as seen in BALB/c although the titres reached are lower
(B.Dutia; personal communication). We made the assumption that MHV-76 would
establish splenic latency at levels similar to infected BALB/c mice and that, as seen
in BALB/c, the recombinant viruses would display attenuation in the spleen of the
ROSA strain. It was hypothesised that if the attenuation was due to an immune
response against EGFP this would be eradicated in these mice and thus the titres of
the recombinant virus would rise to the levels ofMHV-76.
Four mice per virus were infected intranasally with 4xl05 pfu of FL3, PGK-IRES
and MHV-76. After 10 days, the point at which maximum splenic infective centre
titres are achieved in BALB/c mice, the mice were euthanised and their spleens
removed. The titres of cell-associated virus in the spleens were determined by
infective centre assay. As previously there was no obvious splenomegaly induced by
either recombinant virus; the splenocyte numbers are equivalent to those of the
MHV-76 infected group (figure 3.20). Surprisingly it appears that not only the
recombinant viruses but also MHV-76 are severely attenuated, with respect to the




Figure 3.20 Total splenocytes per ml following extraction from the spleens of




Figure 3.21 Spleen infective centre titres. Titres represent the amounts of
cell-associated virus in the splenocytes of infected ROSA mice. Values
represent the mean titre from five animals +/- S.E.M.
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3.5 Purification of KSHV vFLIP protein and attempts to raise antiserum
in rabbits
As vFLIP translation is under the control of an IRES element, both in its natural
setting, KSHV, and in the recombinant viruses that have been constructed, the mere
presence of an mRNA transcript (which is produced, see figure 3.6) does not equate
with protein expression. In order to draw any absolute conclusions from work
carried out using the vFLIP encoding viruses a method through which the presence
of vFLIP protein can be verified must be in place. The obvious means by which the
presence of a protein within a system can be proven is by immunostaining using an
antibody raised against the protein in question. It would be most desirable to confirm
the translation of vFLIP during the course of both of in vivo and in vitro experiments
undertaken.
Additionally, an antibody would allow investigation of the levels of vFLIP
expression in PEL derived cell lines. It would be fascinating to determine whether
there was any change in translational activity throughout the course of the cell cycle.
For instance, is there any decrease in cellular FLIP expression following inhibition of
cap-dependent translation, at the entry to mitosis, and if so does a compensatory
increase in IRES-mediated vFLIP translation take place? It would seem likely that
the expression of vFLIP is closely linked to that of vCyclin as both proteins are
encoded by the same transcript. Moreover, investigation of the kinetics and levels of
expression of the two proteins relative to one another would perhaps give some
indication as to whether a role of vFLIP is to protect virally infected cells as vCyclin
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drives them through the cell cycle. If this is the case then vFLIP could be said to be
acting as an indirect oncogene, protecting proliferating cells from apoptosis.
At present there are no commercially available antibodies against KSHV vFLIP, or
indeed any other viral FLIP. I, therefore, carried out purification of vFLIP and
attempted to raise antiserum by immunisation of rabbits with the resulting protein.
3.5.1 The Glutathione S-transferase (GST) Gene Fusion System
The first attempt to purify vFLIP utilised the GST Gene Fusion System (Amersham).
In this system the protein to be purified is expressed in E.coli as a fusion with
glutathione S-transferase (GST) from Schistosoma japonicum. The fusion proteins
are expressed from an inducible promoter at high levels and can be purified from
bacterial lysate by affinity chromatography using glutathione sepharose 4B;
glutathione is bound by the GST moiety. Following washing steps, to remove non¬
specific binding, the fusion protein can be eluted from the glutathione sepharose or,
alternatively, it can be treated with thrombin to cleave the target protein from the
GST thus eluting vFLIP whilst GST remains bound to the sepharose. The
purification process is monitored by Western blotting using a primary antibody
against GST.
KSHV vFLIP was amplified from BCP-1 DNA by PCR using the primers FLIP
GST-1 and FLIP GST-2 and sub-cloned into the FcoRI and Xliol sites of pGEX4T-l.
This vector enables expression of the vFLIP from the IPTG responsive tac promoter
and encodes a thrombin cleavage site immediately downstream of the MCS into
which vFLIP is inserted. Correct insertion of vFLIP was confirmed by restriction
digest and BigDye sequencing was also performed: the resulting sequences
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confirmed that two of the clones, numbers 3 and 11, contained vFLIP that was
correctly inserted with no deletions.
Protein purification was carried out according to the manufacturer's instructions.
The purification process was monitored by Western blotting using an anti-GST
antibody (Invitrogen). Cultures of E.coli transformed with pGEX4Tl-vFLIP clone 3
were grown in 200ml volumes. Sonicate was prepared in a volume of 10ml and
thrombin cleavage was carried out in a total volume of approximately lOOpl.
Despite extensive attempts to optimise the cleavage reaction in the majority of cases
thrombin treatment resulted in disassociation of the GST-vFLIP fusion protein from
the sepharose. In fact, successful cleavage, which released vFLIP whilst maintaining
GST binding to the glutathione sepharose, was achieved only once (fig 3.22). The
eluted vFLIP was run on a SDS-PAGE gel and coomassie stained. This showed a
band at approximately 21kD, the correct size for vFLIP (gel shattered on drying).
A total of four, monthly, injections were made into a rabbit. The failure to purify
vFLIP more than once meant that only the first two injections were of purified
vFLIP; the final two were of vFLIP-GST fusion protein. The resulting serum was
tested for reactivity against vFLIP by Western blot. Unfortunately the serum acted
against the GST moiety; there was no band at 21kD. It was perhaps not unexpected
that there would be an immune response directed toward GST, however, it is
disappointing that there appears to have been no response against vFLIP.
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Figure 3.22 Western blot of vFLIP purification using the GST system. Lane
1, sonicated cells; lane 2, soluble protein; lane 3, supernatant following
incubation with sepharose; lane 4, eluted GST; lane 5, supernatant following
thrombin cleavage (vFLIP). The primary antibody, mouse anti-GST, was
used at 1/1000 dilution, the secondary, goat anti-mouse alkaline
phosphatase , was used at 1/2,500 dilution. The GST-vFLIP fusion protein is
approximately 46kDa and can be seen in lane 2. This band is no longer seen
following incubation with the sepharose indicating that the protein has bound
successfully. Following thrombin cleavage no GST is seen in the
supernatant (lane 5) whilst the fraction eluted from the sepharose contains
only GST and no fusion protein (lane 4).
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3.5.2 The pTrcHis expression system
A second attempt to purify vFLIP without any large additional tags was made using
the pTrcHis expression system (Invitrogen). The protein of interest i.e. vFLIP, is
expressed with both a His6 and a myc tag at its C-terminus, which adds
approximately 2.5kDa to the total size of the protein. The His6 tag provides an
efficient means of protein purification as it binds with high affinity and specificity to
nickel. Consequently, Hisg-tagged proteins can be separated from a mix of proteins
by affinity chromatography. The myc epitope provides a means by which the
purified protein can be detected, in both Western blotting and
immunohistochemistry, as several companies supply monoclonal antibodies that
recognise it. The vFLIP coding sequence was amplified by PCR from BCP-1 DNA,
using the primers In flip forward and flip Myc His reverse which also add the Hindlll
and Ncol restriction sites and cloned into the corresponding sites of pTrcHis2A.
Insertion of vFLIP was confirmed by restriction digest and PCR.
A pilot expression experiment was carried out to assess the kinetics of vFLIP
expression following IPTG induction of E.coli transformed with pTrcHis2A-vFLIP.
lml samples of the induced culture were pelleted and lysed in lOOpl SDS PAGE
loading buffer. A 10pl sample was then analysed by Western (fig 3.23). A protein
of the correct size to be Myc-his tagged vFLIP is seen from 1 hour post induction.
Having demonstrated that vFLIP was expressed in the system, larger scale
purification was carried out and monitored by Western blotting (figure 3.24) and
silver staining (figure 3.25). Lanes 3 and 4 of the western blot indicate that vFLIP is
successfully eluted from the Nickel affinity gel; the silver stain shows that there are
no higher molecular weight contaminants of the protein preparation.
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Figure 3.23 Western blot analysis of vFLIP expression following IPTG
induction. Lane 1, 0 hours post induction; lane 2, 1 hour post induction; lane
3, 2 hours post induction; lane 4, 3 hours post induction; lane 5, 4 hours post
induction; lane 6, 5 hours post induction. The primary antibody, mouse anti-
Myc (Invitrogen), was used at 1/ 3,000 dilution. The secondary antibody,
goat anti-mouse alkaline phosphatase, was used at 1/ 2,500 dilution. vFLIP






Figure 3.24 Western blot of vFLIP purification by nickel affinity. Lane 1,
solubilised proteins; lane 2, unbound protein; lane 3, elute 1; lane 4, elute 2.
The primary antibody, mouse anti-Myc (Invitrogen), was used at 1/ 3,000
dilution and the secondary antibody, goat anti-mouse alkaline phosphatase,
at 1/2,500 dilution.
Figure 3.25. Silver stain of purified protein. A clear band is seen at
approximately 21 kD, the correct molecular weight to be vFLIP.
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Once purified, vFLIP protein was concentrated using VIVASPIN columns and stored
at -20°C. Four, monthly injections of lOOpl (approx 150pg) vFLIP were made into a
rabbit.
3.5.2.1 Testing the antiserum
The resulting antiserum was tested in both Western blotting, against purified vFLIP,
and immunostaining, of BCP-1 cytospins, for its activity against vFLIP.
Unfortunately the serum proved to be unreactive in both procedures
3.6 Conclusions
Through the generation of recombinant MHV-76 viruses expressing KSHV vFLIP
we hoped to determine the effects of vFLIP expression on viral pathogenesis. The
first viruses to be constructed utilised the CMV IE promoter to drive expression of
the selection markers and, in the case of FL1 and FL2, vFLIP. In vitro
characterisation by means of a one-step growth curve demonstrated that the three
recombinant viruses replicated with similar kinetics to the wild-type MHV-76 (figure
3.5). However, the vFLIP expressing viruses lagged behind the wild-type and IRES
control viruses in terms of the viral titre achieved at 72 hours p.i. Two possible
explanations for this may be that either the expression of vFLIP is in some way
reducing the lytic replication of the FL1 and FL2 viruses, or the virally infected cells
are surviving longer and thereby increasing the time taken from infection to release
of virus so the curve lags behind that of wild-type virus. Northern blotting of total
RNA extracted from infected C127 cells indicated that transcription of viral genes
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was taking place and that vFLIP transcripts were present in the FL1 and FL2 infected
cells (figure 3.6). As mentioned, in the absence of an antiserum against vFLIP it is
impossible to prove that vFLIP protein is being translated; we must assume that the
strong EMCV IRES results in some protein production. It must be remembered that
KSHV vFLIP is translated via an IRES element (Bieleski and Talbot, 2001) and
therefore one can argue that its dependence upon an IRES for translation in this
system is representative of the situation in KSHV infection.
Both FL1 and FL2, in which insert expression is driven by the CMV IE promoter,
achieved significantly higher titres of infectious virus in the lungs of BALB/c mice at
day 5 p.i. than did the control IRES virus (figure 3.7). They also reached titres
approximately 2 log higher than MHV-76. It is worth noting that the lung titres
observed following MHV-76 infection were lower than normal in this experiment
and so great significance should not be given to this difference. That said the
difference between the vFLIP expressing viruses and the IRES control is large and
real. It may be inferred from this result that vFLIP provides some replicative
advantage at the initial stages of infection. It is possible that use of the CMV IE
promoter results in very high expression of EGFP resulting in a strong immune
response to the recombinant viruses. The expression of vFLIP may delay cell death
for long enough to allow greater levels of viral replication to take place in FL1 and
FL2 infection.
As has previously been noted following infection of BALB/c mice with recombinant
viruses of this type (Douglas et al., 2004; Brass, 2004) all three recombinant viruses
were severely attenuated in terms of the cell-associated viral titre in the spleen
(figure 3.9). The reasons for this are unclear. We hypothesised that the attenuation
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was most likely due to either an enhanced immune response to the inserted
sequences, perhaps EGFP, or a failure of the virus to reactivate from latency. I
attempted to determine whether an immune response against EGFP was responsible
through the infection of EGFP-expressing ROSA mice. Unfortunately determination
of the infective centre titres in the spleens of these mice at day 10 p.i. revealed that
not only the recombinant viruses but also MHV-76 were attenuated, reaching
extremely low titres (figure 3.21). The levels of MHV-76 virus detected are at a
similar level to that seen for the recombinant viruses in the BALB/c experiments
(figures 3.9 and 3.19). Statistically speaking, the recombinant viruses and MHV-76
produce the same infective centre titres in ROSA mice i.e. the previously observed
difference is abolished. One could interpret this as an abolition of the relative
attenuation and therefore conclude that the previously seen deficiency of the
recombinant viruses was due to their expression of EGFP. However, because the
numbers are so small it is impossible to say conclusively. One would need to repeat
the experiment in LI29 mice to confirm that the recombinants reach a significantly
lower infective centre titre than MHV-76 and if the numbers seen in this experiment
are repeated this may well be impossible. The other possibility is that the viruses are
unable to reactivate once they have established latency. Previous studies have
indicated that viral DNA is present in the spleens of animals infected with
recombinant viruses suggesting that there may be inefficient reactivation from
latency (Brass, 2004). Unsurprisingly, given the extremely low recombinant virus
titres in the spleen, no viral DNA was detectable in animals infected one year
previously.
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When it became apparent that the CMV IE driven viruses were attenuated in the
spleen we decided to stop using them. At the time the focus of our experimental
plans was driven by the fact that vFLIP is one of only three truly latent genes
encoded by KSHV and we were therefore interested in looking for more long-term
effects of vFLIP expression in vivo. However, vFLIP is also transcribed during lytic
replication and thus may be important during this stage of the viral lifecycle. In
hindsight the CMV viruses may have proved to be useful tools for investigating
primary infection, especially now that it is clear that all recombinant viruses
expressing EGFP and hygromycin resistance are attenuated.
As we were looking to elucidate the role of vFLIP over the long-term course of
infection and because it has been reported that the CMV IE promoter is silenced over
time (Gerolami et al., 2000) it was decided to construct new recombinant viruses in
which expression of the inserted sequences would be driven by the PGK promoter.
This is a murine promoter of a house-keeping gene and it is known to be active in
most cell types and to be constitutively active (Gerolami et al., 2000). The vFLIP
expressing virus, FL3, and control, PGK-IRES, were successfully constructed and
purified. The replication of the viruses in vitro was investigated by means of a one-
step and a multi-step growth curve: in both cases the recombinant viruses replicated
with identical kinetics to MHV-76 and there was effectively no difference in the viral
titres at any time point (figures 3.13 and 3.14 respectively). As previously, Northern
blotting following infection of CI27 cells with the two recombinant PGK driven
viruses results in viral transcription and vFLIP transcription from FL3 (figure 3.6).
Perhaps significantly the amount of vFLIP transcript present is greatly reduced in
comparison to FL1 and FL2 infection: this demonstrates that the PGK promoter is
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not as strong as the CMV IE promoter and implies that the level of vFLIP produced
following in vivo infection will be lower than that resulting from FL1 and FF2
infection.
Determination of infectious virus titres in the lung shows that, in contrast to the
CMV IE viruses, there is no difference in the replication of the control and vFFIP
expressing viruses (figure 3.15). As PGK is not as strong a promoter as CMV IE,
and consequently EGFP would not be expressed at such high levels, this gives
weight to the theory that the reduced titre of the IRES control virus in the lung seen
previously (figure 3.7) may be due to an immune response against EGFP. Perhaps
when the levels of expression are reduced (because they are driven by the PGK
promoter) the reaction to EGFP is not as severe and, therefore, the protective effect
of vFLIP, which would be at a lower level itself, is not as apparent. The
immunostaining carried out on frozen lung sections (figure 3.17) clearly shows the
presence of virus in the lungs at early time points and its clearance by day 10. There
was no distinct difference in the number or size of the foci of infection between all
three viruses: this is not unexpected as the titres of all three viruses are very similar.
The PGK recombinant viruses were attenuated in the spleen in a similar manner to
the CMV IE viruses (figure 3.19). The failure of the ROSA experiment to shed any
light on the reason for the attenuation is frustrating; it remains unknown whether it is
due to an immune response resulting in rapid clearance of the virus from the infected
mice or because the viruses are unable to reactivate from latency. Whatever is the
case it would seem that the attenuated phenotype is the result of the nature of the
insertion into the LHE of MHV-76. These low infective centre titres in the spleen
have been observed following infection of BALB/c mice with recombinant MHV-76
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viruses expressing the KSHV genes vOx2 and K1 together with EGFP and
hygromycin resistance (Douglas et ah, 2004; Brass, 2004). In contrast, recombinant
viruses in which the gene of interest was inserted into the LHE under the control of
its own promoter and without selection markers are not attenuated in the splenocyte
viral load (Townsley et al., 2004). Ultimately unsuccessful attempts to generate a
recombinant virus in which vFLIP was inserted under the control of the PGK
promoter and without selection markers were made. It seems that, for some reason,
the PGK-vFLIP and PGK-EGFP sequences were not maintained within the viral
genome. This phenomenon has been observed by others attempting to insert a
similarly sized fragment into the LHE of MHV-76 (A.Cliffe; personal
communication). It is possible that the small size of the insert results in a packaging
deficiency for the vims: the addition of "stuffer DNA" sequences into the LHE may
aid future attempts at generating recombinant MHV-76 viruses without EGFP and
hygromycin resistance.
In an attempt to generate antiserum reactive against KSHV vFLIP two different
protein purification systems were utilised. The first of these, glutathione affinity
chromatography, which required vFLIP to be expressed as fusion protein with the
GST moiety proved ultimately frustrating. With one exception all purification
procedures resulted in vFLIP-GST fusion protein: the cleavage of GST from vFLIP
by thrombin was in some way inhibited. Rabbits were injected with the fusion
protein in the hope that there would be a reaction to vFLIP but the resulting serum
was only reactive against a GST-sized protein (figure 3.23).
In terms of protein production, the second system, nickel affinity purification, was
much more successful. Pure vFLIP protein was generated on all occasions.
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However, injection of this vFLIP into rabbits failed to generate reactive antiserum.
The reasons for this are unclear but one possibility may be that the level of homology
between vFLIP and the rabbit cFLIPs was too great and that the KSHV protein was
not recognised as being foreign.
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Chapter 4 Utilisation of recombinant viruses to investigate
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Utilisation of recombinant viruses to investigate establishment of
latency in vitro
4.1 Determination of the ability of recombinant and wild-type MHV-76 to
infect NSO cells
The inability of any of the recombinant viruses to establish a latent infection in vivo
has meant that the mouse model could not be used to elucidate the long-term effects
of vFLIP expression on the progression of disease. An alternative system by which
viral latency could be investigated was therefore sought. It has previously been
reported that MHV-68 can establish latency in the murine B cell line NSO (Sunil-
Chandra et al., 1993). If the same were true for MHV-76 and the MHV-76
recombinant viruses, NSO cells may represent a useful system for studying latency in
vitro. As mentioned previously none of the recombinant viruses were able to
establish detectable latency in vivo; the reason for this is unknown but may be
exacerbated by an immune response to EGFP.
NSO cells are a myeloma cell line derived from the MOPC 21 BALB/c myeloma
(Kohler and Milstein, 1976). Cells were infected at a M.O.I, of 5 and maintained at
37°C, 5% CO2. Initially the cells were thought to be uninfected as there was no
detectable EGFP expression. Nevertheless cellular DNA was extracted at 5 days p.i.
and a PCR for MHV-76 ORE 50 was carried out using primers RTA3F and RTA3R.
This proved positive in the case of all three viruses, although only weakly so for
MHV-76, indicating that the cells were infected (figure 4.1).
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Figure 4.1 PCR for MHV-76 ORF 50 carried out using DNA extracted from
infected NSO cells at 5 days p.i. Lanes 1-3, FL3 infected cells; lanes 4-6,
PGK-IRES infected cells; lane 7, MFIV-76 infected cells; lane 8, water.
Figure 4.2 PCR for GAPDH carried out on cDNA from virally infected cells.
Lanes 1-2, FL3 infected NSO cells; lanes 3-4, PGK-IRES infected NSO cells;
lane 5, BCP-1 cells; lane 6, water.
Figure 4.3 PCR for vFLIP carried out using cDNA generated from virally
infected cells. Lanes 1 and 2, FL3 infected NSO cells (2 separate cultures);
lane 3, BCP-1 cells; lanes 4 and 5, FL3 infected NSO cells -RT; lane 6, BCP-
1 cells -RT; lane 7, water.
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Subsequently mRNA was extracted from recombinant virus infected cells (4 days
p.i.) and cDNA was generated. The quality of the cDNA was checked by PCR for
GAPDH using primers GAPDH 1 and GAPDH 2 (figure 4.2). A PCR for vFLIP was
then carried out using primers 76-1 and 76-2 (figure 4.3). This indicated that vFLIP
was being actively transcribed in infected NSO cells.
Having established that NSO cells were permissive for infection with MHV-76
recombinant viruses and, therefore, presumably wild-type MHV-76, viral replication
and its effects on cell proliferation were investigated.
4.2 Cell proliferation following infection
Infection of fibroblast cells lines e.g. BHK-21, with MHV-76 and the recombinant
viruses results in rapid induction of cytopathic effects. In contrast, the majority of
infected NSO cells appear healthy. After infection at a M.O.I, of 5, measurements of
viable cell numbers were taken over the next 21 days using trypan blue staining to
distinguish viable from dead cells. The cell counts demonstrate that the cells
continue to proliferate post infection (figure 4.4).
During the course of experimental infection dead cells were not removed by
Histopaque-1077 separation in order to prevent loss of infectious virus in the
supernatant. As a result, at later time points, the proportion of dead cells within the
population was increased, however, viable cells remained in the majority at all times.
The rate of cell proliferation is identical following infection with all three viruses
which implies that the expression of vFLIP confers no growth advantage or
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Figure 4.4 Total numbers of viable NSO cells following infection with MHV-
76, FL3 and PGK-IRES. Two infections with each virus were carried out in
parallel; the data represents the mean value per virus at each time point.
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4.3 Virus production and establishment of latency
The levels of virus in the supernatant were measured by plating dilutions of the
supernatant, from a known number of NSO cells, with BHK-21 cells. The
supernatant viral titre was then calculated. This provides an indication of the amount
of infectious virus being released by each cell line. The resulting data can be seen in
figure 4.5. At all time points tested, and for all three viruses, there was infectious
virus present in the supernatant. The titre of each virus decreased over the course of
the experiment with FL3 titre decreasing most slowly. Throughout the course of the
experiment there was more virus released from the FL3 infected cells than from
either the PGK-IRES or MFIV-76 infected cells. This could be because a greater
proportion of the cells within the population were infected or because a larger burst
size was achieved following FL3 infection.
Levels of cell-associated virus were assessed by standard infective centre assay,
titrated on BF1K-21 cells (figure 4.6). Again, there is no particular difference
between the viruses in terms of the kinetics of the curves. The initial titres of FL3
and PGK-IRES are approximately one log greater than MHV-76. This may be
partially due to an inaccuracy in dispensing the viruses, however, as the supernatant
titres are almost identical at Ohrs it may be that the FL3 virus bound to the cells more
efficiently. Whilst the infective centre assay allows calculation of the amount of
cell-associated virus (both latent virus and infectious cell-associated virions)
associated with the NSO cells it gives no indication of the relative amounts of each.
In order to distinguish between the two, the cells were subjected to freeze thaw
treatment prior to titration of the resulting lysate (figure 4.7). Following this
procedure only pre-formed virions will be capable of infecting cells resulting in
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Figure 4.5 Infectious virus titre in the supernatant of infected NS0 cells. Data
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Figure 4.8 Latent virus titres of infected NS0 cells; calculated by subtracting
freeze-thaw titres from infective centre titres.
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Combining the data displayed in figures 4.6 and 4.7 enables the latent virus titre at
each time point to be calculated (figure 4.8). The latent titres achieved following
infection of NSO cells with the three viruses vary considerably. FL3 establishes a
much greater pool of latently infected cells than does PGK-IRES and MHV-76. This
is most pronounced at day 8 p.i. at which point FL3 displays a 4-fold greater latent
titre than PGK-IRES and a greater than 25-fold higher latent titre than wild-type
MHV-76. These titres, calculated by subtracting the freeze-thaw titre from the cell-
associated virus titre, may also prove to be an underestimate of the true extent of
latency. Each plaque formed following titration of the cells following freeze-thaw
treatment represents one infectious virus particle. However, each infected cell would
most likely contain more than one infectious virion and consequently subtraction of
these values will result in an underestimation of latent titre although this may be
equal for all three viruses.
4.4 NF-kB activation following viral infection in vitro
Whilst working toward this thesis it was reported that the expression of KSHV
vFLIP led to the activation of the cellular transcription factor NF-kB (Liu et ah,
2002; Sun et ah, 2003). NF-kB activation is important for the control of cell survival
following a stress-inducing event. There are NF-kB response elements located in the
promoters of more than 150 cellular genes (Pahl, 1999); these include pro¬
inflammatory cytokines and chemokines, immunoreceptors, anti-apoptotic proteins
and factors involved in cell proliferation. Among the anti-apoptotic proteins induced
by NF-kB, in conjunction with at least one other transcription factor, is cFLIP (Kreuz
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et al., 2001). Thus, one result of vFLIP mediated NF-kB activation may be a general
increase in FLIP activity in an infected cell; perhaps representing a kind of positive-
feedback. Additionally, NF-kB activation has been implicated in the progression of
cancers, toward which its anti-apoptotic and pro-inflammatory activity contribute
(reviewed in (Karin et al., 2002; Pikarsky et al., 2004)): again, this may be a
mechanism by which vFLIP can contribute toward the pathogenesis of KSHV.
Finally, NF-kB activation has been shown to play an important role in the lifecycle
of herpesviruses including HCMV, which requires functional IKK2, an NF-kB
activator, to complete productive replication (Caposio et al., 2004) and EBV, which
is dependent on NF-kB for LCL survival (Cahir-McFarland et al., 2004). Co-
transfection of reporter plasmids under the control of gammaherpesvirus lytic
promoters, together with their activators and increasing amounts of the
transcriptionally active (p65) subunit of NF-kB, indicates that NF-kB is able to
inhibit promoter activity in a dose dependant manner (Brown et al., 2003). As NF-
kB appears to promote the survival of latently infected EBV positive cells and
perhaps to inhibit reactivation, via its suppression of lytic promoters, the possibility
that activation of NF-kB contributes toward the increase in numbers of latently
infected NS0 cells following FL3 infection was investigated.
An electrophoretic mobility shift assay, using the NF-kB response element as the
probe, was carried out in order to establish the kinetics of NF-kB activation
following infection of NS0 cells with the recombinant viruses FL3 and PGK-IRES
and the wild-type MHV-76. Cells were infected at a M.O.I, of 5 and subsequently
maintained at 37°C, 5% CO2. At each time point lxlO7 cells were harvested and
nuclear extracts prepared. Uninfected NS0 cells were used as a negative control and
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BCP-1 cells, which display constitutive activation of NF-kB (Cerimele et al., 2001),
as a positive control. Samples were taken at days 1, 3, 5, 8 and 21 post infection.
With the exception of the day 21 samples, dead cells were not removed by
Histopaque-1077 separation; however, the cells were supplied with extra growth
medium. EMSAs were carried out as described in Materials and Methods and can be
seen in figures 4.9 to 4.13. At day 1 p.i. a shift can be seen in all lanes, except
uninfected NSO, indicating that NF-kB was activated in all virally infected cells
(figure 4.9). The shift observed using the BCP-1 nuclear extract is at a slightly
different location to those observed using NSO extracts: this is most likely to be due
to the different amino acid composition and thus relative charge of the human and
murine NF-kB subunits. These differences would be reflected in differences in
mobility through the non-denaturing gel. In all three cases the activation of NF-kB
was maintained throughout the time course of infection, up to day 8 p.i. The amount
of protein used in each binding reaction was kept relatively constant through use of
the same numbers of cells in each nuclear extract preparation and the same volume
of extract in each reaction. By day 21 p.i. the shift in MHV-76 infected cells is much
less intense than that in FL3 infected cells (figure 4,13), in fact it has almost
disappeared. The intensity of the band in the PGK-IRES infected cells is less than
that of the FL3 infected cells at day 21 p.i.: densitometry analysis (table 4.1)
indicates that the PGK-IRES band is less than half as intense as the FL3 band
suggesting that there is greater NF-kB activation in cells latently infected with FL3
than with the control.
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Figure 4.9 EMSA to show activated NF-kB in nuclear extracts of virally
infected cells at day 1 post infection. Lane 1, probe only; lane 2, BCP-1; lane
3, NSO only; lane 4, NSO + FL3; lane 5, NSO + PGK-IRES; lane 6, NSO +
MHV-76.
168
Figure 4.10 EMSA to show activated NF-kB in nuclear extracts of virally
infected cells at day 3 post infection. Lane 1, probe only; lane 2, BCP-1; lane
3, NSO only; lane 4, NSO + FL3; lane 5, NSO + PGK-IRES; lane 6, NSO +
MHV-76.
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Figure 4.11 EMSA to show activated NF-kB in nuclear extracts of virally
infected cells at day 5 post infection. Lane 1, probe only; lane 2, BCP-1; lane
3, NSO only; lane 4, NSO + FL3; lane 5, NSO + PGK-IRES; lane 6, NSO +
MHV-76.
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Figure 4.12 EMSA to show activated NF-kB in nuclear extracts of virally
infected cells at day 8 post infection. Lane 1, probe only; lane 2, BCP-1; lane
3, NSO only; lane 4, NSO + FL3; lane 5, NSO + PGK-IRES; lane 6, NSO +
MHV-76.
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Figure 4.13 EMSA to show activated NF-kB in nuclear extracts of virally
infected cells at day 21 post infection. Lane 1, probe only; lane 2, BCP-1;
lane 3, NSO only; lane 4, NSO + FL3; lane 5, NSO + PGK-IRES; lane 6, NSO
+ MHV-76.
FL3 PGK-IRES Ratio FL3: PGK-IRES
51.465 20.026 2.57: 1
Table 4.1 Table showing densitometry data from latent EMSA (figure 4.13).
Readings are integrated optical density.
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4.5 Conclusions
This work demonstrates that the recombinant viruses, FL3 and PGK-IRES, and wild-
type MHV-76 are able to infect a B cell line, NSO, and establish a persistent, latent,
infection of these cells. Cell-associated virus could be detected up to 35 days p.i. by
infective centre assay (data not shown). This suggests that the inability of the
recombinant viaises to establish latency in vivo, demonstrated in chapter 3, may be
the result of some kind of immune response directed against one or more inserted
products, most likely EGFP: such a response would be lacking in vitro.
Consequently, it appears that any elucidation of the contribution of vFLIP towards
long term in vivo pathogenesis would be impossible using these recombinant viruses.
However, NSO cells represent a system whereby some of the reported activities of
vFLIP may be assessed in the context of a latent viral infection.
There is a marked difference between the in vitro phenotypes displayed following
FL3 infection of NSO cells when compared to infection with the control recombinant
virus, PGK-IRES, and MHV-76. The amount of infectious virus produced by FL3
infected cells is greater than that released from PGK-IRES and MHV-76 infected
cells (figure 4.5). Moreover, FL3 infection results in a greater cell-associated virus
titre and higher titres of infectious virions per culture. Subtracting the cell-associated
infectious virion titres (figure 4.7) from the infective centre titres (figure 4.6) allows
calculation of the latent viral titre (figure 4.8). This demonstrates that FL3 initially
establishes a greater degree of latency than do PGK-IRES and MHV-76. The
difference is most distinct at day 8 p.i. after which the FL3 latent titre begins to fall.
From this data it appears that vFLIP expression infers an advantage in the
establishment of a latently infected pool of cells. This is particularly striking at
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earlier time points: by day 8 post infection the FL3 infected cells display more than
4-fold greater latent titres than the PGK-IRES control and an even greater difference
in titre when compared to wild type MHV-76 (approximately 25-fold). Thus, in this
system, the expression of vFLIP confers an advantage to the virus through the
establishment of a larger pool of latently infected cells than that established by the
control recombinant virus or MHV-76. If such behaviour is indicative of its in vivo
role this would imply that expression of vFLIP aids the initial viral infection and
enhances the establishment of latency.
It would seem very unlikely that the differences observed in this system are a result
of the directly anti-apoptotic activity of vFLIP i.e. its prevention of caspase-8
activation. This being so one must turn to vFLIPs other properties to determine how
it elicits this effect. Over the last few years a second property of vFLIP has come to
the fore namely its activation of the transcription factor NF-kB. This may be
mediated by association of vFLIP with the IKK complex, via IKKy (Field et al.,
2003), resulting in constitutive phosphorylation of the IkBcx subunit (Liu et al., 2002)
and release of active NF-kB which is subsequently imported into the nucleus. The
activation ofNF-kB has been demonstrated to be necessary for the survival of KSHV
infected PEL cells (Keller et al., 2000); vFLIP is responsible for maintaining
constitutive NF-kB activity in these latently infected cells and vFLIP expression is
essential for their survival (Guasparri et al., 2004).
In the light of this work the activation of NF-kB as a result of infection by the
recombinant viruses, FL3 and PGK-IRES, was assessed and compared to the
32activation resulting from MHV-76 infection. This was done by EMSA using a P-
labelled NFkB binding site as the probe. Infection with all viruses resulted in
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activation of NF-kB: this was expected as viral infection is one of the many events
capable of activating NF-kB (reviewed in (Pahl, 1999)).
NF-kB remains activated in all virally infected cell cultures up to day 8 p.i. Once
latency is established, assessed at day 21 p.i., there is almost no activated NF-kB in
the MHV-76 infected cell culture. This is in contrast to the recombinant viruses.
Whilst a quantitative measurement ofNF-kB activation is difficult it is apparent that
FL3 results in constitutive activation of NF-kB, but that this is not observed
following MHV-76 infection. The day 21 data also seem to suggest that PGK-IRES
infection results in the constitutive activation of NF-kB albeit at an apparently lower
level than results from FL3 infection. If NF-kB activation is indeed responsible for
the enhanced viral titres and establishment of latency observed in FL3 infection, the
activated NF-kB in the PGK-IRES infected NSO cultures explains why this
recombinant virus displays a higher latent titre than the wild-type MHV-76 (figure
4.8). At this point one can only speculate as to the reason why PGK-IRES infection
should result in long-term activation of NF-kB. It would seem very unlikely to be a
result of EGFP-hyg expression; however, it is perhaps a possibility that the EMCV
IRES in the inserted sequence at the LHE of PGK-IRES is able to drive expression
from the first MHV-76 ORF in the virus. There is a short section of MHV-68 M4
sequence incorporated into pAB13 (Brass, 2004) and thus pFL3; this corresponds to
the final 84 amino acids at the C-terminus of the M4 protein (56 of which follow the
first methionine residue encoded). It has been suggested that M4 has a role in both
the establishment of latency and in immunoregulation (Townsley et al., 2004).
Consequently, if there is some leaky expression of a C-terminal fragment of M4 it is
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a possibility that it is able to mediate NF-kB activation or to influence latency via
some other mechanism.
I would hypothesise that FL3 infection results in a greater and longer lasting
activation ofNF-kB than either the control recombinant PGK-IRES or the wild type
MF1V-76 and that this is responsible for the greater latent viral titres seen following
infection ofNSO cells in vitro.
It has previously been reported that vFLIP, through its activation of NF-kB, is
essential for the survival of latently infected PEL cell lines (Guasparri et al., 2004).
The data presented in this chapter indicates that this property of vFLIP also enhances
the initial establishment of latency immediately following infection.
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Identification of IRES interacting factors
Since the initial identification of internal ribosome entry as a mechanism of
translation, the range of viral and cellular genes shown to be translated via an IRES
has grown rapidly. The additional factors necessary for IRES function range from
the 80s ribosomal subunits only (Wilson et ah, 2000) to the canonical translation
initiation factors together with several cis-acting factors. The KSHV IRES has
previously been shown to be active only in KSHV positive cell lines (Bieleski and
Talbot, 2001). This cell type specificity would make it unlikely that ribosome
assembly occurs directly and raises the possibility that cis-acting factors are required.
To date, only a limited number of IRES transactivating factors (ITAFs) have been
identified. These include polypyrimidine tract binding protein (PTB), upstream of
N-ras (unr) and members of the eIF4G family of translation initiation factors.
Attempts were made to identify protein factors from PEL cell lines that are able to
interact with the KSHV IRES.
Several different assays to determine RNA-protein interactions have been described.
These include the yeast-3-hybrid system, cross-linking assays and pull down assays.
Attempts to identify proteins capable of interacting with the KSHV IRES utilised a
range of these techniques.
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5.1 Yeast 3-hybrid assay
The aim behind conducting a yeast 3-hybrid screen was to carry out screening of all
proteins expressed in a KSHV positive cell line; that is all the proteins present in a
system in which the IRES is functional. It was hoped that proteins capable of
interacting with the IRES sequence would be identified and that these could then be
further characterised to establish whether they were necessary for translation
initiation from the IRES.
The yeast 3-hybrid screen was developed to allow the detection of RNA-protein
interactions independently of the biological role of the elements of interest
(SenGupta et al., 1996). Based upon the yeast 2-hybrid system (Fields and Song,
1989; Chien et al., 1991), which is used to detect protein-protein interactions, the
system enables analysis of large libraries of RNAs or proteins to identify specific
interacting species. The basic principle by which the system works is illustrated in
appendix 3. The intention was to utilise the system to screen a library of proteins
derived from the KSHV-positive BCP-1 cell line for species that interacted
specifically with the IRES RNA. A primary lambda phage library of BCP-1 cDNA
in the ElybriZAP vector (Stratagene) had previously been constructed. This was
converted to a pAD-GAL4 phagemid library, by in vivo mass excision, and titred at
1.6xl09 colony forming units/ml. Plasmid DNA containing the DNA inserts was
purified using a Qiagen maxiprep kit following incubation of the XLOLR bacterial
host strain with the phagemid particles. The minimal IRES sequence was cloned into
the vectors pIII/MS2-l and pIII/MS2-2 (provided by Marvin Wickens, University of
Wisconsin) by annealing the oligos 3 HYB IRES 3 and 3 HYB IRES 4 and ligating
the annealed oligos into Smal digested vectors. Sequencing confirmed the insertion
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of the IRES in the correct orientation and without mutations. The yeast strain L40
coat (provided by M.Wickens) was successfully transformed with both plasmids,
separately, with selection on medium lacking uracil. The next stage was to optimise
the transformation of the yeast expressing the IRES sequence with the library
plasmids. In order to ensure as complete representation of the library as possible it is
necessary to achieve a 10-fold greater number of transfectants than there are cDNAs
within the library. Despite carrying out the transformation on many separate
occasions and changing a number of variables including: the order of transformation
(i.e. IRES or library first or double transformation); amount of DNA; heat shock
time; method of library DNA preparation (Qiagen kits and CsCE) and yeast strain,
the efficiency with which the yeast could be transformed with the library was never
great enough to allow screening to proceed.
5.2 Investigation of specific ITAFs
The failure of the yeast 3-hybrid screen was particularly disappointing as it would
have allowed a global screening approach with all possible binding partners
examined. The alternative strategies, whilst valid methods for the identification of
interacting partners, were inferior, in that some idea as to the possible identity of the
KSHV ITAFs was required. The decision was made to concentrate on factors
already identified as ITAFs for other IRES elements and to investigate whether any
of these could interact with the KSETV IRES.
Upon analysis of the IRES sequence the most striking feature to emerge is the
presence of a polypyrimidine tract (PPT) (see figure 1.8). Using a number of
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different bicistronic reporter constructs the minimum RNA sequence required for
IRES activity has been determined; the PPT was shown to be fundamental (Bieleski
et ah, 2004). The polypyrimidine tract binding protein, PTB (hnRNP I), has been
shown to associate with a number of different viral and cellular IRES elements.
Viral IRES elements with which PTB interacts include FMDV (Luz and Beck, 1991;
Luz and Beck, 1990), ECMV (Jang and Wimmer, 1990), poliovirus (Hellen et ah,
1994) and hepatitis C virus (Ali and Siddiqui, 1995). Subsequent work has
demonstrated that, in the majority of cases, PTB not only interacts with these IRESs
but that this interaction is necessary for efficient cap-independent translation to
occur. An example of this is the HCV IRES; the inhibition of PTB by the addition of
an excess of its RNA binding site (Anwar et ah, 2000) or by the expression of siRNA
against PTB (Zhang et ah, 2004) ablated IRES activity. In terms of cellular IRES
elements, PTB associates with the Apaf-1 IRES and is proposed to be involved in
altering the mRNA structure to allow interaction with the ribosome (Mitchell et ah,
2003; Mitchell et ah, 2001). In the light of its regular identification as an ITAF and
the presence of the PPT within the KSHV IRES, PTB was investigated as a possible
KSHV ITAF.
Whilst IRES mediated translation does not require the full translation initiation
complex (eIF4F and associated factors) most cases investigated so far do not work
independently of all elFs. In particular, members of the eIF4G family have
frequently been identified as being necessary for IRES activity. eIF4G itself, of
which there are two functional homologues eIF4GI and eIF4GII (Gradi et ah, 1998),
can be regarded as a modular protein of at least 154kDa (Yan et ah, 1992), consisting
of three domains each of which interacts with different components of the
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translational machinery. The N-terminus associates with the cap-binding protein
eIF4E (Lamphear et ah, 1995) and the polyA binding protein (PABP) (Le et al.,
1997); the middle section contains binding sites for eIF4A, which unwinds the DNA,
and eIF3 which recruits the 40S ribosomal subunit to the mRNA (Imataka and
Sonenberg, 1997); the C-terminus interacts with eIF4A and the eIF4E kinase Mnkl
(Pyronnet et al., 1999). The hepatitis A virus (FIAV) IRES requires full length
eIF4G for its activity; the cleavage of eIF4G by FMDV Lb protease or rhinovirus 2A
protease inhibits HAV IRES activity (Borman and Kean, 1997). This is in stark
contrast to all other picornavirus IRES elements characterised to date, all of which
display enhanced translational activity following cleavage of eIF4G. It has been
appreciated for many years that picornavirus infection results in cleavage of eIF4G,
down-regulation of cellular protein synthesis and preferential translation of viral
proteins (reviewed in Belsham and Sonenberg, 1996). The altered translation pattern
is the result of eIF4G cleavage mediated by viral proteases, for example the 2A
protease of poliovirus (Etchison et al., 1982) and the Lb protease of FMDV
(Devaney et al., 1988). The picornavirus proteases cleave eIF4G at specific sites
within its protein sequence; 2A protease cuts between amino acids 486 and 487
(Lamphear et al., 1993) and Lb protease between amino acids 479 and 480
(Kirchweger et al., 1994). As a result, the eIF4E and eIF3 binding sites of eIF4G
become dissociated (Lamphear et al., 1993) thus inhibiting 5' cap-dependent
translation. In addition to its inhibitory effect on 5'cap- dependent translation, the
picornavirus mediated cleavage of eIF4G results in protein fragments that are
necessary for viral IRES function. It has been demonstrated that the EMCV IRES
requires only the central, eIF4A-binding, domain of eIF4G for activity (Pestova et
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al., 1996). Following picornavirus induced eIF4G cleavage the C-terminal fragment,
which includes this central domain, is able to promote cap-independent translation
(Ohlmann et ah, 1996; Pestova et ah, 1996; Borman et ah, 1997). Whilst 2A
protease can directly target eIF4G (Lamphear et ah, 1993), cleavage has been
reported to proceed very inefficiently (Bovee et ah, 1998); however, there are more
recent reports indicating that, in vitro at least, the reaction proceeds more efficiently
than previously thought (Glaser and Skern, 2000). In any case, there is evidence that
in addition to direct cleavage, 2A protease activates an as yet unidentified cellular
protease which goes on to target eIF4G (Zamora et ah, 2002; Bovee et ah, 1998).
Interestingly, eIF4G mRNA itself apparently contains an IRES (Gan et ah, 1998)
although the levels of activity are disputed (Han and Zhang, 2002). Besides eIF4GI
and eIF4GII, another member of the same protein family, death associated protein 5
(DAP5/ p97/ NAT1) can act as an ITAF for some IRES elements (Henis-Korenblit et
ah, 2000; Henis-Korenblit et ah, 2002; Nevins et ah, 2003). DAP5 was identified
independently through screens to identify genes of the eIF4G family (Imataka et ah,
1997) and mediators of apoptosis (Levy-Strumpf et ah, 1997). DAP5 shares
homology with the central sections of eIF4GI and eIF4GII, which are responsible for
eIF4A and eIF3 binding, and totally lacks the eIF4G N-terminal domain. DAP5
itself can be translated via an IRES and accumulates in apoptotic cells in which cap-
dependent translation is compromised in a translation reaction dependent on
complete DAP5 or a caspase-cleaved fragment, DAP5/p86 (Henis-Korenblit et ah,
2000).
The cleavage of eIF4G can also be initiated through the action of caspases following
the induction of apoptosis (Clemens et ah, 1998). The fragments generated are
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different from those resulting from poliovirus protease cleavage; three relatively
long-lasting fragments termed C-FAG, M-FAG and N-FAG are produced (Bushell et
ah, 2000). It is proposed that the middle fragment, which maintains interactions with
eIF3, eIF4A and the ribosome, is able to support limited levels of cap-independent
translation (Bushell et ah, 2000).
One hypothesis could be that following infection with KSHV members of the eIF4G
family are cleaved, either as a result of apoptosis or activation of a cellular protease
by a KSHV protein, and the resulting fragments may be able to promote vFLIP
translation. Alternatively it is a possibility that the IRES may be more similar to
HCV and require full length eIF4G. As they are frequently identified as being
necessary for both viral and cellular IRES function, members of the eIF4G family
were investigated as possible KSHV ITAFs.
5.2.1 Pull down assay using full-length IRES
A pull down assay was developed based on the method described by Stassinopoulos
and Belsham (Stassinopoulos and Belsham, 2001). The premise of the assay is to
use the IRES sequence as a probe to deplete a protein extract containing species
suspected of being able to associate with the RNA sequence. In order to achieve this
the sequence of interest is cloned into a vector from which it can be expressed with a
polyA tail. Once mixed with magnetic beads with covalently attached poly dT
sequences, the RNA associates with the beads through base pairing. The beads, with
attached probe, are then incubated with the protein extract after which the beads can
be separated from the mixture using a magnet. After washing steps, to remove non-
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specifically bound proteins, any species that have associated with the probe sequence
can be eluted with a denaturing buffer and subjected to further analysis.
In the following experiments the full length KSHV IRES sequence (233bp) was used
as a probe. The IRES sequence was amplified from BCP-1 DNA using the primers
IRES forward and IRES reverse, for the sense direction, and Anti-IRES forward and
Anti-IRES reverse, for the antisense direction. Both PCR products and the vector
pSP64poly(A) (Promega) were digested with HindWl and Sacl, gel purified and
ligated together to give the contructs pSP64sense and pSP64antisense. Correct
insertion was confirmed by AatU digestion. These constructs were then used as
templates in in vitro transcription reactions to produce the probes. The IRES inserted
in the antisense direction serves as a control for the specificity of any interactions
(the antisense IRES had no activity when tested in a bicistronic reporter assay;
Bieleski and Talbot, 2001). Proteins that were eluted from the beads were subjected
to Western blotting using primary antibodies against proteins suspected as possible
ITAFs.
An initial experiment was carried out using rabbit reticulocyte lysate (Promega) as
the protein extract. Whilst this will not contain any KSHV proteins it should contain
the majority of cellular proteins and therefore most previously identified ITAFs. The
captured proteins and depleted extract were run on a 12% SDS PAGE gel and
subjected to Western blotting using an anti-PTB antiserum (a gift from R.J.Jackson,
University of Cambridge; Hunt and Jackson, 1999). This first assay (figure 5.1)
indicated that PTB was able to interact with the KSHV IRES sequence: no PTB was
detected following incubation of the beads alone with RRL, however, a clear doublet
at ~65kD can be seen in both the sense and antisense lane.
185
Having demonstrated that the pull-down assay was functional, using RRL as the
source of proteins, it was decided to use a more physiologically relevant protein
extract. To this end S10 extract was prepared from BCP-1 cells: the KSHV IRES is
functional in these cells and therefore they contain all the factors necessary for its
activity. The pull down assay and Western blot were repeated as before. The
resulting Western blot (figure 5.2) again shows that PTB was captured by the IRES
transcribed in the sense orientation. Using the BCP-1 S10 extract the interaction is
specific for the IRES in the sense orientation only.
In addition to PTB, the possibility that some form of eIF4G was able to associate
with the KSHV IRES was investigated. An antibody against the C-terminus of
eIF4G (Santa Cruz Biotechnology) was used in Western blotting against proteins
eluted from the beads and depleted extract. RRL was used as the source of proteins.
The Western blot (figure 5.3) shows clear bands in the lanes containing protein
eluted from both the sense and antisense orientation RNA. However, these bands are
approximately 75kD in size, much smaller than the 154kD size of intact eIF4G.
Bands of this size were consistently pulled down, by both probes, when the assay
was repeated using RRL making it unlikely to be an artefact. The requirement for
eIF4G as an ITAF for IRES activity was investigated by means of a dual luciferase
reporter assay, see section 5.3.
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Figure 5.1 Western blot of pull down assay carried out using a 233bp IRES
as probe and RRL. Lane 1, RRL proteins; lane 2, beads only captured
protein; lane 3, beads only depleted extract; lane 4, sense RNA captured
protein; lane 5, sense RNA depleted extract; lane 6, antisense RNA captured
protein; lane 7, antisense RNA depleted extract. Primary antiserum, rabbit
anti-PTB, used at 1/1000 dilution; secondary antibody, mouse anti-rabbit




Figure 5.2. Western blot of pull-down assay using BCP-1 S10 extract. Lane
1, antisense RNA depleted extract; lane 2, antisense RNA captured protein;
lane 3, sense RNA depleted extract; lane 4, sense RNA captured protein;
lane 5; BCP-1 S10. Primary antiserum, rabbit anti-PTB, at 1/1000;







Figure 5.3 Western blot of pull down assay carried out using a 233bp IRES
probe and RRL. Lane 1, sense orientation captured proteins; lane 2, sense
orientation depleted extract; lane 3, antisense orientation captured proteins;
lane 4, antisense orientation depleted extract. The primary antiserum was
goat anti-elF4G at 1/500 dilution; secondary antibody, mouse anti-goat
alkaline phosphatase, at 1/2,500 dilution.
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Western blotting of the captured proteins was also carried out using an antibody
against DAP5 (Cell Signalling Technology) to address the possibility that the bands
seen in figure 5.3 were due to cross-reactivity of the anti-eIF4G antibody with DAP5
or a cleavage product of DAP5. No bands were detected using this antibody.
5.2.2 Pull down assay using minimal functional IRES sequence
Since the initial characterisation of the KSHV IRES sequence (Bieleski and Talbot,
2001) further work has been able to demonstrate that the PPT is absolutely required
for its activity and that this sequence alone is able to direct translation of a
downstream cistron (Bieleski et al., 2004). We were interested to investigate the
ITAFs able to interact with this "minimal" IRES sequence. To this end the oligos
3HYB IRES 3 and 3HYB IRES 4, which contain the PPT and produce a blunt ended
fragment, were annealed together and ligated into the vector pSP64poly(A) which
had been digested with Smcil. Insertion of the IRES sequence and the orientation in
which it had been inserted were determined by AatW digestion. The resulting
plasmids were termed pSP64 60bp sense and pSP64 60bp antisense. These plasmids
were used as templates in in vitro transcription reactions to produce probes for use in
pull-down assays with BCP-1 S10 extract. Western blotting was earned out on
captured proteins and depleted extract using the anti-PTB and anti-eIF4G antisera.
On no occasion were bands observed in any of the captured protein lanes (data not
shown).
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5.3 Luciferase reporter assay to assess the impact of elF4G cleavage on
IRES activity
The size of the bands resulting from Western blotting of the captured RRL proteins
with an antibody against eIF4G (figure 5.3) was reminiscent of the 76kD M-FAG
fragment generated as a result of caspase cleavage (Bushell et ah, 2000). As
mentioned above this fragment is proposed to be able to support some cap-
independent translation (Bushell et al., 2000). In an effort to investigate whether a
cleavage product of eIF4G was necessary for activity of the KSHV IRES a dual
luciferase reporter assay was utilised. This is the experimental system most
commonly used to identify RNA sequences with IRES activity (Vagner et al., 2001).
Following co-transfection of a dual luciferase reporter plasnrid (figure 5.4), encoding
the full-length KSHV IRES (pdLUC8; Bieleski and Talbot, 2001), and a plasmid
encoding the rhinovirus 2A protease (pAA802; gift of L.Roberts, University of
Surrey (Roberts et al., 1998)) the level of IRES activity was determined as described
in section 2.9. Assays were performed initially in HEK 293 cells. The KSHV IRES
is not functional in these cells (Bieleski and Talbot, 2001), however, it was
hypothesised that if cleaved eIF4G is an ITAF some IRES activity may be restored
when 2A protease is also present in the cell. As a control for transfection the plasmid
pRL-TK (Promega) was used; the translation of Renilla luciferase (RL) transcribed
from this plasmid is cap-dependent. The construct pdLUC-EMCV, containing the
EMCV IRES sequence, (Bieleski and Talbot, 2001) was used as a control for IRES
activity. The results following transfection ofHEK 293 cells can be seen in table 5.1
and those for BCP-1 cells can be seen in table 5.2.
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Figure 5.4 Schematic representation of pdLUC plasmid. The coding
sequences of the Renilla and firefly luciferase enzymes are cloned
downstream of the T7 RNA polymerase promoter. Ordinarily the FF would
be inefficiently accessed by ribosomes which had completed translation of
RL; insertion of an IRES sequence results in enhanced translation of the
downstream cistron. pdLUC8= KSHV IRES; pdLUC-EMCV= EMCV IRES.
Plasmid RL FF
pRL-TK 1123 0.864
pRL-TK + pAA802 12.39 0.051
pdLUC8 8057 35.6
pdLUC8 + pAA802 5.483 0.00
pdLUC-EMCV 5051 2401
pdLUC-EMCV + pAA802 1.296 44.06
Table 5.1 The activities of the RL and FF enzymes (in relative light units)




pRL-TK + pAA802 131.5 1.446
pdLUC8 5351 442.0
pdLUC8 + pAA802 1.005 0.305
pdLUC-EMCV 2157 873.9
pdLUC-EMCV + pAA802 0.311 4.782
Table 5.2 The activities of the RL and FF enzymes (in relative light units)
following transfection of BCP-1 cells. Data from a representative experiment
is shown.
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The results show that, as previously observed, the KSHV IRES is not functional in
HEK 293 cells. The cleavage of eIF4G by 2A protease did not restore any IRES
activity in these cells: it is clear that the protease was active as the translation of RL,
which is 5' cap dependent, has been inhibited. When the constructs are transfected
into BCP-1 cells the KSHV IRES displays activity of translation at approximately
10% the efficiency of 5' cap dependent translation. This agrees with previously
published data (Bieleski and Talbot, 2001). As observed previously, in HEK 293
cells, the co-transfection of pAA802 resulted in obliteration of RL translation. In
these cells the KSHV IRES activity was not maintained following the cleavage of
eIF4G by 2A protease. It must also be noted that the EMCV IRES activity was lost
following 2A expression in BCP-1 cells; this contradicts previous findings that this
IRES only requires the central third of eIF4G for its activity (Pestova et al., 1996).
This suggests that the expression of 2A protease affects more than just eIF4G in
these cells and, consequently, the obliteration of KSHV IRES activity cannot be
definitively attributed to eIF4G cleavage.
5.4 Electrophoretic mobility shift assay
As an alternative method of investigating protein binding to the IRES an EMSA was
employed. As mentioned previously the KSHV IRES activity is cell type dependent;
there is very little or no activity in KSHV negative cell lines e.g. HEK 293 cells
(Bieleski and Talbot, 2001). The radiolabeled IRES has been used as a probe in an
EMSA. Specific protein complexes were formed when the probe was incubated with
whole cell lysate from BCP-1 cells (a KSHV positive PEL cell line). These
complexes were not formed following incubation with HEK 293 cell lysate and were
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BCP-1 293
Cell extract - + + + +
Competitor RNA - - + +
Non-complexed
RNA - M
Figure 5.5 EMSA showing the formation of specific complexes between the
KSHV IRES and components of BCP-1 S10 extract. These complexes are
not replicated when HEK 293 cell extract is used and are specific as they are
not formed in the presence of competitor, unlabelled, RNA. Taken from
Bieleski et al, 2004.
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competed out by an excess of unlabelled IRES indicating that they are specific
(figure 5.5; Bieleski and Talbot, 2001).
The isolation of proteins from a polyacyrlamide gel, following gel shift, has been
described previously (Heaton et al., 2001; Ranish and Hahn, 1991). The possibility
of using this technique to isolate the components of the IRES-protein complexes was
consequently investigated.
The probe was derived from the plasmid pSP64polyA sense, which was originally
constructed for use in the pull-down assay. The plasmid DNA was linearised by SacI
digestion, which removes the polyA tail, prior to use as the template in an in vitro
transcription reaction. Two transcription reactions were carried out; one with cold
UTP and the second with 32P-UTP. Following overnight transcription the template
was removed by DNase treatment and unincorporated nucleotides were removed by
passage through a G-25 column. The probes were then used in binding reactions
with S10 extract from BCP-1 cells. The P labelled reaction was as described in
section 2.8.8.1. The cold reaction was performed on a larger scale; 200pl of S10
extract was used in a total volume of 1ml. Following 20 minutes incubation at room
temperature the samples were run on a 5% polyacrylamide gel in 0.5x TBE running
buffer. Once run, the gel was exposed to film at -20°C overnight prior to
development to detect the position of the high molecular weight complexes. Using
the labelled complexes as a guide the corresponding sections of the gel, where the
unlabelled reaction was run, were excised and the proteins contained therein eluted.
The eluted proteins were concentrated using spin columns and 10pl of the resulting
extract was run on a 12% SDS PAGE gel and subjected to silver staining (figure 5.6).
Two bands can clearly be seen at approximately 75 and lOOkD in size.
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Figure 5.6 Silver staining of SDS PAGE gel of proteins eluted from EMSA.
Lane 1, size markers; lane 2, eluted proteins. Two bands can clearly be
seen in lane 2, one at approximately 100kD and the second at approximately
75kD; a third, weaker band is visible at approximately 150kD.
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Western blotting was subsequently earned out using antisera against PTB, eIF4G and
DAP5 but no bands were revealed in any blot.
As a final attempt to determine the identity of the proteins eluted from the EMSA the
extract was run by SDS PAGE, stained using Sypro Ruby (Molecular Probes) and
the individual bands cut from the gel. The band of approximately lOOkD in size was
subjected to MALDI-TOF mass spectrometry (carried out at the Edinburgh Protein
Interaction Centre). This protein was identified as heat shock protein 90.
5.5 Conclusions
Unfortunately, attempts to carry out a large-scale yeast 3-hybrid screen for ITAFs
proved unsuccessful. This would have been the ideal starting point in the search for
viral and/ or cellular components of the vFLIP translation machinery as,
theoretically, all possible interacting factors would have been represented. Despite
trying a wide variety of different transformation conditions the efficiency with which
the BCP-1 library DNA could be transformed into yeast remained too low for a
screen to be carried out. This meant that efforts to identify any proteins that interact
with the IRES sequence had to be carried out in a more focused manner; proteins
previously identified as interacting with other IRES elements were investigated as
possible ITAFs. The presence of a PPT within the minimal IRES sequence (Bieleski
et al., 2004) and its frequent identification as an ITAF led to PTB being a strong
candidate for a role in vFLIP translation. PTB was demonstrated to associate with
the IRES by pull-down assay although it was not detectable by Western blotting
following protein elution from an EMSA gel. There may be several reasons for this
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apparent disparity, principal among which must be the possibility that the transcribed
IRES does not fold correctly under one set of assay conditions.
Western blotting of proteins captured by the pull-down assay with an antibody
against the C-terminus of eIF4GI revealed a band of approximately 76kDa associated
with the IRES in both orientations (figure 5.3). This raised the possibility that a
cleavage product of eIF4G was required for KSE1V IRES function. In order to
investigate this hypothesis a dual-reporter luciferase assay was employed and IRES
function was assayed in HEK 293 and BCP-1 cells and in the presence of a protease
that specifically cleaves eIF4G. The data obtained from these assays indicate that
once cleaved eIF4G is not able to act as an ITAF. There was no enhancement of
IRES activity in HEK 293 cells and in BCP-1 cells IRES activity was obliterated in
the presence of the protease (tables 5.1 and 5.2). Correspondingly, the inhibition of
KSHV IRES activity in BCP-1 cells following co-transfection of pAA802 suggests
that full-length eIF4G may be required for translation to take place. There is a very
faint band of approximately 150kD visible in the silver stain of proteins isolated
following EMSA (figure 5.6); it is possible that this is eIF4G. One note of caution in
relation to this must be the lack of EMCV IRES activity following 2A protease
expression. Infection of cells with EMCV, unlike other picornaviruses, does not
result in eIF4G cleavage. Instead, inhibition of cap-dependent translation is achieved
through activation of the translational repressor 4E-BP (Gingras et al., 1996).
However, it has been demonstrated that despite this lack of intrinsic cleavage, the
EMCV IRES only requires the C-terminal fragment of eIF4G for its activity (Pestova
et al., 1996) which is not reflected in the dual-luciferase assay data. Use of a stem-
loop upstream of the RL coding sequence to inhibit cap-dependent translation,
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through prevention of the assembled translation complex scanning along the mRNA
to the start codon, has no effect upon levels of translation from the IRES (Bieleski
and Talbot, 2001). Therefore, the inhibition of IRES activity following transfection
of pAA802 suggests that the 2A protease has more effect upon the cell than merely
cleavage of eIF4G. Consequently 2A protease may be responsible for the inhibition
of IRES activity through secondary mechanisms. In light of this observation further
studies must be carried out before one can conclude that full-length eIF4G is an
ITAF for the KSHV IRES.
The abundant cellular protein Hsp90 was identified following mass spectrometry
analysis of protein eluted from an EMSA gel using the full-length IRES sequence as
a probe. Whilst this may well prove to be an artefact it is interesting to note that the
same protein has been identified as a component of the IKK complex (Chen et al.,
2002) with which vFLIP also interacts (Field et ah, 2003). Addition of an inhibitor
of Hsp90 resulted in inhibition of vFLIP induced NF-kB activation and led to the
death of PEL cells (Field et ah, 2003). If the interaction of Hsp90 with the IRES is
real then this would also suggest a mechanism by which newly translated vFLIP
could interact efficiently with the IKK complex.
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Chapter 6 Discussion
6.1 The contribution of vFLIP toward viral pathogenesis
6.2 Identification of ITAFs that interact with the KSHV IRES
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Discussion
The work described in this thesis was performed to investigate two separate aspects
of KSHV vFLIP biology, firstly its effect on viral pathogenesis and secondly the
factors necessary for its translation. In this discussion I shall address each issue in
turn.
6.1 The contribution of vFLIP toward viral pathogenesis
The relative ease with which the genome of the murine gammaherpesvirus MHV-76
can be manipulated was exploited to generate several recombinant viruses containing
the selection markers EGFP and hygromycin resistance, and KSHV vFLIP at their
LHE; FL1, FL2 and FL3. Expression of these genes was controlled by either the
CMV IE or murine PGK promoter. Control recombinant viaises lacking vFLIP were
also constructed; IRES and PGK-IRES. Southern blotting and PCR screening
showed that the recombinant viruses contained the inserted sequences in the correct
location and orientation and that there was no contamination of the viral stocks with
wild-type MHV-76.
Following intranasal infection of BALB/c mice with 5xl04 pfu of virus, the titres of
infectious virus in the lung and infective centres in the spleen were determined. In
the lung the recombinant viruses displayed similar kinetics of infection to the wild-
type virus; peak viral titres were achieved around day 5 p.i. and the viruses were
completely cleared by day 10 p.i. When expression of the inserted sequences was
driven by the strong CMV IE promoter the vFLIP expressing viruses, FL1 and FL2,
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reached a higher titre at day 5 p.i. than the control, IRES, and wild-type viruses.
Whilst the apparent attenuation of lytic replication of the IRES control virus has been
noted elsewhere (Brass, 2004) it appears from these results that vFLIP provides a
replicative advantage to the FL1 and FL2 viruses. This phenotype is not replicated
following infection of BALB/c mice with recombinant viruses in which expression
of the insert is driven by the PGK promoter i.e. FL3 and PGK-IRES. Following
intranasal infection with these viruses there is no difference in the titres of infectious
virus in the lung between the two recombinants and the wild-type virus at any time
point. This result indicates that the attenuation of the IRES control is a result of
CMV IE driven expression of the LHE. The CMV IE promoter is much stronger
than the PGK promoter (Gerolami et al., 2000) and thus will result in higher levels of
EGFP and vFLIP in infected cells. It is possible that the high concentration of EGFP
in the lungs following infection of mice with FL1, FL2 and IRES elicits an immune
response against the virally infected cells. In the case of IRES this results in
clearance of the majority of virus from infected animals. KSHV vFLIP is known to
have anti-apoptotic properties; it acts directly to inhibit activation of pro-caspase 8 at
the DISC (Djerbi et al., 1999) and activates NF-kB (Liu et al., 2002) which mediates
the transcription ofmany cellular genes including some involved in the prevention of
apoptosis (Pahl, 1999). The expression of vFLIP, by FL1 and FL2, may provide
protection for these virally infected cells against the immune response raised against
EGFP and thus enable lytic replication to continue at a greater level than the control
virus. When expression of the inserted sequences is driven by the weaker PGK
promoter, i.e. following FL3 and PGK-IRES infection, the resulting concentrations
of EGFP and vFLIP will be lower than in CMV IE virus infected cells. As a result,
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one would expect the immune response against PGK-IRJES to be much less
significant than that against IRES and hence levels of viral replication to be
maintained. This is seen to be the case as the previously observed attenuation of the
control virus in the lung is obliterated when the PGK promoter is used to drive
expression. Infection of mice with a vFLIP expressing virus, FL3, does not result in
a greater viral titre than the control recombinant virus, PGK-IRES. There will be an
immune response against these viruses, however, it is probably not exacerbated by
EGFP and there is probably not enough vFLIP present in the system to provide a
replicative advantage to FL3. In order to further clarify whether the expression of
vFLIP by FL1 and FL2 does elicit a protective effect in the lungs of infected mice it
will be necessary to establish that vFLIP is being expressed and determine the
relative levels of vFLIP protein. Without an antibody against vFLIP this has not
been possible. Antibody against KSHV vFLIP has been successfully produced (Low
et al., 2001) and if it does become available to us it will be interesting to stain lung
sections for vFLIP and correlate this with EGFP expression and viral titre. Such an
antibody would also allow determination of the amount of vFLIP protein present
following infection with FL3 and assessment of the efficiency of the EMCV IRES in
this system.
No splenic infective centres were detected after day 10 p.i. following titration of
splenocytes isolated from mice infected with any of the recombinant viruses. Thus,
these viruses are either failing to establish latency in the spleen or, alternatively, they
are attenuated in their reactivation from latency. An experiment using EGFP-
expressing ROSA mice failed to elucidate whether an immune response against
EGFP in infected BALB/c mice was responsible for this splenic attenuation.
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The unsuitability of the recombinant viruses expressing EGFP for studies of latency
in vivo and the inability to generate recombinant viruses without the selection
markers (76inFLIP and 76inEGFP) meant that a different system had to be
developed to study the establishment of latency. To this end NSO cells were utilised.
It was shown that these cells can be infected with MHV-76 and MHV-76
recombinant viruses and that the viruses can establish latency. Assays of infected
cell cultures show that whilst the rate of cell proliferation is consistent, independent
of the virus with which the cells have been infected, the viral titres achieved vary
considerably. The expression of vFEIP results in higher titres of supernatant and
cell-associated virus at all time points assayed. Moreover, at early time points there
is a considerably larger pool of latently infected cells following FF3 infection in
comparison to PGK-IRES and MHV-76. Thus it appears that vFFlP is able to
enhance the initial establishment of latency. This effect may be mediated, at least in
part, by vFEIP's ability to activate the transcription factor NF-kB. This property is
known to be vital to the survival of KSHV infected cells once latency has been
established (Guasparri et al., 2004) and it would follow that it may also aid the
establishment of latency. Whilst NF-kB was activated in all samples immediately
post infection the intensity of the gel shift decreased more quickly in the MHV-76
infected NSO cells than in those infected with the recombinant viruses. Whilst the
assay is not quantitative it is clear that activated NF-kB is lost from the cells fastest
after infection with wild-type virus and that over time FF3 infection leads to a
greater level of activation than does PGK-IRES infection. The reason that activated
NF-kB is maintained in NSO cells latently infected with PGK-IRES is unclear at
present, one possible explanation may be the presence of a short C-terminal section
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of the M4 gene from MHV-68 in the recombinant viruses. The relative levels of
activated NF-kB observed correspond with the levels of virus produced in each
infected culture: that is, higher viral titres are reached in those cultures containing the
most activated NF-kB. In future it would be desirable to determine a quantitative
readout of the activation of NF-kB by each of these viruses over the course of
infection. Additionally, it would be interesting to investigate the establishment of
latency of the recombinant viruses FL1, FL2 and IRES in NSO cells and to assess the
levels of NF-kB activated as a result of infection. Infection with both FL1 and FL2
should result in higher levels of vFLIP protein within the cells which may result in a
greater activation of NF-kB. If this proves to be the case it would be fascinating to
relate this to the viral titres achieved and determine whether increasing levels of
activated NF-kB do indeed correspond to increased establishment of latency.
KSHV vFLIP has previously been attributed more than one function during the
course of viral infection; protection of infected cells from death receptor mediated
apoptosis and activation of NF-kB resulting in the maintenance of latency. The data
presented here supports these roles for vFLIP and suggests that it may also play a
part in the initial establishment of latency. The in vivo data from BALB/c mice
infected with FL1 and FL2 implies that vFLIP has a protective effect during lytic
replication of the virus, probably counteracting host attempts to initiate apoptosis via
the death-receptor mediated pathway. The gammaherpesviruses encode a number of
anti-apoptotic products that target various components of the apoptosis pathways,
however, MHV-76 does not encode a direct inhibitor of pro-caspase 8 activation.
The inclusion of vFLIP within the KSHV genome may reflect a difference in the
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routes of infection or immune response mounted against KSHV infection as
compared to MHV-76.
Alternatively, the possibility that the anti-apoptotic activity of vFLIP is secondary to
its activation ofNF-kB and that the rescue of the control, IRES, phenotype witnessed
in vivo is an artefact of artificially high levels of vFLIP protein within the system
must be considered. The recombinant viruses reflect the reality of KSHV infection
in that the translation of vFLIP is mediated by an IRES element. As this is the case
one would perhaps expect only low levels of vFLIP in KSHV positive cells. Having
said this it should be noted that it has been demonstrated that, in PEL cells at least,
this appears not to be the case as immunostaining using a monoclonal antibody
against KSHV vFLIP demonstrates significant levels of protein in the cytoplasm of
some of the cells (Low et al., 2001). Whilst acknowledging this observation it
remains the case that the CMV IE promoter is very strong and the EMCV IRES also
has high activity relative to other elements including the KSHV IRES (Bieleski and
Talbot, 2001); together these factors may result in artificially high levels of vFLIP
following infection with FL1 and FL2. If this is the case then FL3, with the much
weaker PGK promoter, is probably more representative of KSHV infection. The
data obtained using this virus do not show any difference in lung virus titres and
indicate that the protective effect of vFLIP is minimal when it is present at lower
concentrations. It therefore seems likely that the predominant role of vFLIP is its
activation ofNF-kB: these results suggest that its expression aids the establishment,
as well as the maintenance, of latency most probably due to activation of NF-kB.
The data gained during this study and others (Brass, 2004) indicates that recombinant
viruses containing selection markers are unsuitable for addressing questions
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regarding the establishment of latency in the mouse. Work carried out utilising
recombinant MHV-76 in which a gene is inserted into the LHE without additional
sequences show that such constructs can establish latency (Townsley et ah, 2004). It
would have been greatly beneficial to have successfully generated the viruses
76inFLIP and 76inEGFP and, in hindsight, efforts to construct such viruses should
have been continued using "stuffer" DNA to increase the insert size and try to
overcome any packaging problems. This work would be valuable in future and if
successful it would allow investigation of the relevance of the NSO data to the in vivo
role of vFLIP.
In its activation of NF-kB the function of KSHV vFFIP resembles that of the EBV
latent protein LMP-1 which is expressed during latency II and latency III and also
activates NF-kB (Huen et ah, 1995). Both viral proteins, vFFIP and FMP-1, are
necessary for the growth of transformed cell lines, PEE and FCL respectively (Keller
et ah, 2000; Izumi et ah, 1997), and they achieve this via NF-kB activation (Cahir-
McFarland et ah, 2004; Guasparri et ah, 2004). KSHV vFFIP has been implicated as
a viral oncogene (Djerbi et ah, 1999) and its activation of NF-kB supports such a
role. Recent work has implicated NF-kB as a component in the development of
cancer and maintenance of malignant cells. The target genes of NF-kB constitute
four broad categories: immunoregulatory and inflammatory; anti-apoptotic; positive
regulators of cell proliferation and negative regulators of NF-kB, all of which can
contribute toward tumourigenesis (reviewed in Karin et ah, 2002). Generation of
the recombinant viruses 76inFFIP and 76inGFP would also enable investigation of
vFFIP as a mediator of oncogenesis. If the viruses were able to establish a latent
infection, one could monitor the development of tumours in animals infected with
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76inFLIP in comparison to those infected with 76inEGFP and the wild-type MHV-
76.
6.2 Identification of ITAFs that interact with the KSHV IRES
A large scale screening programme, yeast 3-hybrid assay, for cellular proteins able to
interact specifically with the KSHV IRES sequence proved impossible to carry out
due to inefficient transformation of yeast with library DNA. In light of this a pull¬
down assay was utilised to investigate the ability of specific ITAFs to interact with
the IRES. By means of this pull-down assay, in which the full-length IRES sequence
was used to deplete a BCP-1 cell protein extract, the polypyrimidine tract binding
protein (PTB) was shown to associate with the IRES in the sense orientation. This is
perhaps unsurprising as the IRES contains a polypyrimidine tract and PTB has been
identified as an ITAF for a large number of IRES elements including EMCV (Hellen
et al., 1993), FMDV (Kolupaeva et ah, 1996) and Apaf-1 (Mitchell et ah, 2001). To
date experiments have not been performed to assess the functional significance of the
interaction between PTB and the IRES, and a supershift assay did not show complex
formation using antiserum against PTB (data not shown). These are both issues that
must be addressed before PTB can be classed as a true ITAF for the KSHV IRES.
The failure of the supershift assay to confirm an interaction between the IRES and
PTB may be attributable to any of a number of different reasons: the reaction
conditions used may inhibit the interaction between either PTB and the IRES or PTB
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and the antiserum; the IRES may not fold to its correct conformation or a secondary
factor may be needed for the interaction to occur. This latter explanation is a
possibility as it has been shown by Mitchell et al that PTB is only able to interact
with the Apaf-1 IRES when the cellular protein upstream of N-ras (unr) is pre-bound
to the RNA (Mitchell et al., 2003).
The translation initiation factor eIF4G has been identified as an ITAF for a number
of IRES elements including those of EMCV (Pestova et al., 1996) and HAV
(Borman and Kean, 1997). It was therefore investigated as a possible interacting
partner of the KSFIV IRES by means of the pull-down assay. Western blotting of
proteins captured in a pull-down assay using RRL, with an antibody against the C-
terminus of eIF4G identified a band of approximately 76kD. As this is the same size
as the M-FAG fragment generated following caspase mediated cleavage of eIF4G
(Bushell et al., 2000) the possibility that cleavage of eIF4G, resulting from KSFIV
infection, produced a fragment capable of promoting IRES activity was investigated.
If a requirement for eIF4G cleavage was demonstrated this may explain the cell-type
specificity of the KSHV IRES (Bieleski and Talbot, 2001) as viral infection would
be required for its induction. It was hypothesised that any cleavage induced by
KSHV infection would be as a result of caspase activation, in this investigation the
picornavirus protease 2A was used to model eIF4G cleavage. IRES activity was
determined by means of a dual-reporter luciferase assay. Two cell lines were used;
one, HEK 293, in which the KSHV IRES is not normally functional and a second,
BCP-1, in which IRES activity is seen. IRES activity was not restored in HEK 293
cells following eIF4G cleavage and neither was it maintained in BCP-1 cells. This
implies that full-length eIF4G is needed for KSHV IRES function, analogous to the
208
HAV IRES (Borman and Kean, 1997). However, inhibition of the EMCV IRES was
also seen following eIF4G cleavage which contradicts the published properties of
this IRES (Pestova et ah, 1996) and suggests that the 2A protease may have a more
far-reaching effect than just cleavage of eIF4G. Further studies must be carried out
to confirm whether full-length eIF4G interacts with the IRES; these could include
UV cross-linking assays and identification of proteins that were shifted by EMSA.
The luciferase assay results suggest that the band observed following Western
blotting of captured RRL proteins with an antibody against the C-terminus of eIF4G
may be either an artefact or it has no functional significance. If proved to be the case
this will explain why a similar band was not observed following a pull-down assay
using BCP-1 S10 extract (data not shown).
It should be noted that there has been increasing speculation about the validity of
some reports of IRES activity, especially those pertaining to cellular IRES elements
(Kozak, 2003; Van Eden et al., 2004; Han and Zhang, 2002). As KSHV is a DNA
virus, and consequently its IRES sequence may share more features with cellular
IRESs than those encoded by RNA viruses, the possibility that the identified IRES
sequence is an artefact of aberrant splicing activity or contains a cryptic promoter
must be considered. When the KSHV IRES was first identified the bicistronic
reporter was transcribed from a T7 RNA polymerase promoter thus bypassing the
necessity for nuclear transcription. Use of a stem-loop upstream of the RL coding
sequence obliterated the activity of this luciferase whilst FF luciferase remained
unaffected (Bieleski and Talbot, 2001). Additionally, Northern blotting, using the
downstream cistron as the probe, was carried out to confirm that the bicistronic
transcript was present and to demonstrate that a monocistronic transcript, which
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would imply that splicing had taken place, was not (Bieleski and Talbot, 2001). The
sensitivity of Northern blotting utilised in this manner has since been questioned
(Van Eden et ah, 2004). Van Eden et al used RT-PCR and RNAi technology to
demonstrate that the XIAP 5'UTR (reported to contain an IRES; Holcik et al., 1999))
contains a splice acceptor site and that bicistronic transcripts containing the XIAP
IRES actually underwent splicing events to produce monocistronic mRNAs that had
not been detected by Northern blotting (Holcik et al., 2003). The authors conclude
that the activity of the XIAP IRES is much weaker than that proposed by the
researchers who identified the IRES (Van Eden et al., 2004).
With this in mind the possibility that the KSHV IRES activity is weaker than first
proposed must be considered. In support of the presence of a functional IRES are the
Northern blot data, stem-loop data, (Bieleski and Talbot, 2001) and the fact that a
monocistronic vFLIP transcript has never been detected in KSHV positive cells.
It is clear from the EMSA data that there are proteins that interact specifically with
the KSHV IRES sequence. PTB has been identified as being able to interact with the
IRES sequence, although the inability to demonstrate this by supershift assays raises
the possibility that either further ITAFs are required for the interaction or that it is
not fundamental to IRES activity. Alternatively, one possibility is that PTB
associates with the IRES sequence in its capacity as a mediator of splicing reactions.
PTB was first identified as a result of its binding to the polypyrimidine tract which
typically precedes the 3' splice site of eukaryotic introns (Garcia-Blanco et al.,
1989). It was subsequently recognised to be a member of the hnRNP family of
proteins that bind to nascent RNA, playing a number of roles in its processing, but
that dissociate once splicing complexes assemble (Bennett et al., 1992). It was then
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proposed that PTB plays a role in repression of splicing events (Mulligan et al.,
1992); further evidence that PTB negatively regulates splicing has been forthcoming
(reviewed in Valcarcel and Gebauer, 1997). Those that question the true nature of
some IRES elements propose that PTB is found to be associated as a result of its role
in splicing and that these IRESs probably contain splice sites (Van Eden et ah, 2004).
On the other hand, those that advocate its role as an ITAF postulate that PTB binding
enables structural remodelling of the mRNA allowing access to the transcriptional
machinery (Pickering et ah, 2003). In either case it is clear that PTB can associate
with the KSHV IRES. There is no splice acceptor site within a suitable distance
from the PPT for splicing to occur (S.Talbot; personnal communication) and
consequently, I believe that PTB is most likely to act as an ITAF and that it is highly
unlikely that it binds to the sequence to repress an, as yet unknown, splice site within
the putative IRES sequence.
Further work is needed to confirm the functional significance of the PTB and eIF4G
interactions identified in this thesis and to determine the nature of any further ITAFs
that are necessary for translation from the KSHV IRES. The most obvious
conclusion to be drawn from the cell-type specificity of the IRES is that there is a
viral determinant of its activity either directly, through expression of a KSHV
protein, or indirectly, through virally induced modification of a host protein. If this
is indeed the case and if full-length eIF4G is an ITAF then there is almost certainly at
least one other ITAF still to be identified. Methods utilised to identify ITAFs could
include: identifying the proteins isolated from shifted complexes following EMSAs;
UV cross linking assays; further pull-down assays and Westerns for other possible
ITAFs e.g. unr. Confirmation of the functional significance of any potential ITAFs
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could be achieved by expression of identified proteins in non-permissive systems to
assess whether they restore IRES function or by targeting the expression of the
putative ITAF, for example by RNAi, and monitoring IRES activity in its absence.
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Appendix 1b: pAB13 plasmid maps
f
CMV Hyg-EGFP IRES vOX2 [ LHE-MHV76
K J
pAB13; vector was constructed as described in Brass; 2004 by subcloning of
insert fragments into pBlueScriptllKS-76LHE. The vector pAB14 is identical
except that the insert CMV to vOX2 is in the reverse orientation.
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Appendix 2 Oligonucleotide Sequences and appropriate PCR amplification
conditions
RTA3F 5' GAC GGA TCC GGC ACA TTT GCT GCA GAA CCC 3'
RTA3R 5' TGC CTT AAG GAA CGG CGC CTG TGT ACT C 3'
94°C 30 sec; 60°C 45 sec; 72°C 30 sec. 30 cycles.
M4B 5' CGC GGA ATT CGG TTC TAG AAA GTC ATA AAT CTC AAT 3'
Trepeat 5' GCG CCA GGA GGA GCT AGG CCA CG 3'
94°C 45 sec; 55°C 45 sec; 72°C 1 min. 35 cycles.
FLIP GST-1 5' GCA TGA ATT CGC CAC TTA CGA GGT TCT CTG 3'
FLIP GST-2 5' GCA TCT CGA GCT ATG GTG TAT GGC GAT AGT G 3'
94°C 1 min; 55°C 1 min; 72°C 1 min. 30 cycles.
FLIP 76-1 5' GCA TGG CGC GCC ATG GCC ACT TAC GAG GTT CTC 3'
FLIP 76-2 5' GCA TGG CCG GCC CTA TGG TGT ATG GCG ATA GTG T 3'
94°C 1 min; 55°C 1 min; 72°C 1 min. 30 cycles.
In FLIP forward 5' GCA TGG ATC CAT GGC CAC TTA CGA GGT TC 3'
FLIP polyA 5' GCA TGG ATC CCA AAA CTT GTT AGT GTT TAT TAA ATC
A
94°C 1 min; 55°C 1 min; 72°C 1 min. 30 cycles.
FLIP Myc HisA rev 5' GCA TAA GCT TTG GTG TAT GGC GAT AGT GTT
GG
pJ27Bglllfor 5' GCCGCTCTAGAACTAGTAGATCTTCAATATTGGCC 3'
pJ27Bglllrev 5' GGCCAATATTGAAGATCTACTAGTTCTAGAGCGGC 3'
3HYB IRES 3 5' P- GAC GGA CGT CAC TTC CTT CTT GTT ACT TAA ATT
GCT GGG GGG CTC CCA ACA CCT GGA C 3'
3HYB IRES 4 5' P- GTC CAG GTG TTG GGA GCC CCC CAG CAA TTT
AAG TAA CAA GAA GGA AGT GAC GTC CGT C 3'
IRES forward 5' GTA CAA GCT TCC GCG GCA GAC TCC TTT TCC C 3'
IRES reverse 5' GTA CGA GCT CGC TGA TAA TAG AGG CGG GCA AT 3'
94°C 30 sec; 65°C 30 sec; 72°C 30 sec. 30 cycles.
Anti-IRES forward 5' GTA CGA GCT CCC GCG GCA GAC TCC TTT TCC C
3'
Anti-IRES reverse 5' GTA CAA GCT TGC TGA TAA TAG AGG CGG GCA
AT 3
94°C 30 sec; 65°C 30 sec; 72°C 30 sec. 30 cycles.
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PP1 5' TCG AGA CGG ACG TCA CTT CCT TCT TGT TAC TTA AAT TC 3'
PP2 5' CAT GGA ATT TAA GTA ACA AGA AGG AAG TGA CGT CCG TC 3'
94°C 1 min; 55°C 1 min; 72°C 1 min. 30 cycles
GAPDH 1 5'TGGATATTGTTGCCATCAATGACC
GAPDH 2 5'GATGGCATGGACTGTGGTCATG







Appendix 3 Yeast 3-hybrid scheme
General 3-hybrid scheme
•2 hybrid proteins are produced;
.DNA binding domain +
RNA binding domain
.RNA binding domain +
Activation domain
•The RNA sequence tethers the 2 proteins
together bringing the activation domain into
position so that it can initiate transcription of
the reporter gene.
•RNA-protein interactions of sub-nM to p.M
affinities have been detected.
Generalised yeast 3-hybrid scheme (top) and protein and RNA domains
utilised in this work (bottom), taken from SenGupta etal, 1996.
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We have identified a novel internal ribosome entry site (IRES) within a latently expressed
Kaposi's sarcoma-associated herpesvirus (KSHV) gene (vCyclin) that controls the expression
of a downstream open reading frame encoding an inhibitor of apoptosis (vFLIP). This IRES is
the first such element to be identified in a DNA virus and may represent a novel mechanism
through which this virus controls gene expression. We have used a dual luciferase reporter assay
to identify important sequence elements essential for the activity of the IRES. A sequence of
32 nucleotides incorporating a polypyrimidine tract (PPT) was found to be required for the proper
functioning of the IRES. We also show, using an electrophoretic mobility shift assay (EMSA),
that proteins specific to a KSHV-infected cell line (BCP-1) but not a KSHV-negative cell line
(HEK293) were able to form complexes with the IRES. By using an in vitro RNA binding assay, the
cellular polypyrimidine tract binding protein (PTB, hnRNP-l) was found to bind to the IRES RNA.
Received 20 October 2003 These results suggest that the interaction of PTB with the PPT may contribute to the correct
Accepted 5 December 2003 functioning of the KSHV IRES in infected cells.
INTRODUCTION
Kaposi's sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus-8 (HHV-8), is the most
recently identified member of the herpesvirus family to
infect humans (Chang et al., 1994). KSHV, a gamma-2-
herpesvirus, has been proposed as the aetiological agent for
Kaposi's sarcoma as well as other malignancies such as
primary effusion lymphoma (PEL) (Cesarman et al., 1995)
and multicentric Castleman's disease (MCD) (Soulier et al.,
1995).
KSHV is closely related to three other herpesviruses with
oncogenic potential; herpesvirus saimiri (HVS), murine
gammaherpesvirus (MHV-68) and, more distantly, to
Epstein-Barr virus (EBV). The complete nucleotide se¬
quence of KSHV DNA has revealed several genes which
have probably been captured from the host cell during
virus evolution, and whose products could also play a role
in cellular transformation and tumour induction (Neipel
et al., 1997; Russo et al., 1996). The three genes encoded
by open reading frames (ORFs) K13, 72 and 73 [vFLIP (Fas-
associated death domain-like IL-l/l-converting enzyme-
inhibitory protein) vCyclin and LANA] are transcribed
from a common transcription start site in cell lines latently
infected with KSHV. The resulting transcript is spliced to
yield a 5-32 kb message encoding LANA, vCyclin, vFLIP and
a 1-7 kb bicistronic message encoding vCyclin and vFLIP
(Dittmer et al., 1998; Talbot et al., 1999).
The observation that a bicistronic transcript (Talbot et al.,
1999) encodes vCyclin and vFLIP led to the investigation
of the mechanism of translation of the vFLIP ORF. We
(Bieleski & Talbot, 2001) and others (Grundhoff &
Ganem, 2001; Low et al., 2001) were able to identify a
novel internal ribosome entry site (IRES) within the latently
expressed vCyclin gene that controls the expression of the
downstream vFLIP ORF. This IRES is the first such ele¬
ment to be identified in a DNA virus. Recently, an IRES
element has been described in the untranslated region of
the Epstein-Barr nuclear antigen-1 (EBNA1) gene, which
may contribute to the regulation of latent gene expression
(Isaksson et al., 2003).
IRES elements were first identified in the 5' untranslated
regions (UTR) of picornaviruses and are essential for the
cap-independent translation of the viral polyprotein (Jang
et al., 1988; Pelletier & Sonenberg, 1988). More recently
IRES elements have been characterized in several cellular
genes which encode growth factors (FGF-2, VEGF) (Stein
et al., 1998; Vagner et al., 1995), proto-oncogenes (c-myc)
(Nanbru et al., 1997) and an inhibitor of apoptosis (X1AP)
(Holcik & Korneluk, 2000). IRES-dependent translation
of these mRNAs may be essential for the survival and pro¬
liferation of cells under stressful conditions (Holcik et al.,
2000). IRES elements in two cellular mRNAs [encoding
ornithine decarboxlyase (Cornelis et al., 2000) and PITSLRE
protein kinase (Pyronnet et al., 2000)] have been identified,
and are regulated in a cell cycle-dependent manner. These
0001-9733 © 2004 SGM Printed in Great Britain 615
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data reveal a novel role for IRES elements in the trans-
lational regulation of protein expression during cell cycle
progression. The IRES element that we have identified
potentially controls the expression of a virus-encoded anti-
apoptotic protein, vFLIP (Thome et al., 1997), which is
intimately linked to the expression of a cell growth pro¬
moting protein, vCyclin (Cesarman et al., 1996; Godden-
Kent et al., 1997).
This paper investigates sequence elements within the KSHV
IRES essential for efficient translation of the downstream
ORF. In addition the cell type-specific activity of the IRES
and cell-specific protein factors interacting with the IRES
are investigated.
METHODS
Cells. The KSHV-positive primary effusion lymphoma (PEL) B-cell
line, BCP-1 (Boshoff et al., 1998), was grown in RPMI (Invitrogen)
supplemented with 20% (v/v) fetal calf serum (FCS), 2 mM gluta-
mine, 60 pg penicillin ml"1 and 100 pg streptomycin ml"1. HEK293
cells (Graham et al, 1977) were grown in DMEM (Invitrogen) sup¬
plemented with 10% (v/v) FCS, 2 mM glutamine, 60 pg penicillin
ml"1 and 100 streptomycin pg ml"1. Cells were incubated at 37°C
under 4% C02.
Plasmids. The plasmids pdLUC and pdLUC-SL were constructed
as described previously (Bieleski & Talbot, 2001). The IRES sequence
from encephalomyocarditis virus (EMCV) or fragments of KSHV
vCyclin/vFLIP were cloned into the Smal-Ncol or Xhol-Ncol sites of








AGGAAGTGACGTCCGTC) were annealed and cloned directly in
the Xhol-Ncol sites of pdLUC and pdLUC-SL to yield the PPT-
encoding plasmid.
The KSHV IRES [nucleotides 123206-122973, GenBank accession no.
U75698 (Russo et al., 1996)] was cloned into the pSP64Poly(A) vector
(Promega) for use in the pull-down assay. Primers GTACAAG-
CTTCCGCGGCAGACTCCTTTTCCC and GTACGAGCTCGCTGA-
TAATAGAGGCGGGCAAT (sense orientation) or GTACGAGCTC-
CCGCGGCAGACTCCTTTTCCC and GTACAAGCTTGCTGATAA-
TAGAGGCGGGCAAT (antisense orientation) were used to amplify
the KSHV IRES by PCR. The DNA was then inserted into the
Hmdlll-Sad sites of the vector.
Transfection of cells. BCP-1 cells (1 x 105 cells per well), HEK293
(5 x 104 cells per well) were seeded in 24-well trays and incubated
overnight. The cells were infected with vTF7-3 (Fuerst et al., 1986),
a recombinant vaccinia virus expressing T7 RNA polymerase, at
5 p.f.u. per cell in 200 pi serum free medium (OptiMEM; Gibco-
BRL) for 60 min at 37 °C. The inoculum was removed and the cells
washed once with OptiMEM. The cells were then transfected with
0-5 pg of linearized (Aflll and Notl) plasmid DNA and 1-5 pi
Transfast transfection reagent per well according to the manufac¬
turer's instructions (Promega). After incubation at 37 °C for 60 min,
1 ml of growth medium was added to the wells. The cells were
assayed for luciferase activity 24 h later as described below.
Dual luciferase assays. Transfected cells were washed twice in
PBS, and then lysed by addition of 200 pi of passive lysis buffer
(PLB, Promega). After incubation for 15 min at room temperature
the cell lysates were transferred to Eppendorf tubes and snap-frozen
on dry ice. The lysates were then thawed, vortexed for 1 min and
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Fig. 1. (a) Schematic diagram of the plasmids
pdLUC, showing the coding sequence for the
Renilla and firefly luciferase enzymes cloned
downstream of a T7 RNA polymerase promoter,
(b) RNA sequence of vCyclin IRES. The
sequence between the Sacll and £co47lll sites
(nucleotides 123206-122973, Genebank
accession no. U75698 (Russo et al., 1996),
and positions of restriction sites used in dele¬
tion analysis are shown. The 5' ends of oligo¬
nucleotides (1, 2, 3 and 4; see Methods) used
to PCR-amplify portions of the IRES are also
indicated by arrows. The 11 nucleotide se¬
quence complementary to 18S rRNA is shown
in bold, and (c) the PPT is underlined and in
bold.
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activity of Renilla and firefly luciferase was assayed using the dual
luciferase system as described by the manufacturer (Promega).
Luciferase activities were measured using a Labsystems benchtop
luminometer and the ratio of firefly luciferase to Renilla luciferase
activity was calculated and used as a measure of IRES function.
Electrophoretic mobility shift assays (EMSAs). RNA was trans¬
cribed in vitro from 0-2 pg of linearized plasmid using T3 RNA
polymerase and labelled internally with [«-32P]UTP according to
manufacturer's instructions (Life Science). Whole-cell lysate was
prepared from BCP-I or HEK293 cells by sonication for 15 min at
4°C in binding buffer [20 mM HEPES/KOH pH 7-5, 50 mM KC1,
10 mM MgCl2, 0-01% (v/v) NP40, 5% (v/v) glycerol], and the
cellular debris was removed by centrifugation at 10000 g for 5 min.
The binding reaction was carried out in binding buffer containing
25 000 c.p.m. of labelled RNA, 6 pg protein, 1 unit RNasin, and
0-05 pg poly(dl-dT), in a total volume of 20 pi in the presence or
absence of 10-fold excess of unlabelled competitor transcripts. After
15 min incubation at 20 °C, the samples were loaded on a 5% (w/v)
non-denaturing polyacrylamide gel containing 0-5 x TBE. The gel
was run in 0-5 X TBE for 1 h at 30 mA before exposure to x-ray
film (Hyperfilm) at — 80 °C with an intensifying screen.
Preparation of S10 cell extract. Cells (1 x 108) were centrifuged
and washed three times with isotonic buffer (35 mM HEPES pH 7-4,
146 mM NaCl, 11 mM glucose), resuspended in 2 vols of hypotonic
buffer (20 mM HEPES pH 7-4, 10 mM KC1, 1*5 mM magnesium
acetate, 1 mM DTT) and incubated on ice for 10 min. The cells
were disrupted with 25 strokes of a Dounce homogenizer (on ice),
before addition of 0-1 vols of 10 x buffer (0-2 M HEPES pH 7-4,
1-2 M potassium acetate, 40 mM magnesium acetate, 50 mM DTT).
The nuclei were removed by centrifugation at 2000 r.p.m. for
10 min at 4°C, followed by addition of CaCl2 (1 mM) and 75 units
of S7 nuclease (Roche) per ml of supernatant. After incubation at
20 °C for 15 min the S7 nuclease was inactivated by adding EGTA to
2 mM. The S10 supernatant was centrifuged at 10 000 r.p.m. at 4°C
for 15 min before freezing in aliquots at -80°C.
RNA-protein pull-down assays. Plasmids derived from the
pSP64Poly(A) vector were linearized with EcoRI, and then used as
templates for transcription reactions. RNA transcripts [containing a
3' poly(A) tail of 30 residues] were produced and purified according
to the manufacturer's instructions (Ambion; SP6 megascript). The
KSHV vCyclin IRES RNA (sense or antisense) was captured onto
oligo(dT) Dynabeads (Dynal, 0-5 ml) as described previously
(Stassinopoulos & Belsham, 2001). The immobilized RNA trans¬
cripts were then incubated with BCP-1 cell S10 extract at 4°C for
60 min on a rotating wheel. The magnetic beads were captured and
the depleted S10 was removed. The beads-RNA-protein complex
was washed twice in binding buffer, resuspended in SDS sample
buffer, and incubated at 4°C for 10 min. These samples were
analysed by SDS-PAGE and Western blot analysis. The anti-PTB
polyclonal antibody was a gift from R. J. Jackson (University of
Cambridge, UK) (Hunt & Jackson, 1999; Mitchell et al., 2001).
RESULTS
A polypyrimidine tract is essential for the
activity of the vCyclin IRES
We have described previously a 233 nucleotide sequence
within the vCyclin gene of KSHV that efficiently promotes
the translation of the downstream vFLIP orf via internal
ribosome entry (Bieleski & Talbot, 2001). We noted the
presence of two sequence elements within the IRES that
could potentially modulate its activity. The first was a
pyrimidine-rich sequence and the second an 11 nucleotide
sequence complementary to a sequence in 18s rRNA
(Fig. lb). We have used a combination of restriction
enzyme-directed deletion and PCR to determine the
minimal sequence necessary for the activity of the IRES.
These sequences were cloned into the pdLUC plasmid as
shown in Fig. 1(a). These plasmids were transfected into
the BCP-1 cell line (latently infected with KSHV), which
had been infected with vaccinia vTF7-3 (Fuerst et al., 1986)
at an m.o.i. of 5. The Renilla luciferase and firefly luci¬
ferase activities were measured in cell lysates 24 h post-
transfection. The ratio of firefly luciferase to Renilla
luciferase activity was calculated and used as a measure of
IRES function. As shown in Table 1 we were able to delete
the 18S rRNA sequence without significantly affecting IRES
function, but deletion of the polypyrimidine tract (PPT)
resulted in loss of IRES function. Two of these constructs
(Primer 1&4 and 1&3) revealed a higher IRES activity than
the other constructs and equivalent to the activity of the
EMCV IRES. This may be due to the removal of inhibitory
sequences or the presentation of the KSHV IRES in a more
favourable structural conformation.
To confirm that the PPT was necessary and sufficient for
IRES activity we cloned this sequence alone into the pdLUC
plasmid using oligonucleotides encompassing the PPT
(Fig. 1c). As seen in Table 1, the PPT alone was able to
direct efficient expression of the downstream firefly luci¬
ferase. The cap-independent activity of this PPT sequence
was confirmed using an equivalent reporter construct that
contained an inverted repeat, with the potential to form a
stable 28 bp stem-loop structure in the 5' UTR immedi¬
ately upstream from the Renilla luciferase start codon.
Translation of the first cistron was efficiently inhibited by
the presence of the stable stem-loop structure, whereas
translation of the second cistron via the PPT sequence
Table 1. Activity of the vCyclin IRES and deletion deriva¬
tives in BCP-1 cells
Sequence Activity of IRES [FF:RL (%)]*
EMCV IRES 12-3 ± 1-1
Sacll-Eco47lll 7-0+1-7
Faul-Faul 5-2 + 0-6
Smtt-Eco47lU 5-1 + 1-3
Mnll-Mnh 5-1+0-5
Aat\l-Eco47ll\ 0-4 + 0-2
Primers 1 and 4 14-2 + 1-9
Primers 1 and 3 13-7+1-4
Primers 2 and 4 0-8 + 0-5
Primers 2 and 3 0-4 + 0-2
PPTt 6-9 + 0-7
*The ratio (%) of the firefly (FF) and Renilla (RL) luciferase
activities are shown from an experiment performed in triplicate.
tPPT (polypyrimidine tract); see Fig. 1(c).
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within the vCyclin gene was unaffected by the presence of
the stem-loop (data not shown).
Cell-type specificity of KSHV IRES activity
We noted previously that the IRES activity was high in the
PEL cell line BCP-1 (latently infected with KSHV) but
that there was little or no activity in the cell lines HEK293,
HeLa or KSIMM (Bieleski & Talbot, 2001). This suggests
that cell-specific and/or KSHV-specific factors play an
important role in the modulation of IRES activity. EMSA
is a technique used to study the interaction of proteins with
specific nucleic acid targets (DNA or RNA). Radiolabelled
RNA encompassing the IRES was produced by in vitro
transcription using T7 RNA polymerase mixed with protein
(whole-cell lysate) and then electrophoresed through a
non-denaturing polyacrylamide gel. Any RNA-protein
complexes that are formed run with a slower mobility
through the gel in comparison with non-complexed RNA.
We have used this system to investigate the possibility of
proteins interacting with the KSHV IRES. As shown in
Fig. 2, several specific RNA-protein complexes (indicated
by *) are formed when in vitro-transcribed IRES RNA is
mixed with crude cell lysate from BCP-1 cells but not with
cell lysate from HEK293 cells. The specificity of these RNA-
protein interactions was confirmed by the fact that excess
unlabelled IRES RNA successfully competed out these
complexes. These data confirm the presence of specific
protein factors present in the KSHV-positive BCP-1 cell line








Specificity of proteins interacting with IRES
We have defined a minimal fragment of vCyclin coding
sequence that is able to function as an IRES in our dual
luciferase assay. The most striking feature of this sequence
is a PPT, 17 nucleotides in length. The presence of a PPT
has been noted in several other IRES elements in viruses
and cellular mRNAs (Pyronnet et al., 2000). Pyrimidine-
rich sequences have been shown to interact with the PTB
(hnRNP-I), and this protein is known to affect the func¬
tion of certain IRES elements (Gosert et al., 2000; Hunt
& Jackson, 1999; Mitchell et al., 2001). To test the possibi¬
lity that PTB may bind to the KSHV IRES, we used an
in vitro binding assay (Stassinopoulos & Belsham, 2001).
The KSHV IRES (Fig. lb; SacII and £co47III) was cloned
in both the sense and antisense direction into the plasmid
pSP64poly(A) allowing the production of RNA tailed with a
30 nucleotide poly(A) sequence. This RNA was bound to
oligo(dT) Dynabeads and the complex incubated with S10
protein extract from BCP-1 cells. Proteins bound to the
RNA were analysed by SDS-PAGE and Western blot. As
shown in Fig. 3, PTB was found to bind specifically to the
KSHV IRES in the sense but not the antisense orientation.
DISCUSSION
We have previously reported the presence of an IRES
element within the coding region of the vCyclin ORF
encoded by KSHV that directs the expression of the vFLIP
ORF on a bicistronic message (Bieleski & Talbot, 2001).
We determined that the sequence requirements for the
correct functioning of the IRES fell within a 233 nucleotide
fragment. We noted that there were two potentially
interesting sequence motifs within the IRES that might
contribute to its efficient functioning. These were an
11 nucleotide sequence complementary to a sequence in
18S rRNA, and a 20 nucleotide PPT. Deletion of the 18S
rRNA sequence had no effect on the functioning of the
IRES, whereas deletion of the PPT abolished IRES activity
in a dual-luciferase reporter assay. To confirm the essential
role for the PPT, we tested this sequence (32 nucleotides) in
isolation for IRES activity and found that it efficiently
directed expression of a downstream ORF on a bicistronic
message. The presence of pyrimidine-rich sequences has
Non-complexed
RNA BHHLejb
Fig. 2. EMSA showing the formation of complexes between
the vCyclin IRES and whole-cell extract from BCP-1 cells, but
not with cell extract from HEK293 cells. Approximately 6 pg of
protein was mixed with 25 000 c.p.m. of in v/fro-transcribed
KSHV IRES RNA in the presence or absence of 10-fold
excess of unlabelled KSHV IRES RNA. The positions of four
RNA-protein complexes are indicated by *.
Fig. 3. In vitro RNA-protein binding assay showing the inter¬
action of PTB (Hunt & Jackson, 1999; Mitchell et al., 2001)
with the vCyclin IRES. Lanes 1 and 2, antisense RNA; lanes 3
and 4, sense RNA; lane 5, BCP-1 S10 input. Lanes 1 and 3,
unbound protein; lanes 2 and 4, bound protein eluted from
beads. PTB runs as a dimer of approximately 60 kDa.
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been noted in several other IRES elements in viruses and
cellular mRNAs (Pyronnet et al., 2000).
We have used an EMSA to define IRES-protein com¬
plexes within permissive (BCP-1) and non-permissive cells
(HEK293). Four distinct IRES-protein complexes were
observed with BCP-1 lysate, whereas no distinct species
were identified in HEK293 cells. In order to identify
potential interacting proteins we used an in vitro binding
assay using poly(A)-tailed IRES RNA and oligo(dT)
magnetic beads. Proteins interacting with the IRES RNA
were enriched from BCP-1 S10 extract and analysed by
SDS-PAGE and Western blot. Using this technique we
were able to show that the cellular PTB (hnRNP-I)
selectively bound to KSHV IRES RNA, but not to the
antisense IRES RNA used as a control. Clearly, PTB is not
the sole determinant of IRES activity since it is expressed
in a wide variety of cell types including HEK293 cells in
which the KSHV IRES is non-functional. The potential
interaction of PTB with the PPT of the IRES may provide a
framework for the binding of further cellular and/or viral
factors. We tested whether the expression of PTB in an
in vitro transcription/translation system (rabbit reticulo¬
cyte lysate) would enhance the activity of the IRES, but
found that it had no effect (data not shown). This also
supports the idea that multiple protein factors are required
for efficient IRES activity.
Some viral IRESs, e.g. the EMCV IRES, do not appear to
require proteins other than canonical translation initiation
factors for function (Pestova et al., 1996), while others
require an additional complex set of factors for activity.
Such factors include PTB, which binds specifically to several
viral IRESs, although the absolute requirement of viral
IRESs for this factor differs. For example, PTB stimulates
the initiation of translation by internal ribosome entry
from hepatitis C and A virus RNA in vivo (Gosert et al.,
2000) and from the human rhinovirus (HRV) and polio-
virus IRESs in vitro (Hunt & Jackson, 1999) but is not
necessary for the activity of wild-type EMCV (Kaminski
& Jackson, 1998). PTB is a cellular protein known to be
involved in splicing and branch point selection (Grossman
et al., 1998). It has been shown that the IRES element
controlling the expression of the cellular gene Apaf-1,
involved in the apoptotic cascade, requires both PTB and,
upstream ofN-ras (unr), two cellular RNA-binding proteins
previously identified to be required for rhinovirus IRES
activity (Mitchell et al., 2001). This study showed that
PTB binding to the Apaf-1 IRES occurred only if unr was
present.
We have shown that a PPT is essential for the activity of
the KSHV IRES and that PTB interacts with KSHV IRES
RNA in vitro. Additional IRES RNA-protein complexes
were observed using an EMSA that are yet to be identified.
Further investigations will be required to determine other
binding and regulatory components necessary for the
correct functioning of the KSHV IRES.
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